Unnamed: 0,patient_filename,t,text,type,n,cmem_n_reasoning,cmem_n_ans_str,cmem_n_num_update
675,TCGA-A8-A09K.56C24ABB-CF1D-447F-A5A8-B762C4B01566,0,"Diagnosis: 4. Resected material from'l left breast segment with a 1.4 cm poorly differentiated (G3). invasive ductal breast carcinoma. Carcinoma-free resection margins, carcinoma-free skin. Fibrous mastopathy of surrounding tissue. Tumor stage: pTlc pN1mi (intranodal micrometastasis), MX, R0; G3 (L0, V0).",BRCA,1,"The 'pN' category in the TNM staging system for breast cancer refers to the presence and extent of cancer involvement in the lymph nodes. In this report, the 'pN1mi' indicates that there is micrometastasis (small deposits of cancer cells between 0.2mm and 2mm) in 1 to 3 axillary lymph nodes. Therefore, the N stage is N1.",N1,0.0
699,TCGA-AC-A2BM.9F00B6F4-EE91-4A18-B533-127E39EF8554,1,"Print -. Back to List. TEST: Surgical Patholoav. Date & Time: REPORT STATUS: Final. FACILITY: See Addendum. Patient Name : }. ...ge: Service: Surgery. Gender : F. Takeit. Physician (s) : Speciment (s) Received. A: Left sentinel nodes. B: Left sentinel node #2. C: Left breast tissue. D: Left axillary contents. Pathologic Diagnosis. ""A"" -. Left sentinel node: Metastatic carcinoma in one. (of one) lymph node. Two foci of metastatic tumor are present,. the larger measuring 0.: cm. The metastatic tumor is to. confined. the lymph node. ""B"". Left sentinel lymph node #2: One lymph node negative. for malignancy. C. Meft breast tissue;. Histologic Type: t Invasive ductal carcinoma (NOS). Modified B-R Grade: 3. Tubular score: 3. Nuclear score: 3. Mitosis score: 3. Tumor Size: Greatest dimension: 2.5 cm. Additional dimensions: 1.! 5 x. Regional Lymph Nodes: Number of lymph nodes examined: 13. Number of lymph nodes involved: 1. Metastasis dectected by light microscopy. Margins of Invasive Carcinoma: Negative. Invasive carcinoma is located: 3 cm. away from the deep margin. Lymphovascular Invasion : Absent. Ductal Carcinoma In Situ: Absent. Paget's Disease: Absent. Distant Metastasis: Cannot be assessed. Print. Microcalcificatior. Absent. Additional Pathologic Findings : Fibroadenomas. Specimen Type: Mastectomy. Specimen Size: Greatest dimension: 28 cm. Tumor Laterality: Left. Tumor Site: Upper inner quadrant. Lower inner quadrant. Lymph Node Sampling: Sentinel lymph nodes and axillary. dissection. Comment. In Part ""C"", one contiguous lymph node is negative. for. malignancy. H&E and cytokeratin stains examined. pT2 pN1a pMX. ""D"" -. Left axillary contents: Ten lymph nodes negative for. malignancy. Left axillary contents: ESTROGEN AND PROGESTERONE RECEPTOR SYNOPSIS. Estrogen and progesterone receptor immunohistochemistry stains. are performed utilizing the 6f11 (ER) and 1A6 clones (PR) along. with the iview detection kit. The stains are performed on. formalin-fixed paraffin-embedded sections. Both special stains. have adequate controls. ESTROGEN RECEPTORS: Infiltrating malignant cells showing positive staining: 60. PROGESTERONE RECEPTORS: Infiltrating malignant cells showing positive staining: 10. %. ESTROGEN RECEPTOR RESULTS: Positive. PROGESTERONE RECEPTOR RESULTS: Positive. Note: Consensus. Statement on Adjuvant Therapy for Breast Cancer: Any positive nuclear ER immunostaining is considered a positive. result. These mmunohistochemistry reaction patterns were. developed and their performance characteristics determined by. They have not been cleared or. approved by the U.S. Food and Drug Administration. The FDA has. determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be. regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of. 1988 (CLIA) as qualified to perform high complexity clinical. laboratory testing. Primary Pathologist: Addendum. Results from. HER2 by FISH: 1.4/Not Amplified. Clinical History. Left breast cancer. Intraoperative Consultation. A - Left sentinel node: Metastatic cancer. (Microscopic frozen. section) . B - Left sentinel node #2: Negative. (Microscopic frozen. section). Gross Description. A - The specimen is received fresh for frozen section labeled. ""left sentinel node. The specimen consists of a pink-tan lymph. node measuring 2.5 x 1.5 x 0.9 cm. The specimen is bisected and. entirely frozen in cassette ""FS-A1."" "". B - The specimen is received fresh for frozen section labeled. ""left sentinel node.' The specimen consists of a pink-tan lymph. node measuring 3 x 2 x 1.1 cm. The specimen is bisected and. entirely frozen in cassette ""FS-B1. "". C - The specimen is received in formalin and .labeled ""left breast. suture at 6 o'clock.' The specimen consists of a mastectomy. specimen without axillary tissue measuring 28 x 23.5 x 50 cm and. weighing 1559 gm. There is an overlying tan ellipse of skin. measuring 22 x 7 cm and showing an eccentric wrinkled brown. areola measuring 4. x 4.5 cm. Within the center of the areola. there is an inverted soft brown nipple measuring 1.1 x 1.1 x 0.9. cm. There are grossly no healed incisions or biopsy sites on the. skin surface however the medial edge of the areola is partially. stained with blue dye. Attached suture marks the 6 S'clock. margin. The deep margin is inked black and the specimen is. serially sectioned to reveal an irregular firm tumor between the. upper-inner and lower-inner quadrants approximately 1 cm from the. nipple measuring 2.5 x 2 x 1.5 cm. The tumor comes to within 3. cm of the deep margin and within 2 cm of the superficial margin. (inked blue) Further sectioning reveals a well-circumscribed. nodule within the lower-outer quadrant 3.5 cm from the nipple. measuring 1.5 x 1 x 1 cm. This nodule comes to within 3 cm of. the deep margin. The remaining specimen consists of lobulated. fat interspersed with a large amount of tan-white. irregularly-indurated tissue with scattered cysts filled with. clear fluid measuring up to 0.4 cm in diameter. A lymph node is. identified at the axillary margin measuring 1 x 1 x 0.7 cm. Representative sections are submitted in 12 cassettes. Block summary: ""1"" - vertical section of nipple, ""2"". cross-section of nipple, ""3-4"" - tumor, ""5"" - superficial and. deep margin nearest to tumor, ""6"" - nodule within the lower-outer. quadrant, ""7"" - upper-inner quadrant, ""8"" - lower-inner quadrant,. ""9"" - lower-outer quadrant, ""10"" - upper-outer quadrant, ""11"" -. tissue underlying the nipple stained with blue dye, ""12"" -. bisected lymph node at the axillary margin. D - The specimen is received in formalin and labeled ""left. axillary contents. "" The specimen consists of a tan-yellow portion. of axillary fatty tissue measuring 8 x 5.5 x 3.5 cm and weighing. 53 gm. Sectioning reveals 11 potential lymph nodes ranging from. 0.4 to 2.3 cm in greatest dimensions. The lymph nodes are. totally submitted in 4 cassettes. Block summary: ""1"" - 7 lymph nodes 1 of which is bisected, ""2"". 2 bisected lymph nodes, ""3"" - 1 bisected lymph node, ""4"" - 1. bisected lymph node. Microscopic Description. Microscopic examination has been performed on all slides. The. pathologic diagnosis encompasses the essential microscopic.",BRCA,1,"The patient has metastasis in one out of 13 examined lymph nodes (one focus measuring up to 0.4 cm), which falls under N1 according to the rules.",N1,1.0
1191,TCGA-E2-A10E.CFB8EE09-41D3-4A39-A4AE-4CDEC84BB9BC,0,"SPECIMENS: A. WLE VULVA. B. SENTINEL LYMPH NODE #1. C. SENTINEL LYMPH NODE #2. D. SENTINEL LYMPH NODE #3. E. SENTINEL LYMPH NODE #4. F. SENTINEL LYMPH NODE #5. G. LEFT BREAST. H. LEFT AXILLARY CONTENTS. SPECIMEN(S): A. WLE VULVA. B. SENTINEL LYMPH NODE #1. C. SENTINEL LYMPH NODE #2. D. SENTINEL LYMPH NODE #3. E. SENTINEL LYMPH NODE #4. F. SENTINEL LYMPH NODE #5. G. LEFT BREAST. H. LEFT AXILLARY CONTENTS. GROSS DESCRIPTION: A. WLE VULVA. Received is a vulvectomy specimen measuring 4 x 1.7 x 1 cm. The surface of the specimen is tan-gray. and unremarkable. The single right stitch is arbitrarily designated 12 o'clock. The specimen is inked as. follows: 12 o'clock, 3 o'clock, 6 o'clock-blue, 6 o'clock, 9 o'clock, 12 o'clock-orange. The specimen is. serially sectioned from right to left and submitted in toto as follows: A1: 12 o'clock right margin. A2-A4: full thickness sections from right to left. A5: 6 o'clock left margin. B. SLN #1: Received fresh is a tan pink lymph nodes 1.0 x 0.9 x 0.5cm. The specimen is bisected,. touch preps are taken and the specimen is submitted in toto in FSB. C. SLN #2: Received fresh is a tan pink lymph nodes 0.5 x 0.3 x 0.3cm. The specimen is bisected,. touch preps are taken and the specimen is submitted in toto in C1. D. SLN #3: Received fresh is a tan pink lymph nodes 1.0 x 0.5 x 0.5cm. The specimen is bisected,. touch preps are taken and the specimen is submitted in toto in D1. E. SLN#4: Received fresh is a tan pink lymph nodes 1.5 x 1.3 X 0.5cm. The specimen is bisected, touch. preps are taken and the specimen is submitted in toto in E1. F. SLN#5: Received fresh is a tan pink lymph nodes 1.0 x 0.9 X 0.5cm. The specimen is bisected, touch. prepsiare taken and the specimen is submitted in toto in F1. G. LEFT BREAST: Received fresh is a 474 gram simple mastectomy specimen measuring 21 x 19 x 3.5 cm. The. specimen is partially surfaced with a tan-pink ellipse of skin measuring 16 x 16 cm. The skin surface is. remarkable for a centrally located partially raised nipple 1 cm. The areola rim measures 1.3 cm. The. specimen is inked as follows: superior anterior-blue, anterior inferior-orange, posterior-black. The. specimen is serially sectioned from lateral to medial into 10 slices; slice serially sectioned from medial. to lateral in 10 slices; slice 1 the most medial, slice 10 the most lateral. The nipple is located in slice 5. and 6. The cut surface reveals a gray-white firm well circumscribed mass measuring 2.5 X 1.5: 1 cm,. located in slice 5 and 6 and measuring 0.7 cm. from the closest deep margin. The mass is retroareolar. measuring 2 cm. deep from the nipple. A second satellite nodule is identified in slice 8 measuring 1 X. 0.9 X 0.8 cm, 0.4 cm. from the deep margin and 5.5 cm. from nodule #1. A third possible satellite. nodule is grossly identified in slice 7 measuring 0.4 cm. in greatest dimension, greater than 0.1 cm. from. the deep margin and 2.0 cm. from nodule #2 and 4 cm. from nodule #1. Nodule 2 and 3 are both. located in the lower outer quadrant. Remaining cut surfaces reveal predominantly yellow lobulated. adipose tissue inrterdispersed with gray-white fibrous tissue. A portion of the specimen is submitted for. tissue procurement. Representative sections are submitted as follows: G1: nipple serially sectioned slice 5. G2: nipple serially sectioned slice 6. G3: upper inner quadrant slice 3. G4: upper inner quadrant with deep margin slice 4. G5: lower inner quadrant slice 3. G6: lower inner quadrant slice 4. G7: area immediately adjacent to mass #1. G8; slice 4. G9: slice 5. G10: upper central slice 5. G11: lower central slice 5. G12: skin adjacent no nodule #1. G13-G14: nodule #1 with closest deep margin slice 6. G15: area above nodule #1 slice 6. G16: immediately adjacent to nodule #1 with deep margin slice. G17: nodule #3 with deep margin slice 7. G18: lower outer quadrant slice 7. G19: area immediately adjacent to nodule #2 with deep margin slice 7. G20: upper outer quadrant with deep margin slice 8. G21: inferior margin lower outer quadrant adjacent to nodule #2 slice 8. G22: nodule #2 with deep margin slice 8 lower outer quadrant. G23: area immediately adjacent to nodule #2 with inferior and deep margin slice 9. H. LEFT AXILLARY CONTENTS: Received in formalin are multiple tan-pink fragments of fibrofatty tissue aggregating to 7 X 6 X 3 cm. Dissection reveals 15 possible lymph nodes ranging from 0.1 x 0.1 x 0.1 cm to 2 x 1.5 x 1 cm. Section. code: H1: Five possible lymph nodes. H2: Five possible lymph nodes. H3: Four possible lymph nodes. H4: One lymph node serially sectioned. DIAGNOSIS: A. VULVA, WIDE LOCAL EXCISION: - MODERATE TO SEVERE SQUAMOUS DYSPLASIA (VIN II-III). - MILD SQUAMOUS DYSPLASIA PRESENT AT 12 O'CLOCK TO 6 O'CLOCK. MARGIN, SEE NOTE 1. B. LYMPH NODE, SENTINEL #1, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 3.5 MM WITH EXTRANODAL EXTENSION. C. LYMPH NODE, SENTINEL #2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 1.2-CM WITH NO EXTRANODAL EXTENSION. F. LYMPH NODE, SENTINEL #5, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). G. BREAST, LEFL SIMPLE MASTECTOMY: - THREE FOCI OF INVASIVE, DUCTAL CARCINOMA, SBR GRADE 1, LARGEST. MEASURING 1.8-CM. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - TUMOR (LARGEST FOCUS) IS 2.5-MM FROM THE DEEP SURGICAL. RESECTION MARGIN. LOW NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, MICROPAPILLARY,. CRIBRIFORM AND PAPILLARY TYPES. - PERINEURAL INVASION IDENTIFIED. - SEE SYNOPTIC REPORT AND SEE NOTE 2. H. LYMPH NODES, LEFT AXILLARY CONTENTS, DISSECTION: - SIXTEEN LYMPH NODES, NEGATIVE FOR METASTASES (0/16). NOTE 1: Mild squamous dysplasia is present at the 12 o'clock-3 o'clock-6 o'clock margin in multiple. levels. Focally, this margin has cautery artifact which precludes the assessment of degree of dysplasia. NOTE 2: Three foci of invasive ductal carcinoma are identified; largest measuring 1.8-cm is located. centrally. The other two foci measure 1.0-cm and 0.4-cm respectively. All surgical resection margins. are free of tumor. The closest margin is posterior (2.5 mm from the largest tumor mass). SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.8cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: 0.25cm. deep. Tubular Score: 2. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 1. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 2 / 21 Extranodal extension. Micrometastases: DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 2%. DCIS Type: Cribriform. Micropapillary. Papillary. DCIS Location: Associated with invasive tumor. Nuclear grade: Low. Necrosis: Absent. Location of CA++: DCIS. Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 1c N 1a. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Multifocal invasive ca. left breast. INTRAOPERATIVE CONSULTATION: FSB/TPB: Positive for tumor cells. Diagnosis called to Dr. at. by Dr. TPC/TPD/TPF: Negative for tumor cells. Diagnosis called to Dr at. - by Dr. TPE: Positive for tumor cells. Diagnosis called to Dr. at. by Dr. Microscopia/Diagnostic Dictation: Pathologist. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation: Pathologist. Final Review:., Pathologist,. Final: Pathologist,.",BRCA,1,"Based on the pathology report, there are two positive sentinel lymph nodes (SLN #1 and SLN #4) out of a total of 5 sentinel lymph nodes examined. This corresponds to the N1 stage, as per rule 8: '(New) AJCC considers one to three positive axillary lymph nodes as N1 stage'.",N1,2.0
1298,TCGA-E9-A1RG.59D84893-8946-4C5C-A338-3E33A1F7DE00,0,"OC ID:S. Gross Description: Lump with the tumor of 1 x 1.8 cm in size; fatty tissue lymph nodes are dense, hyperemic. Microscopic Description: Infiltrating duct carcinoma; G2. Focal hyalinosis. Ten lymph nodes were examined, four lymph nodes demonstrated metastses. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T1 tumor size 2 cm or less, Venous Invasion: Absent, Margins: Absent, Treatment. Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 1.8x0x1cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 4/10 positive for metastasis (Axillary 4/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",BRCA,2,"The report states that 4 out of 10 examined lymph nodes were positive for metastasis (Axillary 4/10). This corresponds to N2 stage, as per rule 3: 'N2: Metastasis in 4-9 axillary lymph nodes, or in clinically detected internal mammary nodes with clinically negative axillary nodes by imaging.'",N2,3.0
1158,TCGA-D8-A1XZ.1D6EE39C-DE75-4595-943A-CF53873F96BF,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breastiand axillary tissues. Unit in charge: Central Operating Theatre. ref. No. Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic description: Right breastÃ© sized 21 x 15 x 3.5 cm, removed with axillary tissues sized 8 x 8.5 x 3 cm and a skin flap of 21 x 12 cm. Tumour sized. 1.2 x 1.1 x 0.8 found in the lower outer quadrant, located 3.5 cm from the upper boundary, 2 cm from the base and 0.6 cm from. the skin. Microscopic description: Carcinoma ductale invasivum - NHG3 93 + 2 +3: 21 mitoses/10 HPF - visual area 0.55 mm). Glandular tissue, apart of the tumour, showing lesions of the type mastopathia fibrosa et cystica, lipomatosis. AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis (No VI/XIV). Infiltratio capsulae lymphonodorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Metastases carcinomatosae in lymphonodis axillae (NO VI/XIV). (NHG3, pTIc,. pN2a). Invasive ductal carcinoma of the right breast. Cancer metastases of the axillary lymph nodes (No VI/XIV). page 2/2. Examination performed or. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2. protein stained with HercepTestTM by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+ ).",BRCA,2,The report mentions 'Metastases carcinomatosae in lymphonodis (No VI/XIV)' which indicates metastasis in 4-9 axillary lymph nodes. This matches the N2 description in the rules.,N2a,4.0
709,TCGA-AC-A2QJ.E422C6E8-084F-42B8-84E7-4EF387F098C7,3,"Sex: F. Laboratory Patient Report. Print Date/Time. Histopathological Examination. Complete: Pre-op Diagnosis : Left Breast Cancer. Specimens. : breast, left inferior skin. Breast, left. Lymph Node, Left Axillary. Lymph Node, Sentinel Left Axilla. Breast, left, inferior margin. Frozen Diagnosis : Block#. : A-1. Re-Ex?. FS-Diag. : No carcinoma identified. Comment. : none. : GROSS EXAMINATION: A. The specimen is received fresh in a container labeled. with the name of the patient and labeled as breast, left. inferior skin. Tissue: Triangular excision. Size: 0.9 x 0.9 cm. Deep: 0. 3 cm. Sutures: No. Inked No. The specimen is entirely submitted for frozen section in one. block. FROZEN SECTION DIAGNOSIS: No carcinoma identified. B. The specimen is received fresh in a container labeled. with the name of the patient and identified as breast,. left. The specimen consists of a mastectomy measuring en. bloc 19.5 x 15 x 6 cm and weighs 604 grams. There is an. anterior ellipse of skin measuring 14 x 7 cm. Medially. located on the ellipse of skin is a 5 cm areolar complex. with everted nipple. Sections of nipple areola are sampled. in block 1. 2 cm lateral to the areola is a 0.9 cm red-tan. papule which is submitted in block 2. The superficial. superior margin is inked orange and the superficial inferior. margin is inked green. The deep margin is inked blue and. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : the specimen sectioned, showing a red-tan oval mass in the. lateral aspect of the breast. This mass measures 7 cm. greatest dimension. It grossly extends to within 0.5 cm of. the superior margin of resection which is submitted in block. 3, 0. cm of the inferior margin of resection which is. submitted in block 4, and 1 cm of the deep margin of. resection which is submitted in block 5. Additional sections. of the mass are submitted in blocks 6-9. The remaining. breast is composed of yellow lobulated adipose tissue. admixed with islands of gray-white rubbery tissue. The. breast is divided into four quadrants, upper inner, lower. inner, upper outer and lower outer and sampled in blocks. 10-13 respectively. No axillary tissue is present and no. lymph nodes are identified. Formalin fixation time is 32 hours. Ischemic time: 30 minutes. C. The specimen is received in formalin in a container. labeled with the name of the patient and labeled as lymph. node, left axillary. The specimen consists of an oval piece. of tan-pink and yellow soft tissue which measures 2. 1 x 1.8. x 1 cm. The specimen is sectioned and entirely submitted in. three blocks. D. The specimen is received in formalin in a container. labeled with the name of the patient and identified as lymph. node, sentinel left axilla. Pieces: 1. Specimen Size: 2.2 x 1.4 x 1. 1 cm. No. of Nodes: 1. Size of Nodes: 2.2 cm. The specimen is sectioned and entirely submitted in three. blocks. E. The specimen is received in formalin in a container. labeled with the name of the patient and identified as. additional left breast tissue, inferior margin. Size: 14 x 6 x 2.5 cm. Shape: Flattened oval. Spec Board: No. Radiograph: No. Sutures: Yes; short superior, long lateral. Inked: Anterior-Green, Posterior-Blue, Superior-Orange,. Inferior-Yellow, Medial-Red, Lateral- Black. Sectioning shows no discrete masses. Sections are submitted as follows : Full thickness superior. to inferior sections 1-6 with the remaining margins. submitted as follows: anterior 7, posterior 8, medial 9,. lateral 10. Formalin fixation time is approximately 30 hours. Ischemic time: Unknown. DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: A. Skin, left inferior breast, biopsy: - Skin with minimal patchy nonspecific chronic inflammation. - No maliqnancy identified. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : B. Breast, left, mastectomy : - Invasive metaplastic carcinoma, grade 3 (3+3+3) 7 cm in. greatest dimension, present within 3mm (0.3 cm) of superior. margin, 5mm (0.5 cm) of inferior margin, and 10mm (1 cm) of. deep margin. - Invasive carcinoma invades dermis and is associated with. overlying epidermal ulceration. - Background nonproliferative fibrocystic including stromal. fibrosis, apocrine metaplasia, microcystic formation, and. duct ectasia. - See cancer CASA summary checklist. C. Lymph node, left axillary, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1). - See cancer case summary checklist. D. Sentinel lymph node, left, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1) . - See cancer case summary checklist. E. Breast, left, re-excision of inferior margin: - Benign breast tissue with nonproliferative fibrocystic. changes including apocrine metaplasia, stromal fibrosis, and. microcyst formation. - No malignancy identified. - The margins are examined microscopically and are. histologically unremarkable. - See cancer case summary checklist. CANCER CASE SUMMARY CHECKLIST. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy. LYMPH NODE SAMPLING: Sentinel lymph nodes and axillary lymph. node biopsy. SPECIMEN INTEGRITY: Multiple designated specimens (main. excision and identified margin). SPECIMEN LATERALITY: Left. TUMOR SITE (Invasive Carcinoma) : Upper and lower outer. quadrants. TUMOR SIZE: Size of Largest Invasive Carcinoma: 7 cm (70. mm) in greatest dimension. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: - Skin: Invasive carcinoma directly invades into the dermis. with associated skin ulceration. - Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle is present. DUCTAL CARCINOMA IN SITU (DCIS) : No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS) Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive metaplastic. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. carcinoma. HISTOLOGIC GRADE: NOTTINGHAM HISTOLOGIC SCORE: - Glandular (Acinar)/Tubular Differentiation. 3. - Nuclear Pleomorphism: 3. - Mitotic Count: 3. Number of mitoses per 10 high-power fields: 30. Diameter or microscope field: 0.55 mm. - Overall Grade: Grade 3 (score of 9). MARGINS: - Margins uninvolved by invasive carcinoma. - Distance of invasive carcinoma to closest margin = 3 mm. (0.1 cm), superior. - All other margins greater than 1 cm from invasive. carcinoma (including specimens A and E). LYMPH-VASCULAR INVASION: Not identified. Dermal Lymph-Vascular Invasion: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and. nonsentinel) : 2. Number of lymph nodes with macrometastases (>0.2 cm) : 0. Number of lymph nodes with micrometastases (>0.2 mm to. 0.2 cm and/or >200 cells): 0. Number of lymph nodes with isolated tumor cells (0.2 mm and. <200 cells) : 0. Size of largest metastatic deposit: Not applicable. Extranodal Extension: Not applicable. Method of Evaluation of Sentinel Lymph Nodes: H&E, 1 level. PATHOLOGIC STAGING (pTNM) : - Primary Tumor (Invasive Carcinoma). (pT) : pT4b (skin. ulceration). - Regional Lymph Nodes (pN) : pNO (no regional lymph node. metastasis identified histologically). - Distant Metastasis (M) : Not applicable. ANCILLARY STUDIES: Estrogen Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. Progesterone Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. HER2/neu Immunoperoxidase Studies: - Performed on another specimen. - Results: Negative (score 0). Fluorescence In Situ Hybridization (FISH) for HER2/neu: - Not performed. Intradepartmental consultation obtained. M.D., Pathologist. Flantrnninallv Signed by: MD. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. of 4.",BRCA,0,"The report indicates that the patient had one benign lymph node in the left axillary biopsy and one benign lymph node in the sentinel lymph node biopsy, both of which were negative for metastatic carcinoma (0/1). This means that there is no regional lymph node metastasis, which corresponds to N0 stage according to the rules provided.",N0,5.0
1043,TCGA-BH-A0W3.801A4E2F-E26E-424F-BF42-CD0D9CD62BCE,0,"PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: 1.2-cm mass upper inner quadrant left breast, core blopsy Invasive ductal. carcinoma. LMP DATE: Not provided. PROCEDURE: Left segmental mastectomy, sentinel lymph node biopsy. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. ADDENDA: Addendum. Immunostains for HER-2/neu were performed on block 1B. HER2 IMNUNOHISTOCHEMISTRY: Using appropriate formalin fixed (8 - 96 hours), controls and tissue. test block, 4B5 antibody clone is used as part of FDA approved Pathway on the. and interpreted as follows: 2+. A weak to moderate complete membrane staining is. (Equivocal). observed in more than 10% of the tumor cells). NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 15 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 225. HER2/NEU: 2+. INTERPRETATION. nuc ish(D17Z1,ERBB2)x2-6[80]. No amplification of the HER-2/NEU gene was seen by interphase FISH analysis. Fluorescence in situ hybridization (FISH) analysis was performed on a formalin-fixed Block 1B (Left segmental mastectomy 10:00). using the DNA probe for the HER-2/NEU gene. An adequate number of invasive tumor cells were. present and evaluated by four independent observers. The ratio of HER-Z/NEU signals (ERBB2) to chromosome 17 centromere. signals (. was determined to be 1.69. A ratio of greater than 2.2 is considered to be amplified with ratios of 1.80 to 2.20 in. the equivocal range; therefore, this specimen is not amplified. The average number of HER-2/NEU signals per cell was 4.10. The average number of signals for the chromosome 17 centromere was 2.43. Many of the cells exhibited 3 or more signals for. both the HER-2/NEU gene and for the chromosome 17 centromere. This may be indicative of either polyploidy or aneuploidy. for chromosome 17. Concurrent positive and negative control specimens showed the expected results. This FISH test is performed using a modification of the Vysis FDA approved PathVysion HER-2 DNA Probe Kit (1:2 LSI HER-2/neu. / CEP17 probe : T-denhyb-2 buffer). This FISH test was developed and Its performance determined by the. Pursuant to the requirements of CLIA '88, this laboratory has established and vermed the test's. accuracy and precision. FINAL DIAGNOSIS: PART 1: BREAST, LEFT, SEGMENTAL MASTECTOMY AT 10:00-. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR GRADE 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR MEASURES 1.5 CM IN LARGEST DIMENSION (GROSS MEASUREMENT). C. DUCTAL CARCINOMA IN SITU (DCIS), MICROPAPILLARY AND CRIBRIFORM PATTERNS, NUCLEAR GRADE. 2. D. DCIS ACCOUNTS FOR 6% OF TOTAL TUMOR VOLUME, ADMIXED WITH OR CLOSE TO INVASIVE. COMPONENT. E. INVASIVE TUMOR IS 2.5 MM FROM ANTERIOR MARGIN AND 4 MM FROM POSTERIOR MARGIN; DCIS IS. LESS THAN 0.2 MM FROM THE ANTERIOR MARGIN. F. NO LYMPHOVASCULAR INVASION IDENTIFIED. G. ATYPICAL DUCTAL HYPERPLASIA. H. NON-NEOPLASTIC BREAST TISSUE SHOWING PAPILLOMA, FIBROCYSTIC CHANGE AND DUCTAL. EPITHELIAL HYPERPLASIA. I. BIOPSY SITE CHANGES. J. TUMOR IS POSITIVE FOR ER AND PR, HER-2/NEU SCORE 2+ (. PART 2: ADDITIONAL ANTERIOR MARGIN, NEW ANTERIOR MARGIN, EXCISION -. BENIGN BREAST FIBROADIPOSE TISSUE. PART 3: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. A. ONE OF TWO (1/2) LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA (SEE COMMENT). B. THE TUMOR MEASURES 1 CM. PART 4: LEFT SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: LEFT SENTINEL LYMPH NODE #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1).",BRCA,1,The report states that there is metastasis in 1 out of 4 examined sentinel lymph nodes (part 3). This matches the definition for N1 in the rules provided.,N1,6.0
1418,TCGA-LD-A7W5.ADBA741B-AABF-4A33-A61F-C10EE555D175,1,"Amended. DATE OBTAINED: DATE RECEIVED: SUBMITTING MD: DIAGNOSIS. #1-AXILLARY CONTENTS, LEFT: TWENTY THREE LYMPH NODES POSITIVE FOR METASTATIC. CARCINOMA, LARGEST MEASURING 3.7 CM WITH EXTRANODAL EXTENSION (23/23). #2-BREAST, LEFT, 2 O'CLOCK, EXCISIONAL BIOPSY: INVASIVE MAMMARY CARCINOMA. SIZE (INVASIVE): 2.8 cm. LATERALITY: Left. TUMOR FOCALITY: Unifocal. LESIONAL SITE: 2 o'clock. HISTOLOGIC TYPE: Ductal focal lobular features pw BS, lubular features total 73. NUCLEAR GRADE: III of III. HISTOLOGIC GRADE(EEmSBR): II of III (Tubules score 2 + NG score 3 + mitoses score 1). IN-SITU COMPONENT: DCIS solid and cribriform types, nuclear grade III with comedonecrosis. LYMPH NODE SAMPLING. Twenty three lymph nodes positive for carcinoma (23/23). (see specimen #1) with extranodal extension, largest measuring 3.7 cm. AJCC CATEGORIES: Stage IIIC (assuming ""cM0"" status). pTNM: pT2. pN3a. cTNM: cT2. cN1. INTEGRITY/ORIENTATION: Intact specimen with designated margins. MARGINS: Positive posterior/superior margin focally (slide 2K, scut); medial margin 0.5 mm; other. margins widely negative. LYMPHOVASCULAR INVASION: Present. MICROCALCIFICATIONS: Present in association with in situ and invasive carcinoma. NIPPLE/SKIN: (If applicable). Not applicable. SKELETAL MUSCLE: Not present. OTHER: Biopsy site changes, fibrocystic changes. #3-BREAST, LEFT, DEEP MARGIN, REEXCISION: 2 MM FOCUS OF RESIDUAL INVASIVE CARCINOMA. PRESENT 4 MM FROM FINAL DEEP MARGIN; BACKGROUND PROLIFERATIVE BREAST PARENCHYMA WITH. INTRADUCTAL PAPILLOMA. COMMENT. The tumor was grossly measured as 2.4 cm with an additional tumor present at medial slice, not grossly appreciated; with an -. 4mm span to make the final dimension 2.8 cm. The tumor is present 1 mm from deep margin in multiple foci at main specimen, and focally in slice 1K is present at. posterior/superior margin; final deep margin (specimen #3) negative. 88307 X2, 88305. Clinical Diagnosis and History: Left breast Ca. + LN met). cT2; cN1: Clinical Stage IIB. Tissue(s) Submitted: 1: LEFT AXILLARY CONTENTS. 2: LEFT BREAST CANCER @ 2:00 (SUTURE MARKS ANTERIOR). 3: LEFT BREAST TRUE DEEP MARGIN. Gross Description: Specimen #1 is received fresh, subsequently placed in formalin labeled left axillary content and consists of a 10 x 8.5 x 3 cm. aggregate of adipose tissue which is palpated to reveal multiple indurated lymph nodes ranging from 0.3 cm to 3.7 cm in greatest. dimension. A representative section of each node is submitted as follows: 1A-1B- each cassette containing a representative section of each of four grossly positive nodes. 1C-. four halves of grossly four positive nodes. 1D-1E- each cassette containing half of two grossly positive nodes. 1F-. three representative sections of three grossly positive nodes. 1G-. four representative sections of four grossly positive nodes. Additional sections are submitted as follows: 1H-. remaining node corresponding to negative node in slide 1B. 11-. remaining nodes corresponding to fibrofatty tissue in slide 1A. Specimen #2 is received in formalin labeled left breast cancer at 2 o'clock (suture marks anterior) and consists of an oriented. portion of fibrofatty tissue measuring 10 cm from medial to lateral, 7 cm from superior to inferior and 2.7 cm from anterior to. posterior. Loosely received outside of the tissue is a localization wire. The specimen is radiographed to document the loose. localization wire, a mass and a clip. The tissue is inked per protocol such that the superior is blue, the anterior is green, the medial is red, the lateral is yellow, the. anterior is orange, and the posterior is black. The specimen is serially sectioned from lateral to medial into 9 slices to reveal a 2.4. x 2.3 x 2.2 cm indurated gray-white stellate mass in slices #4-8, grossly coming to within 0.5 cm of the posterior and superior. margin, information relayed to the surgeon intraoperatively. The remaining cut surfaces are made up of approximately 10% dense. fibrous tissue. Note the tissue is triaged per. protocol. Representative sections, concentrating on the closest margins, are. submitted as follows: 2A-2B- representative perpendicular sections with lateral margin. 2C-. middle fibrous tissue from slice #2. 2D-. middle fibrous tissue from slice #3. 2E-. posterior margin with tumor slice #4. 2F-. superior posterior margin from slice #4. 2G-. anterior margin with tumor slice #5. 2H-. anterior inferior margin slice #5. 21-. superior posterior margin with tumor slice #5. 2J-2K-. bisected section of posterior superior margin with tumor slice #6. 2L-. anterior inferior margin with tumor slice #6. 2M-. interior margin with tumor slice #7. 2N-. posterior margin with tumor slice #7. 20-. superior margin with tumor slice #7. 2P-2R- representative medial margin. Additional sections are submitted as follows: 2S-2T- tumor slice 8, no real margins, ink run over. 2U-2BB-remaining superior half of medial margin (true margin over-inked red. TIF: approximately. Specimen #3 is received fresh for orientation labeled left breast true deep margin and consists of an oriented portion of fibrofatty. tissue measuring 6 X 5 cm from medial to lateral, 3.5 cxm from superior to inferior and 0.4 cm from anterior to posterior. The true. margin is inked per protocol such that the center is black, the superior edge is blue, the inferior edge is green, lateral edge yellow. and the medial edge is red. The specimen is serially sectioned from medial to lateral into 12 slices to reveal focally dense fibrosis. No tumor is palpated or grossly identified. The specimen is submitted entirely labeled 3A-3K at approximately. Intraoperative Consult Diagnosis. 2A. 2.4CM GROSS TUMOR WITH NEGATIVE MARGINS, POSTERIOR CLOSEST. Amendments. Amended: Reason: Proofreading error. Previous Signout Date:",BRCA,3,"The report states that there are 23 positive lymph nodes out of 23 examined (23/23). This meets the criteria for N3 stage: 'N3: Metastasis in 10 or more axillary lymph nodes, or in inframammary, supraclavicular, or ipsilateral internal mammary lymph nodes with clinically positive axillary lymph nodes.'",N3,7.0
537,TCGA-A2-A1FX.EAFC71A1-D6FC-46EA-BC47-D054C497D705,2,"SURGICAL REPORT. Sexc F. Date Collected: I. Date Received: M.R. Number. Doctor: Account Number. PRE-OPERATIVE DIAGNOSIS. RIGHT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. RIGHT BREASTS CANCER. PROCEDURE. RIGHT SENTINEL LYMPH NODE BIOPSY. TISSUES. A. LYMPH NODE (S) - SENT NODE #1 ""FS. B. LYMPH NODE (S) - SENT NODE #2 FS. C. BREAST EXCISION,NEEDLE LOC,SIMPLE,MARGINS,ETC.- - RIGHT BREAST MASS. D. AXILLARY - AXILLARY CONTENTS. E. MARGINS - ADDITIONAL RIGHT BREAST TISSUE. F. MARGINS - ADDITIONAL LATERAL MAGINS. WRI TISSUE -. FS DIAGNOSIS. A. RIGHT SENTINEL LYMPH NODE#1, F.S. -. ONE POSITIVE LYMPH NODE (1/M). B. FS NOT PERFORMED PER DR. DEFER. C. RIGHT BREAST MASS, F.S. -. TUMOR MASS 4.7 CM. AND INVOLVING SUPERIOR, INFERIOR,. MEDIAL, ANTERIOR SURGICAL MARGINS. TUMOR IS ALSO VERY CLOSE TO POSTERIOR AND LATERAL SURGICAL MARGINS. (WITH SMALL INDURATED NODULES). E. ADDITIONAL RIGHT BREAST TISSUE (GROSS MARGINS ONLY) -. LATERAL SURGICAL MARGIN IS POSITIVE FOR MALIGNANCY. THE REMAINING SURGICAL MARGINS ARE FREE OF TUMOR. F. ADDITIONAL LATERAL MARGIN (GROSS MARGINS ONLY) -. SURGICAL MARGIN is FREE OF LESION. SURGICAL REPORT. nology Number. (Time Reported to Surgeon: FINAL DIAGNOSIS. A. RIGHT SENTINEL LYMPH NODE #1 -. POSITIVE FOR MULTIPLE FOCI OF METASTATIC BREAST. CANCER. B. RIGHT SENTINEL LYMPH NODE #2 -. POSITIVE FOR METASTASIS, SUBCAPSULAR SINUS DEPOSITS,. MEASURING LESS THAN 0.2 MM. IN AGGREGATE (1/1). c. RIGHT BREAST MASS -. POSITIVE FOR INFILTRATING CARCINOMA MEASURING 4.7 CM. IN GREATEST. DIMENSION WITH FOCAL EXTENSION TO THE SUPERIOR, INFERIOR AND MEDIAL. MARGINS WITH EXTENSION TO WITHIN 1/2 MM. OF THE ANTERIOR AND LATERAL. MARGINS RESECTION. D. AXILLARY CONTENTS -. POSITIVE FOR METASTASIS IN FOUR OF TWENTY TWO LYMPH NODES, TWO OF FOUR. DISPLAY SUBCAPSULAR METASTASIS MEASURING MORE THAN 2 MM. IN GREATEST. DIMENSION, ONE OF FOUR DISPLAYS MICROMETASTASIS IN SUBCAPSULAR SINUS. MEASURING LESS THAN 2 MM. AND REMAINING ONE OF FOUR DISPLAYS ISOLATED. POSITIVE CELLS IN SUBCAPSULAR SINUSES (4/22). E. ADDITIONAL RIGHT BREAST TISSUE-. POSITIVE FOR ADDITIONAL CARCINOMA WITH FOCAL EXTENSION TO THE LATERAL,. ANTERIOR, SUPERIOR AND INFERIOR SURGICAL MARGINS OF RESECTION. F. ADDITIONAL LATERAL MARGINS. POSITIVE FOR FOCAL EXTENSION TO THE NEW LATERAL. SURGICAL MARGIN OF RESECTION. PTNM CLASSIFICATION: T2 N2a, MX, STAGE IIIA. Comment: This case is discussed with Dr. The Cytokeratin (AE1/AE3) performed on specimen ""B and 0"" support the diagnosis. given. E-cadherin stain on specimen ""C"" confirms the infiltrative duct carcinoma. (. Signature on file. GROSS DESCRIPTION. SURGICAL REPORT. nology Number. The specimen is received in six separate containers labeled. designated A, B, C, D, E. and F. A. The container is received fresh unfixed labeled ""right sentinel lymph node #1. for frozen section"". The specimen consist of an ovoid mass of pink-tan, firm,. rubbery tissue with attached fat measuring 1.5x 1x 1 cm in greatest overall. dimension. Touch prep and frozen section are obtained by Dr. The entire. specimen, including frozen section, submitted in two blocks. B. The container is received fresh unfixed labeled ""right sentinel lymph node #2. for frozen section"". The specimen consists of an ovoid mass of tan-gray, firm,. rubbery tissue with attached fat measuring 0.9 x 0.8 x 0.4 cm in greatest overall. dimension. A touch prep is obtained by Dr. A frozen section Is not. performed per Dr. Entire specimen one block. C. The container is received fresh unfixed labeled ""gross margins right breast. mass"". The specimen consists of an 18 gram ovoid mass of apparent fatty and fiber incased. ovoid mass which is 5.5 x 3 x 2 cm in greatest overali dimension. There is an Inserted Indicator. wire. There is an attached single suture indicating anterior margin inked with a blue dye. Posterior is inked with a black. There are two short sutures indicating superior margin inked with. a red dye. Inferior is inked with a yellow. There is a long suture indicating lateral margin Inked. with an orange. Medial is Inked with a green. Gross margins are observed by Dr. He. states tumor mass is 4.7 cm and involving superior, inferior, medial, anterior, surgical margins. Tumor mass is very close to the posterior and lateral surgical margin, with small indurated. nodules. The specimen is submitted in twelve blocks. Key note block summary: 1- superior, 2 - Inferior, 3 - anterior, 4 - posterior, 5 -. lateral, 6 - medial. All of those are perpendicular. 7 through 12 - remaining. D. The container is received fresh unfixed labeled ""exiliary contents"". The specimen. consists of an irregular mass of apparent fatty tissue measuring 10 x 8: x 3 cm in. greatest overali dimension. Serial sectioning reveais firm, purple-tan nodules. varying up to 0.9 cm in greatest dimension. The entire specimen is submitted in. five blocks. E. The container is received fresh unfixed for gross margins which are obtained by. Dr. labeled ""additional right breast tissue"". There is a single short suture indicating anterior. margin inked with an orange dye. Deep margin is inked with a black dye. There are two short. sutures indicating superior margin inked with a red dye. Inferior is inked with a yellow. There is a. single long suture indicating lateral margin inked with a green dye. Medial is inked with a blue. Sectioning reveais firm nodules varying up to 4 cm in greatest dimension. Lateral/green margin is. grossly positive. These nodules are chiefly located in the anterior lateral area and approximately. 0.2 cm from the anterior margin. The specimen is submitted in nine blocks. Key note block summary: 1 - lateral, 2 - medial, 3 - anterior, 4 - deep, 5 - superior, 6 - inferior,. 7 through 9 - random. F. The container is received fresh unfixed labeled ""additional lateral margins -. suture on new lateral margin which is inked with a green dye. Gross margins are. observed by Dr. Sectioning reveais firm paipable nodules varying up to. 0,3 cm in greatest dimension. They appear to be 0.4 cm from the new lateral. margin. The specimen is submitted as four sections in four blocks. SURGICAL REPORT. mology Number: MICROSCOPIC EXAM. MICROSCOPIC EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SPECIAL STAINS PERFORMED: E-Cadherin (specimen C); Cytokeratin. (AE1/AE3) (specimens B and D). SURGICAL REPORT.",BRCA,2,"The report states that there are metastases in 4 out of 22 axillary lymph nodes, with two of them having supracapsular metastasis measuring more than 2 mm in greatest dimension. This meets the criteria for N2 stage in the AJCC staging system for breast cancer.",N2,8.0
772,TCGA-AN-A0XP.80E9B7CE-0D5D-4C01-A8E3-E6345BE145EC,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,"The N stage from the report is N1 because it indicates metastasis in 1 to 3 axillary lymph nodes or in internal mammary nodes with clinically negative axillary nodes. The report specifies N Stage: 1, which means there is metastasis in 1 to 3 axillary lymph nodes.",N1,9.0
1050,TCGA-BH-A18H.DF536409-601F-489B-9F8A-A2B372BF9999,0,"PATIENT HISTORY: Site Code : breast, NOS C50.9. CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Left breast cancer 1.3 cm, positive nodes. Right invasive ductal. carcinoma 9 d'clock. LMP DATE: Not provided. PROCEDURE: Bilateral segmental mastectomies, right sentinel lymph node biopsy. left axillary lymph node dissection. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. FINAL DIAGNOSIS: PART 1: BREAST, RIGHTAT 9 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NO SPECIAL TYPE (See comment). B. NOTTINGHAM GRADE 2 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 1;. TOTAL SCORE: 6/9). C. THE INVASIVE TUMOR MEASURES 0.8 CM IN LARGEST DIMENSION. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM, MICROPAPILLARY AND FOCAL. PAPILLARY TYPE WITH CALCIFICATIONS. E. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. F. THE DCIS CONSTITUTES 60% OF THE TOTAL TUMOR VOLUME AND is PRESENT ADMIXED AND. ADJACENT TO THE INVASIVE COMPONENT. G. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. H. RESECTION MARGINS ARE NEGATIVE FOR TUMOR. I. BOTH INVASIVE CARCINOMA AND IN SITU CARCINOMA ARE MORE THAN 0.5 CM FROM ALL MARGINS. J. FOCAL ATYPICAL DUCTAL HYPERPLASIA. K. PREVIOUS BIOPSY SITE CHANGES. L. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. M. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN (H-score 230), POSITIVE FOR. PROGESTERONE RECEPTORS (H-score 180), AND NEGATIVE FOR HER-2/NEU (IHC 2+, FISH not amplified). AS PER THE PREVIOUS PATHOLOGY REPORT. PART 2: RIGHT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR (0/1). PART 3: BREAST, LEFT. AT 12 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA NO SPECIAL TYPE. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 2;. TOTAL SCORE: 8/9). C. THE INVASIVE TUMOR MEASURES 1.3 CM IN LARGEST DIMENSION. D. ADDITIONAL SATELLITE NODULE OF INVASIVE CARCINOMA MEASURING 0.2 CM IS IDENTIFIED. E. THE SATELLITE NODULE IS 0.5 CM FROM THE DOMINANT TUMOR NODUI E. F. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID TYPE. G. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. H. THE DCIS CONSTITUTES 15% OF THE TOTAL TUMOR VOLUME AND IS PRESENT ADJACENT TO THE. INVASIVE COMPONENT. I. FOCAL LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. J. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. K. INVASIVE CARCINOMA IS 0.4 CM FROM THE NEAREST (POSTERIOR) MARGIN. L. DUCTAL CARCINOMA IN SITU IS MORE THAN 0.5 CM FROM ALL MARGINS. M. SKIN IS NEGATIVE FOR TUMOR. N. PREVIOUS BIOPSY SITE CHANGES. O. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. P. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTOR (H-ccore 300), POSITIVE FOR. PROGESTERONE RECEPTOR (H-score 235), AND NEGATIVE FOR HER-2/NEU, AS PER PREVIOUS. PART 4: LEFT AXILLARY CONTENTS, EXCISION -. A. METASTATIC CARCINOMA INVOLVES TWO OF TWENTY-FOUR LYMPH NODES (2/24). B. THE LARGEST METASTATIC FOCUS MEASURES 4.0 CM. C. NO EXTRACAPSULAR EXTENSION IDENTIFIED. COMMENT: Part 1: The gross examination demonstrated an III-defined firm nodule with surrounding fibrous tissue measuring 2.0 x. 1.1 x 0.7 cm. This area was entirely submitted for histologic evaluation and shows Invasive carcinoma in only two. sections of 0.4 cm thickness and therefore, the invasive tumor size is estimated to be 0.8 cm in largest dimension. The. majority of this gross lesion is composed of ductal carcinoma in situ (DCIS). Part 3: The invasive tumor demonstrates scattered cells with intra-cytoplasmic lumina or signet ring cell morphology. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Clook position:9.00. SIZE OF TUMOR: Maximum dimension invasive component: 8 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (Invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of Invasive tumor to closest margin: 6 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 6 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC 1 BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT1b. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 230. PROGESTERONE RECEPTORS: positive, H-score: 180. HER2/NEU: 2+. HER2/NEU (FISH): Not amplified. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: ( Left. PROCEDURE: Segmental. Clock position: 12.00. SIZE OF TUMOR: Maximum dimension invasive component: 13 mm. MULIICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI;. TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 15 mm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Solid. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 4 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 24. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 40 mm. LYMPH NODE METASTASIS(-ES WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 235. HER2/NEU: 1+.",BRCA,0,"Based on the report, the right axillary sentinel lymph node biopsy shows no metastatic tumor (0/1), while the left axillary contents excision indicates metastatic carcinoma involving two of twenty-four lymph nodes (2/24). This indicates that the patient has metastasis in 1 to 3 axillary lymph nodes, which corresponds to N1 according to the rules.",N1,10.0
944,TCGA-B6-A0X4.CA935E8D-ED8A-4485-BDC6-02C07CCE2EA5,1,"age & :-. urgical Pathology: CLINICAL HISTORY: Breast cancer, tumor was 3 x 2.5 x 2 cm. GROSS EXAMINATION: A. ""Left modified radical mastectomy"", received fresh. Submitted is a 2050. gram, 22 x 20 x 8 cm left mastectomy specimen with 10 x 10 x 2 cm axillary. tail. There is a 30 x 20 cm skin ellipse with a 1.5 cm nipple and 6 cm areola. A. sutured 10.5 cm linear incision is present over the lower inner quadrant. The margins are inked in blue. Sectioning reveals a 3 x 2 x 2 cm biopsy cavity. in the lower inner quadrant, 3 cm from the inferior margin, 2 cm from the. medial margin, 4.5 cm from the deep margin, 8 cm from the superior margin, and. more than 15 cm from the lateral margin. The biopsy cavity extends to within. 1. cm of the skin incision. Adjacent to the deep edge of the biopsy cavity is. a. 3 x 2 x 1 cm irregular mass of firm, tan-white tissue. The mass lies. approximately 3.5 cm from the deep surgical margin, 2 cm from the medial. margin, 3 cm from the inferior margin, 7.5 cm from the superior margin, and. greater than 15 cm from the lateral margin. In the upper inner quadrant,. 3.5 cm from the biopsy cavity, is a 1.5 x 1.2 x 0.8 cm well circumscribed. nodule of firm, pale pink-tan tissue. The nodule lies nearest the deep margin,. extending to within 2 cm of this margin. In the lower outer quadrant are two. similar well-circumscribed nodules of pale pink-tan tissue: a 1.1 x 0.6 x 0.5. cm nodule and, 1.5 cm lateral to this, a 0.6 x 0.5 x 0.2 cm nodule. The 1.1. x. 0.6 x 0.5 cm nodule lies 5 cm from the lateral surgical margin and 4 cm from. the inferior surgical margin. The 0.6 x 0.5 x 0.2 cm nodule is 3.5 cm from the. lateral surgical margin and 4 cm from the inferior surgical margin. Further. lateral and inferior within the lower outer quadrant is a small, 0.4 x 0.3 x. 0.2 cm, oblong mass of firm tan tissue, lying 2 cm from the deep and the. lateral surgical margins. In the upper outer quadrant there are small areas. of fibrosis, some associated with small cysts (up to 0.3 cm in diameter) . Within the axillary tail, thirty-two lymph node candidates, 0.5 to 2.2 cm in. greatest dimension, are identified: 8 within the proximal third (zone III),. 6. within the middle third (zone II), and 18 lymph nodes in the distal third. (zone I) . BLOCK SUMMARY: A1- six lymph node candidates from zone III, 0.5 to 1.1 cm in greatest. dimension. A2- two bisected lymph node candidates, 1.2 x 0.9 x 0.7 cm and 1 x 0.6 x 0.5. cm, from zone III. A3- five lymph node candidates from zone II, 0.4 to 1 cm in greatest dimension. A4-A5- one bisected lymph node candidate, 2.2 x 1.5 x 0.4 cm, from zone II. A6- four lymph node candidates, 0.8 to 1.2 cm, from zone I. A7- six lymph node candidates, 0.5 to 1.1 cm, from zone I. A8- six lymph node candidates, 0.8 to 1 cm, from zone I. A9- two bisected lymph node candidates, 1.3 x 1 x 0.4 cm and 1.6 x 1.3 x 0.5. cm, from zone I. A10- section through nipple. A11- sections adjacent to incision extending to the biopsy cavity. A12-A15- sections through 3 cm mass adjacent to biopsy cavity. A16-A17- sections through 1.5 cm nodule in the upper inner quadrant. A18- section through the 0.6 and 1.1 cm nodules in the lower outer quadrant. A19- section through 1.1 cm nodule in the lower outer quadrant. A20- section through 0.4 cm mass in the lower outer quadrant. A21- section extending to the deep surgical margin near the biopsy cavity. A22- section extending to the inferior surgical margin near the biopsy. cavity. A23- sections extending to the superior surgical margin nearest biopsy cavity. Page 2 of. A24- sections extending to the medial surgical margin nearest the biopsy. cavity. A25- - inner upper quadrant. A26- - outer upper quadrant, including portion of fibrous tissue with cysts. A27- outer lower quadrant. A28- inner lower quadrant. A29- section through superior/medial edge of the biopsy cavity. A30- section through deep edge of biopsy cavity. Dr. DIAGNOSIS: A. ""LEFT MODIFIED RADICAL MASTECTOMY"" (MODIFIED RADICAL MASTECTOMY). INFILTRATING DUCTAL CARCINOMA, AT LEAST 3 CM IN GREATEST DIMENSION, NSABP. CYTOLOGIC GRADE 2, HISTOLOGIC GRADE 2. LYMPHOVASCULAR INVASION IS IDENTIFIED. METASTATIC CARCINOMA IN TWO OF TWENTY-ONE LYMPH NODES. DUCTAL CARCINOMA IN SITU OF NON-COMEDO TYPE, EXTENSIVE. SURGICAL MARGINS FREE OF CARCINOMA. BREAST TISSUE AWAY FROM TUMOR MASS SHOWS BENIGN PROLIFERATIVE CHANGES. INCLUDING ATYPICAL INTRADUCTAL HYPERPLASIA, INTRADUCTAL HYPERPLASIA OF. THE USUAL TYPE, INTRADUCTAL PAPILLOMATOSIS, APOCRINE METAPLASIA, BLUNT. DUCT ADENOSIS, MICROCALCIFICATIONS, DUCT ECTASIA, AND MULTIPLE. FIBROADENOMATA. ADDENDUM 1: Tissue was sent to the. where assays for estrogen receptor. and progesterone receptor were performed. Assay for estrogen receptor. revealed an estimated Fmol value of 292 which was interpreted as positive. The. estrogen receptor activity was interpreted as positive with estimated Fmol. value of 268. Please refer to. for the complete report. ADDENDUM 2: ADDENDUM DIAGNOSIS: SURGICAL OPERATIVE MARGINS ARE FREE OF MALIGNANCY. DUCTAL CARCINOMA IN SITU OF NON COMEDO TYPE, EXTENSIVE. BREAST TISSUE AWAY FROM MAIN TUMOR MASS SHOWS BENIGN PROLIFERATIVE CHANGES. INCLUDING HYPERPLASIA, INTRADUCTAL PAPILLOMATOSIS, BLUNT DUCT ECTASIA,. APOCRINE METAPLASIA, MICROCALCIFICATIONS, AND MULTIPLE HYALIZING. FIBROADENOMA.",BRCA,1,"The report states 'METASTATIC CARCINOMA IN TWO OF TWENTY-ONE LYMPH NODES.' This indicates that the patient has metastasis in 2 out of 21 lymph nodes, which falls under the N1 category according to the rules provided: '2. N1: Metastasis in 1 to 3 axillary lymph nodes or in internal mammary nodes with clinically negative axillary nodes.'",N1,11.0
1185,TCGA-E2-A107.BA87D188-A3B3-4A6F-B3AF-1FEB25B9E357,2,"SPECIMENS: A. LEFT BREAST WLE NEEDLE LOC. B. SLN #1. C. SLN #2. D. RIGHT BREAST. E. SLN #3. F. ADDITIONAL SENTINEL LYMPH NODE RIGHT AXILLA. G. RIGHT AXILLARY CONTENTS LEVELS 1 &2. SPECIMEN(S): A. LEFT BREAST WLE NEEDLE LOC. B. SLN #1. C. SLN #2. D. RIGHT BREAST. E. SLN #3. F. ADDITIONAL SENTINEL LYMPH NODE RIGHT AXILLA. G. RIGHT AXILLARY CONTENTS LEVELS 1 & 2. INTRAOPERATIVE CONSULTATION DIAGNOSIS: FSA-left breast: No definitive mass seen, tissue with fibrosis by Dr. to Dr. at. TPB-SLN #1: Lymph node negative for carcinoma. TPC/TPE-SLN #2 & #3: Lymph nodes positive for carcinoma. Called by Dr. to Dr at. GROSS DESCRIPTION: A. LEFT BREAST WLE NEEDLE LOC. Received fresh labeled with the patient's identification and ""left breast WLE needle localization"" is an. oriented (single-anterior, double-lateral, triple-superior) needle localized lumpectomy with out. radiograph. Ink code: anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-. orange. The specimen is serially sectioned into 5 sections revealing dense fibrous tissue without a. distinct mass. No tissue is procured. Entirely submitted: A1-A3: slice 1, lateral margin, perpendicular sections. A4: slice 2, anterior. A5: slice 2, posterior. A6: slice 3, anterior. A7: slice 3, posterior. A8: slice 4, anterior. A9: slice 4, posterior. A10-A11: slice 5, medial margin, perpendicular sections. B. SLN #1. Received fresh is a 3 x 0.8 X 0.5 cm lymph node, A touch prep is performed and the lymph node is. submitted entirely in cassette B1. C. SLN #2. Received fresh is a lymph node measuring 1.4 x 1.2 X 0.5 cm. One touch prep is performed and the. lymph node is submitted entirely in cassette C1. D. RIGHT BREAST. Received fresh labeled with the patient's identification and ""right breast"" is an oriented 678 g, 24 X 21 x. 5 cm mastectomy with 11.5 x 7 the skin ellipse and 1.7 cm everted nipple. Ink code: anterior/superior-. blue, anterior/inferior-orange, posterior-black. The specimen is serially sectioned into 12 slices from. medial to lateral with nipple and slice 5 revealing an area of dense nodular firm fibrous tissue, 10 x 8 X 4. cm, extending from the upper inner quadrant to the mid outer quadrant at is closest to the. posterior/deep margin at 1.5 cm. Representatively submitted. D1: slice 2, lower-superior anterior. D2: slice 2, upper-inferior anterior. D3-D8: slice 3, mid section submitted from superior to inferior. D9: slice 4, lower-superior anterior. D10: slice 4, lower-superior posterior. D11: slice 5, lower-superior anterior. D12: slice 5, lower-superior posterior. D13: slice 5, made anterior. D14: slice 5, mid posterior. D15: slice 5, upper-inferior anterior. D16: slice 5, upper-inferior posterior. D17: slice 6, mid superior. D18: slice 6, lower-superior posterior. D19: slice 6, upper-inferior anterior. D20: slice 6, mid inferior. D21: slice 7, mid superior. D22: slice 7, mid inferior. D23: slice 8, mid lower-superior. D24: slice 8, mid upper-inferior. D25: slice 9, mid upper-inferior. D26: slice 9, mid inferior. D27: slice 10, mid upper-inferior. D28: slice 10, mid inferior. D29: slice 11, upper-inferior posterior. D30: slice 1, mid. D31-D32: nipple, perpendicular sections. D33: skin. D34: 1 axillary lymph node. E. SLN #3. Received fresh is a lymph node, 2 x 1 X 0.5 cm. A touch prep is performed and the lymph node is. submitted entirely in cassette E1. F. ADDITIONAL SENTINEL LYMPH NODE RIGHT AXILLA. Received fresh is a piece of yellow-tan tissue 2.5 x 2.1 x 1 cm. Two lymph nodes are identified. measuring 1.4 and 1.8 cm. Lymph nodes are submitted separately in cassettes F1-F2. G. RIGHT AXILLARY CONTENTS LEVELS 1 AND 2. Received fresh is an aggregate of adipose tissue, 7 x 5 x 1.5 cm. Multiple lymph nodes are identified. ranging from 0.1 to 2.1 cm; they have a variegated pink-tan cut surface. Lymph nodes submitted as. follows: G1-G2: 4 lymph nodes each. G3: 6 lymph nodes. G4: 2 lymph nodes. G5-G8: 1 lymph node each. DIAGNOSIS: A. BREAST/LEFT, WIDE LOCAL EXCISION: USUAL DUCTAL HYPERPLASIA WITHOUT ATYPIA, MICROCALCIFICATIONS IN BENIGN DUCTS. AND FIBROCYSTIC CHANGES WITH FIBROSIS. - FOCAL FAT NECROSIS AND MILD ACUTE INFLAMMATION, NO TUMOR SEEN. B. LYMPH NODE, SENTINEL #1, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #2, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.8-CM WITH NO EXTRANODAL EXTENSION. D. BREAST, RIGHT, SIMPLE MASTECTOMY: 1 - MULTIFOCAL, INVASIVE, LOBULAR CARCINOMA, SBR GRADE 2, MEASURING 10-CM. - INVASIVE TUMOR PRESENT 2-MM FROM DEEP SURGICAL RESECTION MARGIN. - METASTATIC CARCINOMA TO ONE OF TWO AXILLARY LYMPH NODES (1/2). - SEE SYNOPTIC REPORT AND SEE NOTE. E. LYMPH NODE, SENTINEL #3, EXCISION : - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.7-CM WITH FOCAL EXTRANODAL EXTENSION. F. LYMPH NODE, ADDITIONAL SENTINEL, RIGHT AXILLA, BIOPSY: - METASTATIC CARCINOMA TO ONE OF TWO LYMPH NODES (1/2). G. LYMPH NODES, RIGHT AXILLARY CONTENTS, LEVELS 1 AND 2, DISSECTION: TWENTY LYMPH NODES, NEGATIVE FOR METASTASES (0/20). NOTE: Extensive and multifocal invasive lobular carcinoma is identified. The tumor grossly measures. 10-cm. Microscopic examination reveals that the tumor extends from slice #1 to slice #8 (predominantly. in the inner half, central and subareolar region, with extension to outer quadrants. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 10cm. Tumor Site: Upper outer quadrant. Lower outer quadrant. Upper inner quadrant. Lower inner quadrant. Central. Margins: Negative. Distance from closest margin: 0.2cm. deep. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 4 / 27 Extranodal extension. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Negative. HER2: Negative by FISH. Performed on Case: HER2 by FISH performed in outside facility. Pathological staging (pTN): pT 3N2a. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: D1. ER: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Right breast cancer, left abnormal imaging. Microscopic/Diagnostic Dictation:. Pathologist,. Final Review: Pathologist,. Final Review: Pathologist. Final Review: Pathologist,. Final: Pathologist,.",BRCA,2,"Based on the pathology report, there are metastases in 4-9 axillary lymph nodes (4/27 lymph nodes are positive) on the right side. This corresponds to the N2 stage according to the rules provided.",N2,12.0
767,TCGA-AN-A0FZ.8CC70CDC-01EC-4E2B-84C1-F1C946602CCE,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,"The N stage is determined by the number and location of lymph nodes with metastasis. The report indicates that the N Stage is 2, which corresponds to metastasis in 4-9 axillary lymph nodes (N2 stage) according to rule 12.",N2,13.0
899,TCGA-AR-A2LQ.C3537961-4636-4BD1-BC89-892580B36E43,2,"Final Diagnosis. A. Lymph node, left axillary sentinel No. 1, biopsy: A single left axillary sentinel lymph node is. negative for metastatic carcinoma. Blue dye is identified. Immunohistochemical cytokeratin. stain was performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E. impression. B. Lymph node, left axillary sentinel No. 2, biopsy: A single left axillary sentinel lymph node is. negative for metastatic carcinoma. Blue dye is identified. Immunohistochemical cytokeratin. stain was performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E. impression. C. Breast, left, simple mastectomy: Infiltrating lobular carcinoma, Nottingham grade I (of III). [tubules 3/3, nuclei 1/3, mitoses 1/3; Nottingham score 5/9] is identified forming a 0.9 x 0.7 x 0.5. cm mass located in the lower outer quadrant of the breast. Ductal carcinoma in situ is absent. Lobular carcinoma in situ is present. Angiolymphatic invasion is absent. The non-neoplastic. breast parenchyma shows fibrocystic changes and a hyalinized fibroadenoma (0.6 x 0.4 x 0.4 cm,. lower inner quadrant). Calcifications present in benign ducts and acini. Biopsy site changes. present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All. surgical resection margins, including the deep margin, are negative for tumor (minimum tumor. free margin, 0.2 cm, anterior margin). With available surgical material [AJCC pT1bN0(i-)(sn)]. D. Lymph node, right axillary sentinel No. 1, biopsy: A single right axillary sentinel lymph node. is positive for isolated tumor cells (less than 200 cells) on H&E and cytokeratin immunostaining. Blue dye is identified. E. Lymph node, right axillary sentinel No. 2, biopsy: A single right axillary sentinel lymph node. is negative for metastatic carcinoma. Blue dye is not identified. Immunohistochemical. cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissue and. confirms the H&E impression. F. Lymph node, right axillary, biopsy: A single right axillary lymph node is negative for tumor. G. Breast, right, simple mastectomy: Infiltrating lobular carcinoma, Nottingham grade I (of III). [tubules 3/3, nuclei 1/3, mitoses 1/3; Nottingham score 5/9] is identified forming a 12.5 x 6.3 x. 2.2 multinodular, irregular, ill-defined mass with biopsy site changes involving multiple. quadrants from the lateral aspect of the breast to the upper inner quadrant. Ductal carcinoma in. situ is absent. Lobular carcinoma in situ is present. Angiolymphatic invasion is absent. The non-. neoplastic breast parenchyma shows fibrocystic changes. Calcifications present in benign ducts. and acini. Biopsy site changes present. The tumor does not involve the nipple, overlying skin, or. underlying chest wall. All surgical resection margins, after re-excision of the deep margin (see. part H), are negative for tumor (minimum tumor free margin, 0.2 cm, deep margin). With. available surgical material [AJCC 'pT3N0(i+)(sn). H. Breast, new right inferior-lateral chest wall margin, re-excision: Invasive lobular carcinoma. present within the tissue, located 0.2 cm from the new deep margin. ITD:C3537961-4636-4BD1-BC89-892580B36E4.",BRCA,0,"The report states that out of the four sentinel lymph nodes examined (two on the left and two on the right), only one right axillary sentinel lymph node (No. 1) had isolated tumor cells (less than 200 cells). This is considered minimal tumor involvement and does not meet the criteria for N1, N2, or N3 stages. Therefore, the N stage for this patient is N0, which means no regional lymph node metastasis.",N0,14.0
1254,TCGA-E2-A1LG.08A790DE-B01D-4140-BB1C-B4844291D71E,1,"SPECIMENS: A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. RIGHT BREAST UPPER OUTER QUADRANT. D. RIGHT BREAST LATERAL FLAP. E. LEFT BREAST AND AXILLARY TAIL. F. ADDITIONAL AXILLARY CONTENTS. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and ""SLN #1 right axilla"" is a piece of. fibroadipose tissue, 4.5 x 3.1 x 1 cm. It is searched for lymph nodes. Four lymph nodes are identified. measuring 2.5 x 1.1 x 0 6 cm, 1.5 X 1.1 x 1 cm, 0.6 x 0.4 x 0 .2 cm, and 0.6 x 0.5 x 0.2 cm. The 3. smaller lymph nodes are inked orange, green, and black; the lymph nodes are bisected and half of each. is submitted for frozen section diagnosis. Lymph nodes are submitted entirely: FSA1: frozen section of 2 lymph nodes, bisected (1/2 of each). FSA2: frozen section of 2 lymph nodes, bisected (1/2 of each). A3: remainder of lymph nodes from FSA1. A4: remainder of lymph nodes from FSA2. B. RIGHT BREAST. Received fresh labeled with the patient's identification and ""right breast"" is an oriented 1697g, 38 x 30 x. 3cm simple mastectomy with 23 x 20cm tan-brown skin ellipse and 1.3cm everted nipple. Ink code: anterior-superior: blue, anterior-inferior: orange, posterior-black. The specimen is serially sectioned into. 19 slices from lateral to medial with nipple in slice 10 revealing a 4cm area of scar tissue, with a 1cm. central previous biopsy site, 4.6cm from the deep margin in the UIQ of slice 12. The specimen is. radiographed and 3 biopsy clips are identified (in the UC of slice 10, and two in the UIQ of slice 12),. 1.5cm from the closest anterior-superior margin in the UIQ of slice 12. A second possible 1 x 0.9 x. 0.7cm previous biopsy site is identified in 3.8cm from the deep margin in the UOQ of slice 7. Representatively submitted: B1: nipple slice 10. B2: UOQ slice 5. B3: UOQ slice 6. B4: UOQ previous bx site UOQ slice 7. B5: LOQ slice 7. B6: UOQ slice 8. B7: LOQ slice 8. B8: UOQ slice 8. B9: UOQ slice 9. B10: LOQ slice 9. B11-B14: UC with clip ID in B13 slice 10. B15: deep margin and skin UC slice 10. B16: LC slice 10. B17-B18: UIQ slice 11. B19: LIQ slice 11. B20: UIQ skin slice 12. B21-B23: UIQ with 2 bx clips slice 12. B24: LIQ slice 12. B25: UIQ slice 13. C. RIGHT BREAST UPPER OUTER QUADRANT. Received fresh labeled with the patient's identification and ""upper outer quadrant"" is an oriented (suture. at final anterior margin) 30 g, 11.3 x 3.7 x 0.9 cm fibrofatty tissue. Final margin is inked black. Serial. sectioning reveals no discrete lesions. Representatively submitted in cassette C1-C3. D. RIGHT BREAST LATERAL FLAP. Received fresh labeled with the patient's identification and ""right breast lateral flap"" is an oriented. (suture at final anterior margin) 16 g, 6.6 x 3.9 x 1.2 cm fibrofatty tissue. Final margin is inked black. Serial sectioning reveals no discrete lesions. Representatively submitted in cassettes D1-D3. E. LEFT BREAST AND AXILLARY TAIL. Received fresh labeled with the patient's identification and ""left breast and axillary tail"" is an oriented. 1844g, 30 x 27 x 5cm modified radical mastectomy with 25 x 21cm tan-brown skin ellipse and 1.5cm. everted nipple. Ink code: anterior-superior: blue, anterior-inferior: orange, posterior-black. The specimen. is serially sectioned into 13 slices from medial to lateral with nipple in slices 5-9 revealing a 4 x 3 x. 2.8cm tan-white firm well-circumscribed mass in the UOQ of slices 9-10, 3cm from the deep margin. A. dense firm ill-defined fibrous area 2cm in greatest dimension is identified in the UC of slice 6, 2.5cm. from the closest posterior margin. The axillary tail is 11 x 10 x 4cm. Dissection reveals 18 lymph nodes. ranging from 0.2 x 0.2 x 0.2cm to 1.4 x 1 x 1cm. A portion of the specimen is submitted for tissue. procurement. Representatively submitted: E1: nipple slice 5. E2: nipple slice 6. E3: LIQ slice 3. E4: UIQ slice 4. E5: UC slice 5. E6: LC slice 5. E7-E8: nodular area UC slice 6. E9: LC slice 6. E10-E11: UOQ slice 7. E12: LOQ slice 7. E13: UOQ slice 8. E14-E16: mass UOQ slice 9. E17: skin and deep margin UOQ slice 9. E18: LOQ slice 9. E19: mass UOQ slice 10. E20: LOQ. E21: 5 lymph nodes. E22: 5 lymph nodes. E23: 3 lymph nodes. E24: 2 lymph nodes. E25: 1 lymph node. E26: 1 lymph node. E27: 1 lymph node. HW. F. ADDITIONAL AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""additional axillary contents"" are pieces of. yellow-tan fat in aggregate, 3.6 x 2.8 x 0.6 cm; containing a lymph node, 0.8 x 0.6 x 0.2 cm. Submitted. entirely: F1: 1 lymph node. F2-F3: remainder of soft tissue. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - TWO REACTIVE LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/2). B. BREAST, RIGHT, MASTECTOMY: - ADENOID CYSTIC CARCINOMA (3 CM AGGREGATE SIZE). - LOBULAR CARCINOMA- IN- SITU (LCIS), NUCLEAR GRADE 2. - RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. - FIBROADENOMA (0.35 CM). - SCLEROSING ADENOSIS, USUAL DUCTAL HYPERPLASIA, APOCRINE. METAPLASIA. AND MICROCALCIFICATIONS. C. BREAST, RIGHT UPPER OUTER QUADRANT, EXCISION: - FATTY BREAST TISSUE, NO TUMOR IS SEEN. D. BREAST, RIGHT LATERAL FLAP, EXCISION: - FATTY BREAST TISSUE, NO TUMOR IS SEEN. E. BREAST AND AXILLARY TAIL, LEFT, MASTECTOMY: INVASIVE LOBULAR CARCINOMA, MAINLY PLEOMORPHIC TYPE,. SBR GRADE 3, SOLID GROWTH PATTERN. - TUMOR MEASURES 4CM. - RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. - RADIAL SCAR. - EIGHTEEN REACTIVE LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/18). F. LYMPH NODE, ADDITIONAL AXILLARY CONTENTS, EXCISION: - ONE REACTIVE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: SLN #1 RIGHT AXILLA. B: RIGHT BREAST. C: RIGHT BREAST UPPER OUTER QUADRANT. D: RIGHT BREAST LATERAL FLAP. Specimen Type: Mastectomy. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Adenoid cystic carcinoma 8200/3. Tumor size: 3cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: 3.8cm. deep. Necrosis: Absent. Vascular/Lymphati Invasion: Indeterminate. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/2. Non-neoplastic areas: Fibroadenoma, extensive sclerosing adenosis, usual ductal hyperplasia, apocrine. metaplasia. DCIS not present. ER/PR/HER2 Results. ER: Negative. PR: Negative. Performed on Case: Pathological staging (pTN): pT 2 NO. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: E: LEFT BREAST AND AXILLARY TAIL. F: ADDITIONAL AXILLARY CONTENTS. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 4cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: 3cm. deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: LCIS. Lymph nodes: Axillary dissection. Lymph node status: Negative 0/19. Non-neoplastic. areas: Sclerosing adenosis, usual ductal hyperplasia, fibroadenomatoid changes, radial. scar. DCIS not present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2 NO. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: year African American with history of ADH and LCIS with radial scar of right breast. WLE done 4-. Was followed with imaging and. was found to have right adenocystic carcinoma and ILC. on left. PRE-OPERATIVE DIAGNOSIS: Bilateral breast cancer. INTRAOPERATIVE CONSULTATION: FSA1-FSA2: One focus with atypical cells defer to permanent. Diagnosis called by Dr. to Dr. at. (A). ADDENDUM: SUMMARY OF IMMUNOHISTOCHEMISTRY/SPECIAL STAINS. Material: Block B6. Population: Tumor Cells. Stain/Marker:Result: Comment: HERCEPTIN Negative. The interpretation of the above immunohistochemistry stain or stains is guided by published results in. the medical literature, provided package information from the manufacturer and by internal review of. staining performance and assay validation within the Immunohistochemistry Laboratory of the. The use. of one or more reagents in the above tests is regulated as an analyte specific reagent (ASR). These. tests were developed and their performance characteristic determined by the Department of Pathology. Laboratory at. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Special stains and/or immunohistochemical stains were performed with appropriately stained positive. and negative controls. Microscopic/Diagnusuc. Final Review: Pathologist, ,. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathoiogisi. Addendum Final: Pathologi.",BRCA,0,"The report states that the sentinel lymph node excision from the right axilla had two reactive lymph nodes, negative for metastatic carcinoma (0/2). Additionally, the additional axillary contents excision had one reactive lymph node, negative for metastatic carcinoma (0/1). The left breast and axillary tail mastectomy had 18 reactive lymph nodes, all negative for metastatic carcinoma (0/18). These findings indicate no regional lymph node metastasis, which corresponds to N0 stage.",N0,15.0
1256,TCGA-E2-A1LI.B3A319BE-2230-43E2-91E5-A3B3C76B85BA,1,"SPECIMENS: A. SENTINEL LYMPH NODE LEFT AXILLA. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. WIDE LOCAL EXCISION LEFT BREAST. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). C. WIDE LOCAL EXCISION, LEFT BREAST: -INVASIVE AND IN-SITU DUCTAL CARCINOMA, SBR GRADE III/III WITH. EXTENSIVE NECROSIS AND CANCERIZATION OF LOBULES, SEE TEMPLATE. Invasive Breast Cancer Template. INVASIVE TUMOR: Histologic type: ductal. Tumor Size (cm): 2.5 cm. Size of Invasive Focus: 2.5 cm. Grade, Histologic: 3. Grade, Nuclear: 3. Mitoses. 3. Scarff Bloom Richardson grade: III. Necrosis: present. Invasion Vasc/Lymphatic: absent. DCIS component. DCIS Quantity: <25%. DCIS Type: Clining. DCIS Location: outside main mass: diffuse. Nuclear grade: high. Necrosis: absent. Margins: DCIS present within 1 hpf of lateral and 1 mm of deep and medial margins. Lymph nodes: Negative (0/2). Stage, Pathology : T2N1. Hormone receptor status (by IHC): ER & PR: PENDING. HERCEPTEST (by IHC): Pending. ADDENDUM. The ER/PR/HER2 status of the invasive breast carcinoma was determined by immunohistochemistry. and quantitated via ACIS (image analysis). Results are as follows: ER. 0%. PR. 0%. HER2. 2.3 (borderline). A separate ACIS report has been generated. NOTE: FISH analysis for HER2 gene amplification has been ordered. Addendum. Fluorescence in situ hybridization (FISH) for Her-2 gene amplification. Her-2/neu gene: Not amplified. Ratio of Her-2/neu to CEP17: 1.21. The assay is performed on formalin fixed, paraffin embedded section using Her-2 DNA probe kit from. Vysis. The quality of the fluorescence signals and tissue section is adequate for analysis. The signals of. both Her-2 and CEP17 are counted in 60 invasive tumor nuclei. The Her-2 gene is considered amplified. when the ratio of Her-2 to CEP17 signal is >2.0. SPECIMEN(S): A. SENTINEL LYMPH NODE LEFT AXILLA B. SENTINEL LYMPH NODE #2 LEFT AXILLA C. WIDE. LOCAL EXCISION LEFT BREAST. CLINICAL HISTORY: None. FROZEN SECTION DIAGNOSIS: A. SENTINEL LYMPH NODE LEFT AXILLA. Touch prep: No tumor seen by Dr. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Touch prep: No tumor seen by Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE LEFT AXILLA. Received fresh is a 1x0.8x0.5cm. lymph node. It is bisected and touch prep done. Specimen entirely. submitted for permanent section. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh is sentinel lymph node left axilla measuring 0.7x0.5x0.4cm. It is bisected and touch prep. done. Submitted in toto in cassette B for permanent section. C. WIDE LOCAL EXCISION LEFT BREAST. Received fresh is an oriented portion of breast tissue measuring 6x5.5x2.7cm Sectioning shows a well. circumscribed tan nodular tumor mass measuring 2.5x1.8x1cm. It closely approaches the superior. posterior medial margin. Specimen is inked as follows: superior red, inferior orange, medial green,. lateral yellow, posterior black. Tumor tissue and normal tissue given for tissue procurement and tumor. sent for flow cytometry. Representative sections submitted in seventeen cassettes. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist. Addendum: Pathologist. Addendum Review: Pathologist. Addendum Final: Pathologist. Addendum: Pathologist, 1. Addendum Review: Pathologist,. Addendum Final: Pathologis.",BRCA,1,"The report states that two sentinel lymph nodes were examined and no tumor was found in either (0/2). However, the final pathology stage is T2N1, indicating that there is metastasis in 1 to 3 axillary lymph nodes. This information is not explicitly stated in the report, but it is part of the final pathologic stage provided.",N1,16.0
657,TCGA-A8-A08X.CA911D90-5DDA-49F1-993F-68FCA77A8558,3,"Diagnosis: Poorly differentiated invasive ductal carcinoma with focal intraductal components and. angioinvasion (maximum microscopic tumor diameter: 4.0 cm). Diagnosis: 1. Ablated (left) breast sample with extensive further invasive and angioinvasive. tumor components, as well as foci of further intraductal tumor components in the. cavity region of the sample excision (maximum spread: 8 cm). Massive subepidermal. carcinomatous lymphangitis of the skin spindle. Dorsal resection margin tumor-free. Comment: The massive subepidermal carcinomatous lymphangitis in the region of the skin. spindle could correlate closely with the clinical appearance of an inflammatory. carcinoma, although there is no ulceration of the skin spindle. This gives rise to the concluding tumor classification NOS, G III, pT3N3aL1V1R0.",BRCA,3,"The report mentions 'pT3N3aL1V1R0', where 'N3' indicates metastasis in 10 or more axillary lymph nodes, or in inframammary, supraclavicular, or ipsilateral internal mammary lymph nodes with clinically positive axillary lymph nodes.",N3,17.0
683,TCGA-A8-A09X.F72703A2-2C57-459A-9015-94BD3D302491,1,"Diagnosis: Poorly differentiated invasive malignant tumor (tumor diameter 3.5 cm). with focal in situ spread and marked angioinvasion. In conjunction with the preliminary finding, this gives rise to the following tumor. classification: lobular carcinoma, NOS, G III, oT2N3aL1V1RX. (circle): Primary. pitial. Noted.",BRCA,3,"The 'oT2' in the report indicates a tumor size of 2.1 to 5.0 cm, and 'N3a' means metastasis in 10 or more axillary lymph nodes. This corresponds to N3 stage.",N3,18.0
1431,TCGA-LL-A6FQ.5C3D9179-7434-4776-A2FF-68CEA0149C68,1,"RUN DATE : RUN TIME : RUN USER: ACCT # : AGE/SX: ROOM. REG DR: BED: SPEC #: RECD. COLL. TIME IN FORMALIN: 29:21. nrs. CLINICAL INFORMATION: Pre-Op Diagnosis: Breast CA. Remarks: Specimen(s : Right breast stitch marks axillary contents. MICKOSCOPIC DIAGNOSTS. BREAST. RIGHT. MODIFIED RADICAL MASTECTOMY: MULTIFOCAL INVASIVE DUCTAL CARCINOMA - SEE COMMENT. LARGEST TUMOR MEASURES 4 CM: GRADE 2. ANGIOLYMPHATIC INVASION PRESENT. SEVEN (7) OF EIGHTEEN (18) AXILLARY LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA. WITH FOCAL EXTRACAPSULARY EXTENSION PRESENT. MARGINS NEGATIVE. COMMENT(S). In addition to the two larger tumors present within the upper outer quadrant, a tumor is. also present associated with the nipple measuring 2 cm. This section was evaluated with. E-cadherin with appropriate controls demonstrating that the infiltrating carcinoma is. strongly positive for a E-cadherin confirming ductal type. Additionally, a couple of the. lymph nodes were evaluated with PanKeratin stain with appropriate controls. A section from. the larger mass was evaluated for a breast prognostic panel. PROTOCOL FOR EXAMINATION OF SPECIMENS WITH INVASIVE CARCINOMA OF THE BREAST. PROCEDURE. Total mastectomy. LYMPH NODE SAMPLING: Axillary disection. SPECIMEN LATERALITY: Right. HISTOLOGIC TYPE OF. INVASIVE CARCINOMA. Invasive ductal carcinoma (NOS). TUMOR SIZE: Greatest dimension of largest focus 4 cm. HISTOLOGIC GRADE : Nottingham histologic score. Glandular differentiation Score 3. Nuclear pleomorphism Score 2. Mitotic index: Score 1. Overall grade: Grade 2. TUMOR FOCALITY: Multiple foci of invasive carcinoma. DUCTAL CARCINOMA IN SITU: No DCIS is present. MACROSCOPIC AND MICROSCOPIC. RUN DATE : RUN TIME: RUN USER: Continued). SPEC #. COMMENT (s). EXTENT OF TUMOR: Skin: Invasive carcinoma directly invades into the. dermis without skin ulceration. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 3 cm. LYMPH NODES: Number of sentinel lymph nodes examined : 0. Total number of lymph nodes examined (sentinel and. non-sentinel) : 18. Number of lymph nodes with macrometastasis: 5. Number of lymph nodes with micrometastasis: 2. PATHOLOGIC STAGING: Primary tumor: pT2. Regional lymph nodes: pN2a. Distance metastasis: Not applicable. ANCILLARY STUDIES: See microscopic description (ER+, PR+ Her2-). GROSS DESCRIPTION: Received fresh for selection of tissue for tissue banking labeled with the patient's name. is a modified radical mastectomy specimen. The axillary contents measure 16 x 11 x 4 cm,. palpation of which reveals clinically suspicious lymph nodes. The breast weighs ,457. g. and measures 30 x 18 x 6 cm. Skeletal muscle fibers are present on the deep margin. Ã large mass is palpated in the upper outer quadrant. The deep margin adjacent to this area. is inked blue. The breast is covered by a 30 x 18 cm ellipse of dark brown skin. The. nipple and areolar complex is centrally placed. The nipple measures 2.5 cm in diameter and. is somewhat firm on palpation The breast is serially sectioned revealing a. well-circumscribed grayish-white tumor within the upper outer quadrant measuring 3 x 3.5 x. measures 4 3 cm. The tumor lies 1.5 cm from the skin surface. On further evaluation. there. cm Ã portion of the tumor is provided to the tissue bank coordinator. The deep margin. is an apparent separate tumor in the upper outer quadrant with a core needle biopsy. track. and this tumor measures 1.5 x 1 x 1 cm. This tumor is well away from the surgical margins. The remainder of the breast tissue is fatty in nature. No other discrete lesions are. identified. Examination of the axillary contents reveals multiple lymph nodes which range. from 0.5 cm to 3.5 cm in greatest dimension each. Some of these are grossly involved by. tumor. Some are fatty in nature. Cassette Summary: 1. nipple. 2. deep margin adjacent to larger tumor. sections of larger tumor. 8. tissue between larger tumor and smaller tumor. 9.10 -. sections of smaller tumor. 11-13-. sections of lateral. central. and medial breast tissue. respectively. 14. two highest axillary lymph nodes. 15. smaller whole lymph nodes. 16-21-. one lymph node each sectioned and entirely submitted. 22.23-. representative section of two large fatty lymph nodes. 24-26-. representative section of each grossly positive lymph node. RUN DATE. RUN TIME. RUN USER. Continued). SPEC #. MICROSCOPIC DESCRIPTION: BREAST PROGNOSTIC PANEL - LARGEST TUMOR. ASSAY TYPE. % TUMOR STAINED. INTENSITY. Estrogen Receptor. 100. 3. POSITIVE. Progesterone Receptor. 85. 2. POSITIVE. Ki-67. 24. 2. HIGH. SCORE. 1+. NEGATIVE. Her2/neu. REFERENCE RANGES: ER/PR; Negative <1%, Positive >=1%. : Ki-67; Low <10%, Boderline 10-20%, High >20%. Her2/neu: Negative 0-1+, Equivocal 2+, Positive 3+. Her2/neu results are reflexed to FISH. All immunohistochemical staining and the. were performed at. performed scoring and. interpretation utilizing. Clone MIB-1. Antibody clones: Clone 6F11;. Clone PgP1294; Ki-67,. Her2/neu,. CAP/ASCO guidelines for ER and PgR IHC: formalin fixation time 6-72 hours; cold ischemia. time 1 hour or less. CAP/ASCO guidelines for Her2 testing: formalin fixation time 6-48. hours: cold ischemia time 1 hour or less. Testing outside of these guidelines may affect. results. INTRAOPERATIVE CONSULTATION: RIGHT BREAST TISSUE: TUMOR ADEQUATE FOR TISSUE BANKING WITH PORTION OF TUMOR PROVIDED TO TISSUE BANK. COORDINATOR. Image. Image. Image. Image. (signature on file).",BRCA,2,"The report states that 7 out of 18 axillary lymph nodes are positive for metastatic carcinoma. This corresponds to the N2 stage, as per rule 12: N2 stage corresponds to metastasis in 4-9 axillary lymph nodes.",N2,19.0
844,TCGA-AR-A0TY.12A4A731-1ADF-4D36-88F3-16C9642484F3,1,"Breast, right, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III) is identified. forming a 2.4 x 2.2 x 1.8 cm mass (AJCC pT2) in the right upper outer quadrant of the breast. A. significant component of in situ carcinoma is not identified. A benign fibroadenoma (0.6 x 0.4 x 0.4 cm). is identified in the upper inner quadrant. Skin, nipple, and resection margins are free of tumor (closest is. anterior/superior, free by 3.8 cm). Multiple (8) right axillary lymph nodes are negative for tumor. Lymph nodes, right axillary sentinel, excision: Multiple (7) right axillary sentinel lymph nodes are. negative for tumor [AJCC pNo(sn-)]. Blue dye is identified in right axillary sentinel lymph nodes No. 1A. and No. 1B. Blue dye is not identified in right axillary sentinel lymph nodes No.1C, No. 1D, No. 1E, No.2,. and No.3. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel. lymph node tissue and confirms the H&E impression. Breast, left, simple mastectomy: Benign breast tissue with non-proliferative fibrocystic changes. characterized by apocrine metaplasia, cyst formation, and multiple (2) fibroadenomas (upper inner. quadrant, 0.9, and inferior central, 1.1 cm). A single left axillary lymph node is negative for tumor. Estrogen and progesterone receptor analysis and Her-2/NEU have been ordered on paraffin embedded. tissue from the right breast.",BRCA,0,"The report states that multiple (8) right axillary lymph nodes are negative for tumor and multiple (7) right axillary sentinel lymph nodes are also negative for tumor (AJCC pNo(sn-)). This indicates that there is no regional lymph node metastasis, which corresponds to N0 stage.",N0,20.0
914,TCGA-B6-A0IE.DFCA9C6E-710E-4645-9CFC-A908AAD583F3,2,"Surgical Pathology: Final. CLINICAL HISTORY: Inflammatory breast ca. Breast cancer. GROSS EXAMINATION: A. ""Left breast biopsy, received fresh. A fragment of skin which is 3.3 cm. long and 0.4 cm in diameter attached to underlying fibroadipose tissue which. is 2.7 cm thick x 3.5 x 1 cm in greatest dimensions. The specimen has been. previously partially sectioned revealing a poorly defined area of pink tissue. measuring approximately 2.5 x 1.5 x 1 cm in greatest dimensions. This does. not represent the true sides of the lesion. Portions of the tissue have. submitted for ER/PR evaluation. It is noted that this is a representative. fragment of larger lesion and margins are not require for the specimen. Representative sections are submitted in Blocks A1 and A2. DIAGNOSIS: A. BREAST, LEFT, INCISIONAL BIOPSY: POORLY DIFFERENTIATED CARCINOMA WITH EXTENSIVE VASCULAR INVASION. IN SITU CARCINOMA IS NOT PRESENT. NOTE: THE TUMOR HAS FEATURES OF LOBULAR CARCINOMA, BUT AN IN SITU COMPONENT. IS NOT PRESENT. eBrowser Result for: 1 of 1.",BRCA,1,"The pathology report does not mention any information about lymph node metastasis, thus the N stage is N0.",N0,21.0
1224,TCGA-E2-A15P.8C7442C0-540C-4023-BBFA-8482935259A7,0,"SPECIMENS: A. RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. SPECIMEN(S): A. RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A- right breast: 1.5-cm mass at 0.5 cm from posterior margin. TPB/TPC- SLN #1, #2 right axilla: Negative for tumor. Diagnoses called by Dr. to Dr. at : (A) and. (B,C). GROSS DESCRIPTION: A. RIGHT BREAST NEEDLE LOC. Received fresh labeled with the patient's identification and ""right breast needle loc"" is a previously inked, oriented. (single stitch-anterior, double-lateral, triple-anterior) 31 g, 3.5 x 3.1 x 3.1 cm needle localized lumpectomy with. radiograph. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. Specimen is serially sectioned from superior to inferior into 8 slices revealing a 1.5x1.3 x 1.1 cm firm tan stellate. mass that is closest to the posterior margin at 0.5 cm. Tissue is procured. Representatively submitted: A1: superior margin, perpendicular sections. A2: slice 2, posterior medial. A3: slice 3, anterior medial. A4: slice 4, posterior lateral. A5: slice 5, anterior lateral (mass, clip). A6: slice 5, posterior lateral (mass). A7: slice 5, mid anterior. A8: slice 5, mid posterior. A9: slice 5, medial. A10: slice 6, anterior lateral (mass). A11: slice 6, posterior lateral. A12: slice 7, anterior lateral. A13: slice 7, posterior lateral. A14: slice 7, anterior medial. A15: slice 7, posterior medial. A16: inferior margin, perpendicular sections. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and ""sentinel lymph node #1"" is a 2 x 1 x 0.8 cm lymph node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette B1. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. Received fresh labeled with the patient's identification and ""sentinel lymph node #2"" is a 1 x 0.8 x 0.5 cm lymph. node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette C1. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.1-CM. INTERMEDIATE NUCLEAR GRADE; DUCTAL CARCINOMA IN SITU, SOLID TYPE. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - FIBROADENOMA (0.2-CM). BIOPSY SITE CHANGES WITH FIBROSIS AND FOREIGN BODY GIANT CELL REACTION. - SEE SYNOPTIC REPORT. B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor. Absent. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1. 1cm. Margins: Negative. Distance from closest margin: 0.5cm. deep. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/2. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. DCIS Location:Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c N 0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: Right lateral breast 1.5-cm invasive breast cancer, posterior near fascia, fascia included with specimen. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A6. ER: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive. Allred Score: 4 = Proportion Score 2 +. Intensity Score 2. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score. (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than. or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochem was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100). provided by Dakc. following the manufacturer S instructions. This assay was not modified. Interpretation of the ER/PR immunohistocnemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 22. CLINICAL EXPERIENCE: Patients with a recurrence score of: 22 in the clinical validation study had an average. rate of Distant Recurrence at 10 years of 14%. ER Score: 11.1 Positive. PR Score: 4.4 Negative. Her2 Score: 10. Negative. Interpretation: ER Negative < 6.5 Positive >= 6.5. PR Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate (. ) report for further information. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist. Addendum: Pathologist,. Addendum Final: Pathologist,.",BRCA,0,"The report states 'Lymph node status: Negative 0/2.' This means that there is no metastasis found in the sentinel lymph nodes (0/2), which corresponds to N0 stage.",N0,22.0
1267,TCGA-E2-A574.F3FAB505-03FF-4FAA-ABB6-96AD20F47871,1,"SPECIMEN(S): A. PAPILLOMA MEDIAL LEFT BREAST. B. EXCISION LEFT BREAST CANCER. C. SENTINEL LYMPH NODE #1 LEFT AXILLA. D. SENTINEL LYMPH NODE #2 LEFT AXILLA. CLINICAL HISTORY: 1) Cancer 2 cm in axillary tail left breast. 2) Medial left breast mass - Papilloma by core biopsy. PRE-OPERATIVE DIAGNOSIS: None Given. INTRA-OPERATIVE DIAGNOSIS. B: Lumpectomy, left breast, excision; margins check: Mass is located 0.2 cm from the. posterior margin. Reported to Dr. by Dr. DIAGNOSIS: A. BREAST, LEFT MEDIAL, EXCISION: - INTRADUCTAL PAPILLOMA. - APOCRINE METAPLASIA AND COLUMNAR CELL CHANGE. - BIOPSY SITE CHANGES. - SURGICAL MARGINS NEGATIVE FOR TUMOR. B. BREAST, LEFT, EXCISION: - INVASIVE DUCTAL CARCINOMA, 2.3 CM IN GREATEST DIMENSION, SBR. GRADE 3. - SURGICAL MARGINS NEGATIVE FOR TUMOR. - BIOPSY SITE CHANGES. - SEE SYNOPTIC REPORT. C. LYMPH NODES, SENTINEL #1, LEFT AXILLA: - TWO LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/2). D. LYMPH NODES SENTINEL #2, LEFT AXILLA: TWO LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/2). SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: B: EXCISION LEFT BREAST CANCER. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.3cm. Additional dimensions: 2. 1cm x 2cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.3cm. deep. Tubular Score: 2. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/4. DCIS not present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2N0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. APILLOMA MEDIAL LEFT BREAST. Received fresh/in formalin labeled with the patient's identification and designated. ""papilloma medial left breast"" is an oriented (single anterior, double lateral, triple. superior), previously inked, 14 g, 4.3 x 3.2 x 2.1 cm needle localized excision. Ink code: anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from medial to lateral into 7 slices revealing firm,. focally hemorrhagic breast parenchyma. No lesions or nodules are grossly appreciated. Entirely submitted as per the attached diagram: A1: Perpendicular sections medial margin. A2-A3: Slice 2, bisected. A4-A5: Slice 3, bisected. A6-A7: Slice 4, bisected. A8-A9: Slice 5, bisected. A10-A11: Slice 6, bisected. A12-A13: Perpendicular sections lateral margin. B. EXCISION LEFT BREAST CANCER. Received fresh labeled with the patient's identification and designated ""excision left. breast cancer"" is an oriented (triple - superior, double - lateral, single - anterior), 46 g,. (Medial to lateral - 6.5 cm, superior to inferior - 5.4 cm, anterior to posterior - 3.5 cm). lumpectomy specimen. (The specimen is previously inked) Ink code: anterior-yellow,. posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is. serially sectioned from medial to lateral into 9 slices revealing a 2.3 x 2.1 x 2 cm, tan-. white to tan-pink, firm to hard mass that is closest to the posterior margin at 0.2 cm, in. slices 6 to 9. Tissue is procured. Representatively submitted in 18 cassettes as per the attached diagram: B1: slice 1 entire, perpendicular sections of the medial margin. B2: slice 2, representative anterior margin. B3: slice 3, representative posterior margin with the mass. B4-B5: slice 4, sections of the mass showing the closest posterior margin,. B6-B7: slice 5, mass with anterior and posterior margins. B8: slice 5, superior margin. B9-B10: slice 6, mass with anterior and posterior margins. B11: slice 6, inferior margin. B12-B13: slice 6, superior margin. B14-B15: slice 7, representative anterior and key and posterior margins. B16: slice 8, posterior margin. B17-B18: slice 9, lateral margin, perpendicular sections. C. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received in formalin with the patient's identification and designated ""sentinel lymph. node #1 left axilla"" is a 3.2 x 1.5 x 1.2 cm fibrofatty tissue within which 2 lymph nodes, 2. x 1.3 x 0.7 cm and 2.5 x 1.2 x 1 cm are identified. The lymph nodes are serially sectioned. and entirely submitted in 2 cassettes, C1-C2. D. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received in formalin with the patient's identification and designated ""sentinel lymph. node #2 left axilla"" is a 3.5 x 2.5 x 0.8 cm fibrofatty tissue within which 2 lymph nodes,. 1.2 x 1 x 0.5 cm and 0.5 x 0.4 x 0.3 cm are identified. The lymph nodes are serially. sectioned and entirely submitted in 2 cassettes, d1-D2.",BRCA,0,"The pathology report indicates that two sentinel lymph nodes from the left axilla were examined and both were negative for metastatic carcinoma (0/2). This corresponds to the N0 stage, which means there is no regional lymph node metastasis.",N0,23.0
1291,TCGA-E9-A1R7.FA19C3C4-E13B-464B-84CC-3AF7E83D5B9C,1,"DC ID: Gross Description: Lump with the tumor of 2.5 x 2.3 cm in size;. lymph nodes are soft, hyperemic, up to 1 cm in their largest dimension. Microscopic Description: Infiltrating duct carcinoma ; G2. Ten dissected lymph nodes demonstrate reactive changes. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 2.3 x 0x 2.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. "". Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",BRCA,0,"The report states that 10 dissected lymph nodes were examined and found to be negative for metastasis (Axillary 0/10). This indicates that there is no regional lymph node metastasis, which corresponds to N0 stage according to the rules.",N0,24.0
1056,TCGA-BH-A18N.60E8A9CF-3E2D-4E36-947D-448BA27C6561,1,"PATIENT HISTORY: DATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: CA L BREAST. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. Lt breast & axillary content. FINAL DIAGNOSIS: FINAL DIAGNOSIS: BREAST AND AXILLA, LEFT, MODIFIED RADICAL MASTECTOMY: - INFILTRATING DUCTAL CARCINOMA (""A2-A7""), 4.5 BY 4.5 BY 3.5 CM, NOTTINGHAM 6/9 (TUBULES 3, NUCLEI 2,. MITOSIS 1), WITH LYMPHOVASCULAR PERMEATION, INVOLVING THE DEEP DERMIS. DUCTAL CARCINOMA IN-SITU, SOLID TYPE, NUCLEAR GRADE 2, LESS THAN 1t. - MARGINS OF RESECTION ARE FREE OF TUMOR. - NIRPLE FREE OF TUMOR. TWO. OF. TWENTY-SIX (2/26) LEFT AXILLARY LYMPH NODES INVOLVED WITH TUMOR, LARGEST LYMPH NODE 2.3 CM IS. REPLACED BY TUMOR. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing was performed on block ""A6"". Cross. refer. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor. proteins is performed by the immunoperoxidase method, and reported according to the. consensus statement. on adjuvant therapy for breast cancer, of. A positive ER or PR tumo. anows any nuclear. immunostaining, and is semiquantitated as indicated below. Result Semiquantitative Statement. ER positive Percent cells staining as: (0- 0% 1+ 10%; 2+ 10%; 3+ 80%). PR positive Percent cells staining as: (0- or; 1+ or; 2+ 10%; 3+ 90%). HER-2/NEU - DAKO HERCEPTEST: A FAINT/BARELY PERCEPTIBLE MEMBRANE STAINING IS DETECTED IN MORE THAN 10% OF. THE TUMOR CELLS. THE CELLS ARE ONLY STAINED IN PART OF THEIR MEMBRANE. HER-2/NEU IS INTERPRITED AS NEGATIVE. (SCORE 1+). NOTE: The Her-2/NEU and estrogen assays were performed with FDA approved. methods The progesterone. receptor immunoperoxidase test used in this case has been developed and the performance characteristics. determined by the Department of Pathology at. They have not been. cleared or approved by the U.S. Food and Drug Actministration.",BRCA,1,"The report states that two out of twenty-six (2/26) left axillary lymph nodes were involved with tumor, which falls under the N1 category according to the rules: '2. N1: Metastasis in 1 to 3 axillary lymph nodes or in internal mammary nodes with clinically negative axillary nodes.' and '11. Metastasis in 1 to 3 axillary lymph nodes corresponds to N1 stage'.",N1,25.0
1504,TCGA-S3-AA12.9F96B0B1-2B88-49AE-8D3C-9FED70F1D950,2,"Surgica Pathology Final Report. Temporary Copy. los. Diagnosis. A. LEFT BREAST AND AXILLARY LYMPH NODES, MASTECTOMY AND. LYMPHADENECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 2, 9.0 CM IN GREATEST DIMENSION. - METASTATIC CARCINOMA ION TWO OF EIGHTEEN LYMPH NODES. - MARGINS OF RESECTION ARE NOT INVOLVED. - SEE SYNOPTIC REPORT AND NOTE. NOTE: biomarkers studies have been ordered and will be reported-in an addendum. B. SKIN OF LEFT BREAST, ADDITIONAL INFERIOR, EXCISION: - SEGMENT OF UNREMARKABLE SKIN. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 27 cm. Additional dimensions: 19 x 11 cm. SPECIMEN LATERALITY: Left. TUMOR SITE: INVASIVE CARCINOMA: Upper inner quadrant. Lower inner quadrant. Central. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 9.0 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma directly invades into the dermis or epidermis without skin ulceration. Nipple: DCIS does not involve the nipple epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative (small foci, less than 5% of the entire tumor). ARCHITECTURAL PATTERNS: Cribriform. Temporary Copy. NUCLEAR GRADE: Grade II (intermediate). NECROSIS: Not identified. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTLATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in. both size and shape. MITOTIC COUNT: Score 1. OVERALL GRADE: Grade 2: scores of 6 or 7. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 15 mm (deep fascial margin). Margins uninvolved by DCIS (if present). Distance from closest margin: 15 mm (deep fascial margin). LYMPH-VASCULARI INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Total number of lymph nodes examined (sentinel and nonsentinel): 16. Number of lymph nodes with macrometastases (>0.2 cm): 2. Size of largest metastatic deposit: 3.5 cm. EXTRANODAL EXTENSION: Not identified. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT3: Tumor >50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. MICROCALCIFICATIONS: Present in non-neoplastic tissue. CLINICAL HISTORY: Palpable mass. Specimen Source. A. LT Breast and Axillary Nodes. B. Additional Inferior Skin. Clinical Information. Temporary Copy. Patient with large mass upper Central breast, core biopsy positive. PRE-OP DIAGNOSIS: Left breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Left mass and axillary node dissection. Gross Description. The specimen is labeled ""LEFT BREAST AND AXILLARY NODES "" and is received in formalin. It consist. of mastectomy specimen with lymph nodes weighing 1330 grams and measuring 27 x 19 x 11 cm with brown. skin ellipse measuring 24 x 13 cm, containing grossly unremarkable 1.8 cm in diameter nipple. The posterior. margin is composed of smooth fascia which is inked black. Superior non-deep margin is inked with red ink and. the inferior non-deep margin is inked with blue ink. The breast is slices in sagittal planes revealing a large well. defined pink-tan lobulated mass measuring 9 x 7 x 6 cm and is located central portion of the breast and. extending upper inner and lower inner quadrant. This mass is 1.5 cm away from the deep fascial margin of. resection, 1.5 cm from the superior non-deep fascial margin and 2 cm from the inferior non-deep fascia margin. of resection. The remaining portions reveal unremarkable yellow mammary fat with streaks of white-gray. mammary parenchyma. The axillary fat pad measuring 10 x 10 x 5 cm. On sectioning multiple lymph nodes are. identified. The largest lymph node is consists of a 2 matted lymph nodes measuring 4 x 3 x 3 cm and is pink tan. and firm in consistency for 3.5 cm. Representative sections are submitted as follows: Al = nipple. A2-A5 = mass. A 6 = mass closest deep fascial margin of resection. A7 = representative sections upper outer quadrant. A8 = representative sections lower outer quadrant. A 9 = mass with closest skin surface. A 10 = six lymph nodes. A 11 = bisection of a single lymph node. A 12 = bisection of a single lymph node. A 13 = bisection of a single lymph node. A 14 = bisection of a single lymph node. A 15 = bisection of a single lymph node. A 16 = bisection of a single lymph node. A 17 = bisection of a single lymph node. A 18 = bisection of a single lymph node. A 19-A 20 = representative sections of 2 matted lymph nodes. Specimen is in formalin more than 6 hours and less than 48 hours. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 45 minutes. Special Stains / Slides. 23 H&E. Temporary Copy. Tissue Code. Addendum Report. Temporary Copy. Addendum Report. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA. ESTROGEN RECEPTORS: 99 %, positive, moderate staining intensity. PROGESTERONE RECEPTORS: <1 %, negative, moderate staining intensity. HER-2NEU: SCORE 1+, negative. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block A4) using the. following monocional antibodies: Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and. Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7, score. 1+. T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary antibodies,. reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in > 10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. (Electronic signature). Verified:",BRCA,1,"The report states that 'METASTATIC CARCINOMA IN TWO OF EIGHTEEN LYMPH NODES' which corresponds to the N1 stage as per rules 2, 11, and 12. The number of axillary lymph nodes with metastasis is between 1 and 3, which falls under the N1 category.",N1,26.0
1086,TCGA-BH-A1FU.58B02C83-2AF7-4978-A3F7-A8B9E0D914A1,0,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RIGHT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY. MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right breast measuring 18.0 by 17.0 by 5.2 cm with 16.0 by 6.3 cm skin and nipple and. partial axillary contents. A tan-white irregular mass measuring 1.8 by 1.0 by 1.2 Cm is identified 1.3 cm. from the deep resection margin. Mass lies in the center of the mass. FS Diagnosis: Infiltrating duct. carcinoma. ER/PRS taken. (1. Delow. FINAL DIAGNOSIS: RIGHT BREAST MASS AND AXILLARY CONTENTS: - MULTIFOCAL INVASIVE DUCTAL CARCINOMA, 1.8 BY 1.2 BY 1.0 CM., POOR NUCLEAR GRADE. - EXTENSIVE DUCTAL CARCINOMA IN-SITU, COMEDO TYPE. - VASCULAR PERMEATION SEEN. - SKIN, NIPPLE AND DEEP MARGINS FREE OF TUMOR. - FIVE (5) LYMPH NODES FREE OF TUMOR. - HEMORRHAGE AND HEMOSIDERIN LADEN MACROPHAGES CONSISTENT WITH BIOPSY SITES. - FIBROCYSTIC CHANGES. NOTE: Within the invasive tumor, the ductal carcinoma ;in-situ component is about 30%. S U P P L x M E N T R E P o R T. (HER2/NEU). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. AS PER THE REQUEST OF. OF THE. c-erb82 (HER-2/NEU). DMMUNOSTAINING IS CARRIED OUT ON PREVIOUS MAGKE SURGICAS. BBOCK ""A4"" (BREAST CANCER) USING A 1:300. DILUTION of DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erbB2) WITHOUT. ANTIGEN RETRIEVAL. DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED IN 90% OF TUMOR CELLS THEREFORE, c-. erbB2 (HER-2/NEU) IS INTERPRETED AS POSITIVE (SCORE 3+). SIGNED COPY ON FILE. s. (ER/PR). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. ""A4"". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED TOCALLY FOR PROGESTERONIS RECEPTOR (20%) BUT NOT FOR. ESTROGEN RECEPTOR. THEREFORE, PROGESTERONE RECEPTOR IS INTERPRITED AS BOR DERLINE AND ESTROGEN RECEPTOR AS. NEGATIVE.",BRCA,0,"The report states that five lymph nodes were found to be free of tumor. According to rule 1, N0 corresponds to no regional lymph node metastasis. Therefore, the N stage for this patient is N0.",N0,27.0
1036,TCGA-BH-A0HP.F13CE7B3-F275-4EEE-90A3-11B8B92FA431,2,"FINAL DIAGNOSIS: BREAST, LEFT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE LOBULARICARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR ATYPIA 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR INVOLVES ALL FOUR BREAST QUADRANTS, MEASURING 11.0 CM IN LARGEST. DIMENSION (GROSS MEASUREMENT). C. THE INVASIVE TUMOR FOCALLY POSITIVE IN DEEP MARGIN IN LOWER-INNER QUADRANT (SLIDE R). D. MICROCALCIFICATIONS ASSOCIATED WITH INVASIVE CARCINOMA. E. LOBULAR CARCINOMA IN-SITU, NUCLEAR GRADE 2, ADMIXED AND AWAY FROM INVASIVE COMPONENT. F. LOBULAR CARCINOMA IN-SITU IS 1.5 CM TO THE NIPPLE SURFACE. G. PAPILLOMA, FIBROCYSTIC CHANGE, AND COLUMNAR CELL CHANGE. H. EIGHT OF SEVENTEEN LYMPH NODES, POSITIVE FOR METASTATIC LOBULAR CARCINOMA (8/17). I. METASTATIC TUMOR MEASURES 1.5 CM IN LARGEST DIMENSION AND SHOWS EXTRACAPISULAR. EXTENSION. J. BIOPSY SITE CHANGES. K. INVASIVE TUMOR IS ER POSITIVE, PR NEGATIVE, AND HER-2/NEU NEGATIVE. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: PROCEDURE: Left. Modified radical mastectomy. Upper outer quadrant. Upper inner quadrant. Lower outer quadrant. SIZE OF TUMOR: Lower inner quadrant. MULTICENTRICITY/MULTIFOCALITY OF Maximum dimension invasive component: 11 cm. INVASIVE FOCI: TUMOR TYPE (invasive component): HISTOLOGIC TYPE: Infiltrating lobular carcinoma. ANGIOLYMPHATIC INVASION: Classical. DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Yes, malignant zones. LCIS. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: LYMPH NODES EXAMINED: Yes, focal. 17. METHOD(S) OF LYMPH NODE EXAMINATION: SENTINEL NODE METASTASIS: H/E stain. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pT3. M STAGE, PATHOLOGIC: pN2a. ESTROGEN RECEPTORS: pMX. PROGESTERONE RECEPTORS: positive. HER2/NEU: negative. zero or 1+.",BRCA,2,"The report states that 8 out of 17 examined lymph nodes are positive for metastatic lobular carcinoma. According to rule 11, metastasis in 1 to 3 axillary lymph nodes corresponds to N1 stage, and rule 12 states that N2 stage corresponds to metastasis in 4-9 axillary lymph nodes. Since there are 8 positive lymph nodes, which is more than 3 but less than 10, the N stage is N2a.",N2a,28.0
1436,TCGA-LL-A7SZ.3FA5FACA-8A6B-4F42-A557-3B69866859E7,1,"RUN DATE: RUN TIME. RUN USER: LOC: AGE/SX: ROOM: REG DR: BED: SPEC # : RECD: COLL: TIME IN FORMALIN: hrs. COLD ISCHEMA TIME: mins. CLINICAL INFORMATION: Pre-Op Diagnosis: Remarks: Specimen (s) : Left breast, stitch left axillary apex. MICROSCOPIC DIAGNOSIS. LEFT BREAST, SKIN-SPARING RADICAL MASTECTOMY: INVASIVE DUCTAL CARCINOMA, HIGH GRADE. NOTTINGHAM HISTOLOGIC SCORE. - GLANDULAR/TUBULAR DIFFERENTIATION SCORE 3. - NUCLEAR PLEOMORPHISM SCORE 3. - MITOTIC RATE SCORE 2. - OVERALL GRADE 3 (8 OF 9). MARGINS UNINVOLVED BY INVASIVE CARCINOMA. CARCINOMA IS 5.5 MM FROM THE CLOSEST MARGIN (POSTERIOR MARGIN). MINUTE FOCUS OF HIGH-GRADE DCIS PRESENT WITHIN AREA OF CARCINOMA (1 MM IN SIZE). LYMPH-VASCULAR INVASION IDENTIFIED. METASTATIC CARCINOMA INVOLVING TWO (2) OF ELEVEN (11) LYMPH NODES (2/11). LARGEST TUMOR DEPOSIT IS 14.5 MM. EXTRACAPSULAR EXTENSION IDENTIFIED. SEE SYNOPTIC REPORT. COMMENT(S). SURGICAL PATHOLOGY CANCER CASE SUMMARY - APPROVED BY. PROCEDURE: Total mastectomy, skin sparing. LYMPH NODE SAMPLING: Axillary dissection. SPECIMEN LATERALITY. Left. TUMOR SITE: Upper outer quadrant. HISTOLOGIC TYPE OF INVASIVE. CARCINOMA: Invasive ductal carcinoma. TUMOR SIZE: Greatest dimension of largest focus of invasion. 25 mm. Additional dimensions: 22 x 20 mm. HISTOLOGIC GRADE (NOTTINGHAM. HISTOLOGIC SCORE) : Glandular/tubular differentiation : score 3. Nuclear pleomorphism: score 3. RUN DATE: RUN TIME. RUN USER: SPEC #: COMMENT (S). Mitotic rate: score 2. Overall grade: grade 3. TUMOR FOCALITY: Single focus of invasive carcinoma. DUCTAL CARCINOMA IN SITU: DCIS is present. Estimated size of DCIS 1 mm. Architectural pattern: comedo. Nuclear grade: grade III. Necrosis: present, central. LOBULAR CARCINOMA IN SITU: Not identified. MARGINS. Invasive carcinoma : Margins uninvolved by invasive carcinoma. Distance from closest margin: 5.5 mm. posterior. DCIS: Margins uninvolved by DCIS. LYMPH NODES: Number of sentinel lymph nodes examined : 0. Total number of lymph nodes examined: 11. Number of lymph nodes with macrometastases: 2. Number of lymph nodes with ITC: 0. Size of largest metastatic deposit: 14.5 mm. Extranodal extension : present. Method of evaluation of sentinel lymph nodes. H&E. multiple levels. LYMPH-VASCULAR INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. PATHOLOGIC STAGING: Primary tumor pT2. Regional lymph nodes: pN1a. Distant metastasis: not applicable. ANCILLARY STUDIES: (RESULTS FROM CASE -. Estrogen Receptor positive (99% of tumor cells. with nuclear positivity). Progesterone Receptor: positive (99% of tumor. cells with nuclear positivity. Her2/neu: Immunoperoxidase studies negative (1+). GROSS DESCRIPTION: Received fresh is a skin-sparing left radical mastectomy weighing 756 grams and measuring. 27 cm from medial to the axillary tail. 18 cm from superior to inferior. and 2.5 cm. anterior to posterior. There is a linear portion of skin including nipple measuring 9 x. 2.1 cm. A mass is palpated in the lower portion of the upper outer quadrant . The deep. margin underlying this tumor is inked black. and the anterior margin is inked blue. A cut. is made from the posterior side. and a portion of tumor is given to the Tumor Bank. The. tumor measures 2.5 x 2.2 x 2.0 cm. It is firm with focal areas of hemorrhage. There is an. adjacent vell-circumscribed tan-white soft. freely mobile area measuring up to 4.5 cm in. greatest dimension. The carcinoma measures 0.8 cm from the posterior black-inked margin. and 0.9 cm from the anterior blue-inked margin. The other margins are greater than 3 cm. RUN DATE. RUN TIME: RUN USER: SPEC #. GROSS DESCRIPTION: (Continued). from the tumor including the nipple. The remainder of the breast is serially sectioned to. reveal no additional masses, cysts or other gross abnormalities There is a fat to fibrous. ratio. of up to 50:50. The most fibrotic areas are closest to the lateral quadrants,. particularly the upper outer quadrant . The detached axillary tail itself measures 13.2 x. 5.5 x 2.6 cm. Serial section reveals multiple lymph nodes, the largest of which measures. 2.2 x 1.5 x 1 cm. Sections are as follows: tumor as it most closely approximates the anterior margin. 2. tumor as it most closely approximates the posterior margin. 3. additional representative section of tumor. 4. representative section of fibrotic area adjacent to tumor. 5. representative section of nipple. 6-7. additional representative sections of very fibrotic areas in the. lateral quadrant. 8. representative sections of the medial quadrants. 9-10. multiple lymph nodes. 11-12. one lymph node each, bisected. PHOTO IXICUMENTATION. (signature on file).",BRCA,1,"The report states 'Number of lymph nodes with macrometastases: 2. Total number of lymph nodes examined: 11.', which indicates that the patient has metastasis in 2 out of 11 lymph nodes. This corresponds to N1 stage according to rules 2, 11, and 19.",N1,29.0
1067,TCGA-BH-A1EV.16DEA43F-4A61-44E3-854F-6B6575B45628,2,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: .1 nnDATE of LMP. DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: L BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: L NOD RAD WAT. CLINICAL HISTORY: MATERIAL SUEMITTED RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: CONSULT: Left breast tissue: Breast tissue with nipple/areola complex: Multilobed, diffuse breast mass. with. multifocal, individual firm secondary masses, malignant. Total dimension to be determined with gross. ADDENDA: Addendum. FINAL DIAGNOSIS: ER/PR. IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. ""A2"". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGKN RECEPTOR (90%) AND PROGESTERONE RECEPTOR. (40%) THEREFORE, BOTH ARE INTERPRETED AS POSITIVE. HER-2/NEU. c-erbB2 (HER-2/NEU) IMMUSTAINING IS CARRIED OUT ON SURGICAL. BLOCK ""A2"" (BREAST CANCER) USING A. 1:300 DILUTION OF DARO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN or c-erb82). WITHOUT ANTIGEN RETRIEVAL. DISTINCT COMPLETE MEMGRANE STAINING IS IDENTIFIED IN 30% or TUMOR CELLS. THEREFORE, c-erb82 (BER-2/NEU) IS INTERPRETED AS POSITIVE (SCORE 2+). My. signature is attestation that I have personally reviowed the submitted material(s) and the final. diagnosis reflects that evaluation. LEFT BREAST, MODIFIED RADICAL MASTECTOMY: INFILTRATING DAND INTRADUCTAL CARCINOMA OF THE BREAST, POOR NUCLEAR GRADE, 9 CM. - INTRADUCTAL CARCINOMA IS COMEDO-TYPE AND COMPRISES APPROXIMATELY 35% OF TUMOR VOLUME. - IN-SITU COMPONENT EXTENDS TO INVOLVE LARGE NIPPLE DUCTS. - NIPPLE SHOWING PAGST'S DISEASE. - TUMOR VASCULAR SPACE INVOLVING IS NOT PROMINENT. - SURGICAL MARGINS TREE OF TUMOR IN PLANES OF SECTION. - TUMOR INVOLVES ALL FOUR QUADRANTS, HOWEVER, RANDOM SECTIONS or QUADRANTS ARE NEGATIVE FOR TUMOR. - METASTATIC CARCINOMA INVOLVING THREE OF TEN (3/10) AXILLARY LYMPH NODES. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block ""A2"".",BRCA,1,The report states that metastatic carcinoma is found in three of ten (3/10) axillary lymph nodes. This corresponds to N1 stage according to rule 2: N1: Metastasis in 1 to 3 axillary lymph nodes or in internal mammary nodes with clinically negative axillary nodes.,N1,30.0
1231,TCGA-E2-A1B4.2F35A09A-7EB3-484C-9738-664C8914C116,0,"SPECIMENS: A. LEFT BREAST WLE NEEDLE LOCALIZATION. B. SLN #1. C. SLN#2. D. SLN #3. E. SLN #4. SPECIMEN(S): A. LEFT BREAST WLE NEEDLE LOCALIZATION. B. SLN #1. C. SLN#2. D. SLN #3. E. SLN #4. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A- left breast, WLE gross examination only: 1 cm tumor located 1 cm from the closest/posterior margin. called by Dr. to Dr. it. TPB/TPC/TPD/TPE-SLN #1, 2, 3, 4: No tumor cells seen by touch prep. Part D. contains only fat tissue. called by Dr. to Dr. at. GROSS DESCRIPTION: A. LEFT BREAST WLE NEEDLE LOCALIZATION. Received fresh with accompanying radiogram is an oriented 41 g lumpectomy specimen with. localization needle. The specimen is oriented with a single suture designating anterior, double lateral,. triple superior. The specimen measures 5.8 cm from anterior to posterior, 5.2 cm from superior to. inferior, and 2.8 cm from medial to lateral. Specimen is inked as follows: inferior-orange, superior-red,. lateral-yellow, anterior-blue, medial-green, posterior-black. Specimen is serially sectioned from superior. to inferior; there is a firm well-circumscribed white-tan nodule measuring 1 cm located 1 cm from the. nearest posterior and anterior margins, 1.8 cm from the lateral margin, 3.1 cm from the medial margin,. and greater than 3 cm from the superior and inferior margins. A gross diagnosis is conveyed to O. R. A. portion of the mass is submitted for tissue procurement. Specimen is submitted entirely as follows: A1-A3: superior margin perpendicular sections. A4: slice 2, medial. A5: slice 2, mid. A6: slice 2, lateral. A7: slice 3, medial. A8: slice 3, mid. A9: slice 3, lateral. A10: slice 4, medial. A11: slice 4, mid {lesion}. A12: slice 4, lateral. A13: slice 5, medial. A14-A15: slice 5, mid {lesion}. A16: slice 5, lateral. A17: slice 6, medial. A18: slice 6, mid-anterior {lesion}. A19: slice 6, mid-posterior {lesion}. A20: slice 6, anterior-lateral. A21: slice 6: posterior-lateral. A22: slice 7, medial. A23: slice 7, mid. A24: slice 7, lateral. A25-A26: inferior margin, perpendicular sections. B. SLN#1. Received fresh is a lymph node measuring 0.7 cm in diameter. One touch prep is performed. The. specimen is submitted entirely in cassette B1. C. SLN #2. Received fresh is one lymph node measuring 0.4 cm in diameter. A touch prep is performed. The. specimen is submitted entirely in cassette C1. D. SLN #3. Received fresh is a piece of fatty tissue measuring 0.5 x 0.3 x 0.3 cm. A touch prep is performed and. the specimen is submitted entirely in cassette D1. E. SLN #4. Received fresh is a lymph node measuring 0.4 cm in diameter. A touch prep is performed the specimen. is submitted entirely in cassette E1. DIAGNOSIS: A. BREAST, LEFT, WIDE LOCAL EXCISION: - INVASIVE, DUCTAL CARCINOMA, SBR GRADE 1, MEASURING 1.2-CM. - INVASIVE TUMOR PRESENT WITHIN 0.15-CM FROM MEDIAL SURGICAL. RESECTION MARGIN. - LOW TO INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU,. CRIBRIFORM TYPE. - DUCTAL HYPERPLASIA INVOLVING INTRADUCTAL PAPILLOMA. - SEE SYNOPTIC REPORTS SEE NOTE. B. LYMPH NODE, SENTINEL #1, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.5-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. C. LYMPH NODE, SENTINEL #2, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.6-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. D. LYMPH NODE, SENTINEL #3, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 2.0-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. NOTE: Two foci of intraductal papilloma with usual ductal hyperplasia are identified, one adjacent to the. invasive tumor and one at the posterior surgical resection margin. p63 and calponin mark the. myoepithelial cell layer in the papilloma. Dr. concurs on this interpretation. Micrometastases are identified in sentinel lymph nodes#1, #2 (AE 1/3 positive) and #4. The largest. tumor metastasis measures 2-mm. The touch preparations were reviewed, no tumor cells identified. Therefore, this discrepancy is due to sampling error. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.2cm. Tumor Site: Upper inner quadrant. Margins: Negative. Distance from closest margin: 0.15cm. medial. Tubular Score: 1. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 1. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Positive 3/4. Micrometastases: DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 5%. DCIS Type: Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. Location of CA++: DCIS. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative. Pathological staging (pTN): pT 1c N mi. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A18. ER: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by Dako. blowing the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A18. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 10%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved Dako HercepTest (TM) test kit (. C. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate,. well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the. joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in breast Cancer Task Force. The Pathology. Department takes full responsibility for this test's performance. CLINICAL HISTORY: Core biopsy proven cancer upper inner quadrant left breast. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 7. CLINICAL EXPERIENCE: Patients with a recurrence score of: 7 in the clinical validation study had. an average rate of Distant Recurrence at 10 years of 6%. ER Score: 11.1 Positive. PR Score: 8.9 Positive. Her2 Score: 9.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate. report for further information. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist.",BRCA,2,"The report indicates that there are metastases in 3 out of the 4 examined sentinel lymph nodes (SLN #1, SLN #2, and SLN #4) with the largest tumor metastasis measuring 2 mm. This corresponds to N1 stage according to the rules provided.",N1,31.0
898,TCGA-AR-A2LO.E5B6771D-450A-49AD-AEBC-7FC056BFCDBE,1,"Final Diagnosis. A. Breast, left, simple mastectomy: Infiltrating lobular carcinoma, Nottingham grade I (of III). [tubules 3/3, nuclei 1/3, mitoses 1/3; Nottingham score 5/9] is identified forming a mass (4.8 x. 2.7 x 1.9 cm) located in the lower outer quadrant of the breast. Biopsy site changes are present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. Lobular. carcinoma in situ is also present. All surgical resection margins, including the deep margin, are. negative for tumor (minimum tumor free margin, 0.3 cm, deep margin and 0.5 cm, superficial. margin). With available surgical material, the AJCC staging is pT2NXMX (see comment). B. Breast, right, simple mastectomy: Benign nonproliferative breast parenchyma. C. Lymph nodes, left axillary, lymphadenectomy: Multiple (14) lymph nodes are negative for. tumor. D. Lymph nodes, left lowest axillary, lymphadenectomy: Fibroadipose tissue, negative for. tumor. No lymphoid tissue identified.",BRCA,1,"The report states that multiple (14) lymph nodes were examined and found negative for tumor in the left axillary lymph nodes (C). Additionally, there is no mention of any metastasis in the lower left axillary lymph nodes (D) as they did not identify any lymphoid tissue. Therefore, the N stage is N0, which indicates no regional lymph node metastasis.",N0,32.0
1011,TCGA-BH-A0E1.891F4C63-8207-4CB8-AB59-A970CC6F1A1A,1,"P.24/33. FINAL DIAGNOSIS. PART 1: LEFT AXILLARY SENTINER. CARCINOMA, EACH DEPOSIT. A. TWO LYMPH. (274). MEASURING LESSTHAD. B. NO EXTRACAPSULARIEXTENSIS. PART 2: LEFT AXILLARY SENTINEL: #2, BIOPSY. TWO LYMPH NODES, NEGATIVE FOR NEOPLASM (0/2)-. PART 3: LEFT BREAST.TOTAL MASTECTOMY. A. INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (NUCLEAR GRADE 2, TUBULE SCORE 3. MITOTIC ACTIVITY SCORE 2; TOTAL SCORE 7/9). B. TUMOR MEASURES 4.5 CM IN GREATEST DIMENSION. C. LYMPHOVASCULAR SPACE INVASION IS PRESENT. D. TUMOR IS PRESENT IN THE LOWER INNER QUADRANT. E. MARGINS ARE NEGATIVE FOR NEOPLASM; TUMOR APPROACHES MOST CLOSELY TO THE ANTERIOR. MARGIN (1.5 MM). F. FIBROCYSTIC CHANGES. G. NIPPLE SKIN IS NEGATIVE FOR NEOPLASM. H. PATHOLOGIC STAGE: pT2 pN1mi pMX. CASE SYNOPSIS: SYNOPTIC . PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Simple mastectomy. Lower inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 4.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1.5 mm. LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 6. METHOD(S) OF LYMPH NODE EXAMINATION: H/F. stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 1 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN1mi. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,1,"The report states that 2 out of 6 examined lymph nodes are positive for metastasis, with the largest metastasis diameter being 1 mm. This corresponds to the N1 stage, as per rules 2, 5, and 19.",N1,33.0
1230,TCGA-E2-A1B1.431AE1CB-9605-45E3-B6C3-5253B24655D6,1,"SPECIMENS: A. SENTINEL LYMPH NODE 1. B. SENTINEL LYMPH NODE 2. C. SENTINEL LYMPH NODE 3. D. SENTINEL LYMPH NODE 4. E. SENTINEL LYMPH NODE 5. F. SENTINEL LYMPH NODE 6. G. SENTINEL LYMPH NODE 7. H. WLE LEFT BREAST. 1. ADDITIONAL MARGIN LEFT BREAST. DIAGNOSIS: SENTINEL LYMPH NODE, #1, EXCISION (PART A). - FRAGMENT OF FIBROADIPOSE TISSUE, NEGATIVE FOR MALIGNANCY, NEGATIVE FOR. LYMPHOID TISSUE. SENTINEL LYMPH NODE #2, EXCISION (PART B). - METASTATIC DUCTAL CARCINOMA (4 MM IN DIAMETER, FOCAL EXTRACAPSULAR. EXTENSION). SEE COMMENT. SENTINEL LYMPH NODES, #3-#7, EXCISION (PARTS C-G). - FIVE LYMPH NODES, NEGATIVE FOR MALIGNANCY (0/5). LEFI BREAST, WIDE LOCAL EXCISION (PART H). - WELL DIFFERENTIATED INFILTRATING DUCTAL CARCINOMA, WITH A MUCINOUS. COMPONENT (3.7 CM IN GREATEST DIAMETER, SBR GRADE T),. - SEE COMMENT. - SURGICAL MARGINS OF EXCISION, NEGATIVE FOR MALIGNANCY. LEFT BREAST, ADDITIONAL MARGIN, EXCISION (PART I). - FIBROGLANDULAR BREAST TISSUE, NEGATIVE FOR MALIGNANCY. SPECIMEN(S): A. SENTINEL LYMPH NODE 1. B. SENTINEL LYMPH NODE 2. C. SENTINEL LYMPH NODE 3. D. SENTINEL LYMPH NODE 4. E. SENTINEL LYMPH NODE 5. F. SENTINEL LYMPH NODE 6. G. SENTINEL LYMPH NODE 7. H. WLE LEFT BREAST. I. ADDITIONAL MARGIN LEFT BREAST. CLINICAL HISTORY: /r old white female abnormal mammogram left upper outer breast. Cone Biopsy shows well. differentiated infiltrating ductal carcinoma with mucinous features. ER+, Pr+ HER2+ by FISH. Right breast MRI showed mass at left upper outer quadrant 3x3x0.8cm. Second enhancing mass at. posterior aspect 7mm measurement. Questionable satellite lesion. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, TPB: Lymph nodes, left axillary sentinel 1 & 2, excision: No malignancy identified, specimen A is. predominantly fat. TPC, TPD: Lymph nodes, left axillary sentinel 3 & 4, excision: No malignancy identified. TPE, TPF, TPG: Lymph nodes, left axillary sentinel 5, 6 & 7, excision: No malignancy identified. By Dr. called in at. and. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE 1: - Received fresh for touch-prep and labeled, Sentinel Lymph Node #1, Left"" is a piece of adipose tissue. measuring 2.4x2x.4cm It is bisected and a touch-prep is performed. Specimen is submitted in toto in. block A1. B. SENTINEL LYMPH NODE 2: - Received in formalin and labeled ""Sentinel Lymph Node #2, Left Axilla"" is a lymph node with fat. measuring 2x3.5x1.1cm Bisected. A touch-prep is performed and lymph node is submitted in toto in. block B1. C. SENTINEL LYMPH NODE 3: - Received in formalin and labeled Sentinel Lymph Node #3, Left Axilla"" is a tan lymph node measuring. 1.3x1.2x0.6cm. Bisected and a touch-prep is performed. Submitted in toto in block C1. D. SENTINEL LYMPH NODE 4: - Received fresh for touch-prep and labeled, Sentinel Lymph Node #4, Left Axilla"" is a piece of yellow-. tan fat and a tan lymph node measuring 1.5x1.2x0.3cm. It is bisected and a touch-prep is performed. Specimen is submitted in toto in block D1. E. SENTINEL LYMPH NODE 5: - Received fresh for touch-prep and labeled, Sentinel Lymph Node #5, Left Axilla"" is a piece of fat and a. tan lymph node measuring 2.3x1.5x0.7cm. The specimen is serially sectioned and touch-prep is. performed. Lymph node is submitted in toto in block E1-E2. F. SENTINEL LYMPH NODE 6: - Received fresh for touch-prep and labeled, Sentinel Lymph Node #6, Left Axilla"" is a piece of yellow-. tan adipose tissue containing a lymph node measuring 1.5x0.7x0.5cm. The lymph node is bisected and. a touch-prep is performed. The lymph node is submitted in toto in block F1. G. SENTINEL LYMPH NODE 7: - Received fresh for touch-prep and labeled, Sentinel Lymph Node #7, Left Axilla"" is a piece of yellow-. tan fat containing a lymph node measuring 1.0x9.0x4cm. It is bisectioned and a touch-prep is. performed. Specimen is submitted in toto in block G1. H. WLE LEFT BREAST. - Received fresh and labeled, Wide Local Excision, Left Breast with Needle Localization"" is an oval. shaped piece of yellow-tan fibrofatty soft tissue weighing 161 grams and measuring 9.2x8.1x3.2cm. The specimen is received with an accompanying radiogram which shows a needle coursing from the. medial aspect to the lateral aspect. The needle is a stellate area of increased density and a surgical. clip is present. The specimen has been oriented in surgery with short designating superior long lateral. and looped anterior. Specimen is inked as follows: inferior-orange, superior-red, lateral-yellow,. anterior-blue, medial-green and posterior black. Specimen is serially sectioned from superior to inferior. and in the inferior aspect of the specimen is an irregularly shaped firm pink-tan mass measuring. 3.7x3.5x1.5cm. Areas of hemorrhage are seen. The mass is within 1. 1cm from the lateral margin,. 1.2cm from the anterior margin, 2.2cm from the medial margin, 1.7cm from the deep margin, 1.7cm. from the inferior margin and approximately 4.4cm from the superior margin. Superior and slightly. posterior from this mass is a firm tan nodule measuring 0.7cm which is located 0.8cm from the larger. mass. It is possible that it is a continuous mass located 1.2cm from the lateral margin, 3.7cm from the. anterior margin, 1.3cm from the posterior margin and 4.8cm from the medial margin. This mass. corresponds with the increased area of density and second needle localization which is present on the. radiogram which is shown superior to the larger mass. Representative sections are submitted as. follows: H1-H6 larger mass including adjacent margins; H7-H8 breast tissue between larger mass and. smaller mass; H9 smaller mass; H10-H13 additional fibrous breast tissue; H14 superior margin; H15. inferior margin. I. ADDITIONAL MARGIN LEFT BREAST: - Received in formalin and labeled Additional Margin Left Breast. This Marks New Inferior Margin"" is. an irregularly shaped piece of yellow-tan fibrofatty breast tissue measuring 4.7x4.7x0.8cm. There is a. stitch present marking the new inferior margin. The margin is inked blue and serially sectioned. On. sectioning little fibrous tissue is seen and no masses or lesions are found. Specimen is submitted in. toto in blocks I1-I10. COMMENT: Review of the original touch prep, for sentinel lymph node #2, shows a single minute focus of metastatic. tumor cells. The metastatic deposit in sentinel lymph node #2 measures 4mm in greatest diameter, and. shows approximately 1mm of extracapsular extension focally. Gross examination of the left breast wide. local excision shows an irregularly shaped 3.7x3.5x1.5cm lesion, which is grossly away from the. margins of excision. On gross examination, there is a separate firm nodule which measures 0.7cm in. diameter which is near the larger tumor mass. Examination of microscopic sections, in the intervening. breast between these two nodules, however shows continuity of the 2nd smaller nodule with the larger. mass, consistent with an irregular, dumbbell shaped single lesion. This patient had ER, PR and HER2. IHC performed on her prior needle core biopsy . These results were ER positive, PR positive and. HER2 was found to be amplified by FISH. Specimens Involved. Specimens: H: WLE LEFT BREAST. BREAST CANCER TEMPLATE. Specimen Type: Excision. Needle Localization: Yes. Laterality: Left. Invasive tumor: Present. Multifocality: No. Specimen size: Size of Invasive focus 3.7cm. Additional dimensions: 3.5cm x 1.5cm. Tumor Site: Upper outer quadrant). Margins: Negative. Distance from closest margin: 0.4cm. Margin: anterior. Tubular score: 1 (>75% tubule). Mitotic score (Olympus 40x): 1 (0-6/10 hpf). Modified Scarff Bloom Richardson Grade: I (3-5 points). Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Nuclear score: 2. Lymph nodes: Sentinel lymph node only. Lymph node status: Positive 1/6 Extranodal extension. DCIS PRESENT?. Pathological staging (pTN): pT 2N1. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation: PATHOLOGIST,. Final Review: PATHOLOGIST. Final Review: PATHOLOGIST. Final:PATHOLOGIST,.",BRCA,1,The pathology report indicates that there is metastatic ductal carcinoma in one of the sentinel lymph nodes (#2) with a 4 mm diameter and focal extracapsular extension. This corresponds to N1 stage according to the rules '2. N1: Metastasis in 1 to 3 axillary lymph nodes or in internal mammary nodes with clinically negative axillary nodes' and '11. Metastasis in 1 to 3 axillary lymph nodes corresponds to N1 stage'.,N1,34.0
941,TCGA-B6-A0WY.C0E92852-4146-468C-9713-2DE9C3316B9F,2,"surgical Pathology;. CLINICAL HISTORY: Breast lesion. GROSS EXAMINATION: A. ""Left breast excision, long lateral, short superior"", in formalin. The. specimen consists of a 9.5 x 8.8 x 2.3 cm sample of firm, white, fibroadipose. tissue with an attached skin ellipse measuring 4.8 x 0.7 cm. The skin. includes a 3.5 cm scar. The specimen is inked as follows: superior margin. blue; inferior margin black; deep surgical margin green. The specimen is. sectioned serially from medial to lateral revealing a firm, white, scirrhous. lesion diffusely involving the entire specimen and extending to all margins. There are focal areas of punctate hemorrhage and cyst formation. BLOCK SUMMARY: A1 representative sample of tissue from extreme medial portion of sample. A2-A6 representative slices of tissue through mid medial portion of sample. showing approach to all surgical margins, divided into five portions. A7-A11 representative slice of tissue taken from mid-lateral portion of. sample, showing approach to all surgical margins, divided into five portions. A12 representative sample of tissue taken from extreme lateral portion of. sample. B. ""Axillary dissection"", fresh. The specimen consists of a 7.5 x 7.0 x 2.0. cm sample of fibroadipose tissue. Several sutures are attached, however, the. specimen is unoriented. Twenty-one lymph node candidates were identified. within the samples. The largest measures 2.0 x 1.3 x 0.8 cm and is firm in. consistency. BLOCK SUMMARY: B1 five lymph node candidates. B2 eight lymph node candidates. B3 six lymph node candidates. B4 one (bisected) lymph node candidate. B5 one (bisected) lymph node candidate. Dr. REVISED DIAGNOSIS. A. ""LEFT BREAST EXCISION, LONG LATERAL, SHORT SUPERIOR"" (EXCISIONAL BIOPSY) : INFILTRATING ADENOCARCINOMA, HISTOLOGIC TYPE INFILTRATING DUCTAL. N.S.A.B.P. HISTOLOGIC GRADE, 2 TO 3, NUCLEAR GRADE, 2. GROSS TUMOR SIZE, 1.6 CM. SIZE OF INVASION COMPONENT, 1.5 CM. IN SITU CARCINOMA, PRESENT. OCCUPYING 10% OF TUMOR. EXTENSIVE INTRADUCTAL COMPONENT, NOT PRESENT. TYPE OF IN SITU CARCINOMA, SOLID. SURROUNDING NON-NEOPLASTIC BREAST TISSUE SHOWS DUCT ECTASIA INTRADUCTAL. PAPILLOMATOSIS, AND APOCRINE METAPLASIA. LYMPHATIC/VASCULAR INVASION, PRESENT AND EXTENSIVE. SURGICAL MARGIN STATUS, CLOSE MULTIFOCALLY WITH CARCINOMA MOST CLOSELY. APPROACHING SUPERIOR MARGIN. ALL MARGINS TECHNICALLY FREE OF MALIGNANCY. ESTROGEN/PROGESTERONE AND CELL CYCLE ANALYSIS PENDING, YES ON FRESH. TISSUE. B. ""AXILLARY LYMPH NODES"" (AXILLARY DISSECTION) : (umor sire. HITAA Primaty. (circie): 1 of 2. initinis. THREE OF TWENTY-ONE LYMPH NODE ARE POSITIVE FOR METASTATIC CARCINOMA. ONE LYMPH NODE SHOWS EXTRACAPSULAR EXTENSION. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). M.D. Pager#. ADDENDUM 1: Material was sent to. for assay of the. Progesterone receptors. The Estrogen receptor was judged as positive within an. estimated fmol valve of 20. The Progesterone receptor activity was judged as. negative with an estimated fmol valve of 4. Please refer to report. for more complete details. M.D. Pager#. 2 of 2.",BRCA,1,"The report states that 3 out of 21 lymph nodes are positive for metastatic carcinoma, which corresponds to N1 stage according to rule 11 and AJCC guidelines mentioned in rules 8 and 9.",N1,35.0
1333,TCGA-EW-A1IX.3CF4FC36-70EF-4EA3-874C-4A514FCDB717,0,"F. Pathologic Interpretation: A. Sentinel node #1 CT. -Metastatic carcinoma in one lymph node. Please see comment. Comment: The tumor is seen on deeper section. Tumor is not identified in frozen section slide. Immunostain for keratin Is used in the interpretation. B. Sentinel node#2. -No malignancy seen In one lymph node (0/1). -Imunostain for keratin is negative. C. Right breast: -Invasive tubulolobular carcinoma, low nuclear grade, Nottingham histologic score grade I. Resection margins are free of tumor. -Microcalcifications are present. Dr. concurs. Please see Tumor Summary. TUMOR SUMMARY: Specimen Type: Mastectomy. Lymph Node Sampling: Sentinel lymph node(s) only. Laterality: Right. Tumor Site: Upper inner quadrant. Size of invasive component: Greatest dimention: 1 cm. Additional dimensions: 1 x 0.6 cm. Histologic Type: Invasive tubulolobular. Histologic Grade: Nottingham Histologic Score: Tubule Formation: Moderate (score=2). Nuclear Pleomorphism: Small (score=1). Mitotic count: Less than 10 mitoses per 10 HPF (score =1). Total Nottingham Score: Grade I. Pathologic Staging: Primary Tumor: pT1b. Regional lymph nodes: pN1a. Distant Metastasis: pMX. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 4 mm. Specify margin: Deep (posterior). Venous/lymphatic: Absent. Comments: Tumor cells are positive for ER and PR and negative for Her2 and by immunohistochemistry. NOTE: Some immunohistochemical antibodies are analyte specific reagente (ASRs) validated by our laboratory (Her 2. Pervo, H. pylori, H8core). Thase ASRs are clinically useful indicators that. do. not require FDA approval. These clones are used: IDS-ER, POR 636-PR, A485-HER2. H-11=EGFR, CCH2/DOG9=CMV, F30.4 THAR and HPV by ISH. All immunohistochemical stains are used. with formalin or molecular fixed, paraffn embedded tiesue. Detection is by LSAB. The reaults are read by a pathologiet as positive or negative. SURGICAL PATHOL Report. As the attending patthologist, / attest that I: (i) Examined the relevent. preparation(s) for the specimen(s); and ("") Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. C. The tumor cells are positive for E-Cadherin by immunohistochemistry. This immunophenotype is most consistent with an infiltrating ductal carcinoma. Intraoperative Consultation. AFS: No malignancy seen in one lymph node examined. BFS: No malignancy seen in one lymph node examined. Clinical History: Patient is a -year-old female with right breast cancer. Pre Operative Diagnosis: Not Provided. Specimen(s) Received: A: sentinel node #1 CT (. B: sentinel node#. C: right breast ( 1 suture superior, 2 sutures lateral ). Gross Description: A. Received fresh and labeled ""sentinel node #1 CT. )"" is a fragment of adipose tissue measuring 2.0 x 1.0 x 0.5 cm. The lymph node is bisected and submitted in toto for frozen section. B. Received fresh and labeled ""sentinel node#. is a fragment of adipose tissue measuring 0.6 x 0,5 x 0.5 cm. The. lymph node is bisected and submitted in toto for frozen section. C. Received in formalin and labeled ""right breast (1 suture superior, 2 sutures lateral)"" is oriented with one suture superior. and two sutures lateral. The specimen weighs 127.0 grams and measures 16.0 x 11.0 x 0.9 cm. The specimen consists. of a nipple and areola, which measures 3.3 x 2.5 cm. There is no retraction or scar. The specimen is inked as follows: superior, blue; inferior, green; medial, red; lateral, orange; posterior (tip), black; anterior, yellow. Cut section revealed a. scar-like, firm lesion is identified in the upper inner quadrant, which measures 1.0 x 1.0 x 0.6 cm. It is located 0.4 cm from. the deep margin, 2.0 cm from the superior margin, 3.0 cm from the medial margin, and 6.2 cm from the inferior margin. The stroma to fat ratio is 70:30. No other masses or lesions are identified. Sections are submitted as follows: 1-4. Mass in toto. 5. Upper inner quadrant. SURGICAL PATHOL Report. 6. Lower inner quadrant. 7. Upper outer quadrant. 8. Lower outer quadrant. 9. Nipple. ICD-9(s): 196.3 174.2.",BRCA,1,"The pathology report states that there is metastatic carcinoma in one sentinel lymph node (1/1). This corresponds to the N1 stage, as per rule 2 and rule 19.",N1,36.0
1006,TCGA-BH-A0DT.C0AFC806-9F96-484F-BF40-89B26ABF8714,0,"P.16/33. and DIAGNOSIS: PART 1: LYMPH NODE, RIGHT SENTINEL NUMBER 1. BIOPSY -. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN ONC LYMPH NODE (0/1). PART 2: LYMPH NODE, RIGHT SENTINEL NUMBER 2, BIOPSY. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN ONE LYMPH NOUE (0/1). PART J: BREAST, RIGMT, TOTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA. D. NOTTINGHAM GRADE 1 (TUBULE FORMATION 2, NUCLEAR PLEOMORPHISM 2, MITOTIC ACTIVITY 1;. TOTAL SCORE 5/9). C. INVASIVE TUMOR MEASURES 1.2 CM IN MAXIMUM DIMENSION (SLIDE 3F). D. DUCTAL CARCINOMA IN SITU (DCIS). NUCLEAR GRADE 1, CRIBRIFORM PATTERN. E. DCI9 CONSTITUTES 10% OF THE TOTAL TUMOR MASS AND 18 PRESENT ADMIXED WITH AND AWAY. FROM THE INVASIVE COMPONENT. r. LOBULAR CARCINOMA IN SITU (LCIS) IS ALSO IDENTIFIED. G. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. H. INVASIVE CARCINOMA EXTENDS FOCALLY TO THE ANTERIOR MARGIN (SLIDE 3E). I. NIPPLE IS NEGATIVE FOR TUMOR. J. ATYPICAL DUCTAL HYPERPLASIA. K. ATYPICAL LOBULAR HYPERPLASIA,. L THE NON-NEOPLASTIC BREAST SHOWS FIBROADENOMA FORMATION. M. PREVIOUS BIOP8Y BITE CHANGES. PART 4: LYMPH NODE, RIGHT SENTINEL NODE NUMBER 3. BIOPSY -. METASTATIC INFILTRATING DUCT CARCINOMA: 4.0 MM MAXIMUM METASTASIS DIMENSION WITHOUT. PERICAPSULAR INVASION, INVOLVING ONE LYMPH NODE (1/1). PART 5: LYMPH NODE, RICHT SENTINEL NODE NUMBER 4. BIOPSY -. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN ONE LYMPH NODE (0/1). PART 6: AXILLARY CONTENTS, RIGHT, DISSECTION -. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN FOURTEEN I.MMPH NODES (0/14). CASE SYNOPSiS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Simple mastectomy. Not specified. SIZE OF TUMOR: Maximum dimension invasive component 1.2. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invesive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. ubule formation 2. Mitolic activity acore. 1. Total Nottingham sexte: 5. Nollingham grade (1,2,3). 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASIÃN: CALCIFICATION: TUMOR TVPE, IN SITU: Cribriform. LCIS. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Yes, fincal. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPM NODES POSITIVE: 1. LYMPH NODES EXAMINED: 18. METHOD(S) OF LYMPH NODE CXAMINATION. H/E Mair. SENTINEL NODE METASTA9IS: SIZE OF NODAL METASTASES: Diameter of largost lymph node 4 u mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: INVOLVED. NON-NEOPLASTI BREAST TIBSUE: AUII, ALH,. T STAGE, PATHOLOGIC: pTic. N STAGE, PATHOLOGIC: pN1. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: RECEPTORS: HER2/NEU: zero or 1. Tumor. Noted. (circia): Initials.",BRCA,1,"Based on the pathology report, there is metastatic infiltrating duct carcinoma in one sentinel lymph node (1/1) with a maximum metastasis dimension of 4.0 mm and no pericapsular invasion. This indicates that the patient has metastasis in 1 to 3 axillary lymph nodes, which corresponds to N1 stage according to the rules.",N1,37.0
902,TCGA-AR-A5QN.A9015F6A-F6BB-4AC8-B681-099232A6DFAC,1,"A. Lymph nodes, left tracheoesophageal groove, excision: Multiple (3) lymph nodes are. negative for tumor. B. Thyroid, left, total lobectomy: Follicular adenoma (3.3 x 3.2 x 1.8 cm). C. Breast, right, simple mastectomy: Fibroadenoma measuring 0.7 x 0.6 x 0.5 cm at the previous. biopsy site in the upper outer quadrant. Remainder shows non-proliferative fibrocystic changes. Multiple (2) right axillary lymph nodes are negative for tumor. D. Breast, left, inferior flap, biopsy: Negative for tumor. E. Breast, left, inferior margin at 6 o'clock, excision: Involved by carcinoma. F. Breast, left, new inferior margin, re-excision: Negative for tumor. G. Breast, left, modified radical mastectomy: Invasive lobular carcinoma, Nottingham grade II. (of III), [tubules 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 6/9], forming multiple (6) masses. (lower inner quadrant, 0.7 x 0.6 x 0.4 cm and 1.4 x 1.0 x 0.5 cm; inferior/central, 3.2 x 2.2 x 1.4. cm; central, 0.6 x 0.5 x 0.5 cm; lower outer quadrant, 1.0 x 0.8 x 0.8 cm and 0.5 x 0.4 x 0.4 cm). in the left breast. Ductal carcinoma in situ and lobular carcinoma in situ are present. The non-. neoplastic breast parenchyma shows nonproliferative fibrocystic changes. A second core biopsy. site is present in the upper outer quadrant which shows biopsy site changes. The tumor does not. involve the nipple, overlying skin, or underlying chest wall. Dermal nevus forming a 1.5 x 1.3 x. 0.3 cm raised, brown, pigmented lesion on the lateral aspect of the skin. All surgical resection. margins, after multiple (2) re-excisions of the inferior margin (see parts E and F), are negative for. invasive carcinoma by 1.2 cm, deep margin. Multiple (10 of 19) left axillary lymph nodes are. positive for metastatic carcinoma. The largest metastasis measures 11.0 mm. Extranodal. extension is not present. MIB-1 has been ordered on paraffin-embedded tissue. This final pathology report is based on the gross/macroscopic examination and the frozen section. histologic evaluation of the specimen(s). Hematoxylin and Eosin (H&E) permanent sections are. reviewed to confirm these findings. Any substantive changes identified on permanent section. review will be reflected in a revised report.",BRCA,3,"The report states that 10 out of 19 examined left axillary lymph nodes are positive for metastatic carcinoma, which corresponds to the N2 stage based on rule 12: N2 stage corresponds to metastasis in 4-9 axillary lymph nodes.",N2,38.0
1101,TCGA-BH-A6R9.1DB8FAFB-FC4A-4401-8316-30FB5352335D,1,"FINAL DIAGNOSIS: BREAST, LEFT, TOTAL MASTECTOMY (120.1 GRAMS) -. A. METAPLASTIC CARCINOMA OF THE BREAST, SPINDLE CELL TYPE, NOTTINGHAM GRADE II (TUBULE. FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 1; TOTAL SCORE 7/9). B. THE INVASIVE TUMOR MEASURES 3.8 CM IN GREATEST DIMENSION. C. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. D. INKED MARGINS ARE NEGATIVE FOR CARCINOMA; HOWEVER, A FOCUS OF INVASIVE CARCINOMA IS LESS. THAN 1.0 MM (LESS THAN 0.1 CM) FROM THE ANTERIOR INKED MARGIN. E. THE INVASIVE CARCINOMA IS LOCATED IN THE CENTRAL AREA. F. THE NIPPLE DERMIS AND ADJACENT SKIN DERMIS, BUT NOT THE EPIDERMIS, ARE INVOLVED BY INVASIVE. CARCINOMA. G. NIPPLE DUCTS WITH SQUAMOUS METAPLASIA. H. PREVIOUS BIOPSY SITE CHANGES. I. THE INVASIVE TUMOR CELLS ARE NEGATIVE FOR ESTROGEN RECEPTOR, WEAKLY POSITIVE FOR. PROGESTERONE RECEPTOR, AND NEGATIVE FOR HER-2, AS PER PREVIOUS PATHOLOGY REPORT. (see comment). J. NON-NEOPLASTIC BREAST WITH RADIAL SCARS. COMMENT: Due to the weakly positive PR result on the core biopsy based on stains performed at. hormone. receptor immunohistochemistry will be repeated and an addendum will follow. Addendum. BREAST TUMOR IMMUNOHISTOLOGY RESULTS. HORMONE RECEPTOR IMMUNOHISTOCHEMISTRY. H SCORE. RAW IMMUNOSTAINING SEMIQUANTITATION. ER: Weakly positive. 10. (0: 91%; 1+: 8%; 2+: 1%; 3+: 0%). PR: Negative. o. (0: 100%; 1+: 0%; 2+: 08; 3+:0%). ESTROGEN/PROGESTERONE RECEPTORS (ER/PR) TEST DETAILS: Using formalin fixed tissues (8-96 hours) and appropriate. positive and negative internal/external controls; the test for the presence of hormone receptor protein is performed by the. immunoperoxidase method according to the ASCO-CAP Guidelines. A positive Estrogen or Progesterane receptor tumor shows. nuclear immunostaining in greater than or equal to 1% of the tumor cells (i.e. and H-score of 1 or higher). The ER and PR. Histologic Score (H-Score, or HS) is calculated as the sum of intensity of staining times the proportion of cells staining and has a. dynamic range of 0 to 300. The semiquantitation immunostaining raw data used to calculate the H-score is also shown above in. the report. Generally, the H-score correlates to percentage of positive cells. According to. the correlation of mean H-score versus percent cells staining for ER is as follows: H-score of 251 (>75% cells staining); H-. score of 130 (51-75% cells staining); H-score of 42 (10-50% cells staining); H-score of 4 (<10% cells staining). Estrogen receptor antibody SP1, an IVD, is performed using the. Progesterone receptor antibody 1E2, an IVD, is performed using the. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Simple mastectomy. Central subareolar. SIZE OF TUMOR: Maximum dimension invasive component: 38 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Metaplastic carcinoma. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMALLYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES EXAMINED: 0. METHOD(S) OF LYMPH NODE EXAMINATION: Other: None. SKIN INVOLVED (ULCERATION): T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pNX. M STAGE: Not applicable. ESTROGEN RECEPTORS: negative. PROGESTERONE RECEPTORS: positive, H-score: 60. HER2/NEU: 0. MICROSCOPIC: Block 1B: Antibody/Antigen. Vimentin. Positive. S-100. Rare weakly positive cells. CK5. Positive. AE1/AE3. Weakly positive. CK17. Positive. P63. Positive. CK14. Positive. Block 1C: Antibody/Antigen. P63. Highlights tumor cells and myoepithelial cells. Smooth muscle myosin heavy chain Highlights myoepithelial cells. Utilizing formalin-fixed (8-96 hour range), paraffin embedded tissue, immunohistology is. performed with the following selected antibodies and designated antibody clone (s), directed. against the following antigenic target (s), with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENDOR. Vimentin. V9. Mesenchymal cells. S-100. Polyclonal Rabbit. Melanoma screen. CK 5. XM26. High molec wt keratin. AE1/AE3. AE1/AE3. carcinomas. CK 17. E3. High molec wt keratin. p63. 4A4. Myoepithelial cells. CK 14. LL002. High molec wt keratin. Myosin. SMMS-1. Myoepithelial cells.",BRCA,0,"The pathology report does not provide any information about lymph node metastasis, except for 'LYMPH NODES EXAMINED: 0'. Therefore, we cannot determine the N stage based on the given report.",N0,39.0
1395,TCGA-GM-A4E0.DB0291E6-E371-40F8-BDB3-0F85F015B3DE,2,"DIAGNOSIS. (A) LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY: METASTATIC CARCINOMA IN ONE LYMPH NODE. LYMPH NODE METASTASIS MEASURES 7.0 MM IN GREATEST MICROSCOPIC DIMENSION. EXTRANODAL EXTENSION IS PRESENT AND MEASURES 2.0 MM IN GREATEST DIMENSION. CYTOKERATIN IMMUNOSTAINING ON REPRESENTATIVE SECTION CONFIRMS THE PRESENCE OF. METASTATIC CARCINOMA. (B) LEFT BREAST, MASTECTOMY: INVASIVE LOBULAR CARCINOMA, MODIFIED BLACK'S NUCLEAR GRADE 1-2 (LOW TO INTERMEDIATE. GRADE) WITH FOCAL SIGNET RING CELL FEATURES. L 9% signate ring pw TSS . INVASIVE CARCINOMA INVOLVES AN AREA OF APPROXIMATELY 8.5 CM IN THE LATERAL ASPECT. Definitive lymphovascular invasion is not identified. A SMALL FOCUS OF INVASIVE CARCINOMA IS PRESENT 8.0 MM FROM THE INFERIOR MARGIN. Other resection margins widely free of tumor. Stromal fibrosis, columnar cell change and cysts. Nipple skin with basaloid follicular hamartoma; no carcinoma identified. (C) LEFT AXILLARY CONTENTS, DISSECTION: METASTATIC CARCINOMA IN NINE OF TWENTY-ONE LYMPH NODES. LARGEST LYMPH NODE METASTASIS MEASURES 5.0 MM IN GREATEST MICROSCOPIC DIMENSION. Focal extranodal extension is present. Entire report and diagnosis completed by. GROSS DESCRIPTION. (A) LEFT AXILLARY SLN #1, BLUE IN VIVO 13, EX VIVO 31 - One blue lymph node 3.0 x 2.0 x 0.7 cm. Serially sectioned and. entirely submitted in A1-A3 for frozen evaluation (A1, suture to hot spot). FS/DX: METASTATIC CARCINOMA. (B) LEFT BREAST - A total mastectomy specimen 26.0 X 21.0 x 8.5 cm with white-tan skin (26.0 x 17.5 cm and nipple 1.2 cm in. diameter). The specimen is oriented with stitch at 12 o'clock. The superior margin inked blue, inferior margin inked orange, deep. margin inked black. The specimen is serially sliced from medial to lateral in twelve slices and nipple at slice #4. An irregular tumor. 8.5 x 4.5 x 2.0 cm is identified in the lateral portion (slice #7-slice #9). The tumor is 2.0 cm to the inferior margin, 5.0 cm to the. superior margin and 6.0 cm to the deep margin. SECTION CODE: B1, B2, nipple B3, tissue adjacent to the tumor from slice #6; B4-B6, tumor from slice #7 from superior. to inferior; B7-B12, tumor and margins from slice #8 (B7-B10, tumor from superior to inferior); B11, inferior margin; B12 (deep. margin); B13-B17, tumor and inferior margin from slice #9; from superior to inferior (B17 including inferior margin); B18, tissue. adjacent to the tumor from slice #10; B19, representative section from upper inner quadrant including superior margin; B20,. representative. section from lower inner quadrant including inferior margin; B21, fibrous tissue from upper outer quadrant with. superior margin from slice #5; B22, fibrous tissue from upper outer quadrant with superior margin from slice #6; B23,. representative section from lower outer quadrant including inferior margin. (C) LEFT AXILLARY CONTENTS - Adipose tissue (11.0 x 5.5 X 2.5 cm). Twenty-two lymph nodes are identified, ranging from. (0.2 x 0.2 x 0.2 cm to 4.5 x 1.5 X 1.0 cm). SECTION CODE: C1-C3, each cassette containing six lymph nodes; C4, three lymph nodes; C5-C9, one lymph node,. serially sectioned. NICAL HISTORY. Left breast cancer. CONSULTANT(S). SNOMED CODES. T-04050, M-85203, T-C4710, M-85206. ""Some tests reported here may have been developed and performance characteristics determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration."". Released by:",BRCA,3,"The report states that there is metastatic carcinoma in nine of twenty-one lymph nodes, which falls within the criteria for N2 (metastasis in 4-9 axillary lymph nodes).",N2,40.0
1104,TCGA-BH-A8G0.22134EA5-5ED5-47B8-9A33-01E59E58B54C,1,"FINAL DIAGNOSIS: PART 1: LEFT AXILLA, SENTINEL LYMPH NODE #1, EXCISION -. ONE LYMPH NODE,. POSITIVE FOR. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #2, EXCISION -. METASTATIC CARCINOMA (1/1). Carcinorna, soluular initiating 0852013. ONE LYMPH NODE, POSITIVE FOR METASTATIC CARCINOMA (1/1). PART SENTINEL LYMPH NODE #3, EXCISION. 3: ONE LEFT LYMPH AXILLA, NODE, POSITIVE FOR METASTATIC CARCINOMA - (1/1). Sute L. PART 4: LEFT NIPPLE, POSTERIOR, BIOPSY -. A. ATYPICAL LOBULAR HYPERPLASIA. B. NO INVASIVE CARCINOMA PRESENT. PART 5: LEFT BREAST, NIPPLE SPARING MASTECTOMY -. A. INVASIVE LOBULAR CARCINOMA, CLASSICAL TYPE, 2.5 x 1.5 x 1.2 CM ASSOCIATED WITH. MICROCALCIFICATIONS. B. NOTTINGHAM GRADE 2 (TUBULES 3, NUCLEAR PLEOMORPHISM 2, MITOTIC ACTIVITY 1; TOTAL SCORE. 6/9). C. LOBULAR CARCINOMA IN-SITU (LCIS) WITH PAGETOID EXTENSION INTO DUCTS AND ASSOCIATED. MICROCALCIFICATIONS. D. NO LYMPHOVASCULAR SPACE INVASION IDENTIFIED. E. SURGICAL MARGINS NEGATIVE. F. INVASIVE TUMOR IS 0.3 CM FROM ANTERIOR MARGIN. G. INVASIVE TUMOR IS LOCATED AT JUNCTION BETWEEN UPPER/OUTER AND UPPER/INNER QUADRANTS. H. SUBAREOLAR TISSUE INVOLVED BY LCIS, BUT NEGATIVE FOR INVASIVE CARCINOMA. I. CHANGES CONSISTENT WITH PREVIOUS CORE BIOPSIES. J. FIBROCYSTIC CHANGES WITH FOCAL APOCRINE METAPLASIA. K. FIBROADENOMATOUS CHANGES. L. UNREMARKABLE SKELETAL MUSCLE. M. BENIGN EPITHELIAL CALCIFICATIONS. N. THE INVASIVE TUMOR CELLS WERE REPORTED TO BE POSITIVE FOR ESTROGEN RECEPTORS, POSITIVE. FOR PROGESTERONE RECEPTORS, AND NEGATIVE FOR HER-2, WITH A KI-67 PROLIFERATION INDEX OF. 1%, AS PER PREVIOUS PATHOLOGY REPORT. CASE SYNOPSIS: SYNOPTIC . PRIMARY INVASIVE CARCINOMA OF BREAST. LATERA. JTY: Left. PROCEDURE: Simple mastectomy. Upper outer quadrant. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 25 mm. MULTICENTRICITY/MULTIFOCALTY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Infiltrating lobular carcinoma. HISTOLOGIC TYPE: Classical. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: LCIS. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 3 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 3. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain, Keratin stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 7 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: NON-NEOPLASTIC BREAST TISSUE: ALH, FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 1+.",BRCA,1,"The pathology report states that there are 3 sentinel lymph nodes excised, and all 3 nodes are positive for metastatic carcinoma. This corresponds to N1 stage based on the rules provided.",N1,41.0
1494,TCGA-PL-A8LV.D35DBECD-5241-4562-85CC-2822BB338279,3,"Sex: Female. Date of Tumour Procurement: 1. GROSS ASSESSMENT: Cut section showed a variegated tumour. 5x3x2cm,. No lymph nodes. 2. MICROSCOPIC ASSESSMENT. Microscopic description: Section shows a necrotic and invasive tumour growing in. trabecular, cords, syncytium, solid nests and trabecular patterns. It is composed of large. cells having pleomorphic hyperchromatic nuclei and amphophilic cytoplasm. The stroma. is desmoplastic containing similar tumour cells and aggregates of lymphocytes. 3. Tumour Type: Malignant. 4. Tumour Site: Right Breast. 5. Distance of invasive carcinoma to closest margin: 3mm. Which margin? Deep resection. 6. HISTOLOGICAL DIAGNOSIS: Medullary Adenocarcinoma. 7. COMMENTS: Nuclear score:3, Pathological TNM stage: pT2. Dr. Reporting Pathologist Name.",BRCA,0,"The pathology report does not provide any information about lymph node metastasis, only the T stage (pT2) is mentioned. Therefore, based on rule 17, the N stage cannot be determined without lymph node information. However, the absence of lymph node metastasis information is often assumed to be negative, so the N stage is most likely N0.",N0,42.0
1338,TCGA-EW-A1J3.79C0D757-50BE-4375-AF69-E577629EE0CA,0,"0. Pathologic Interpretation: A. Left axiliary lymph node biopsy. - One lymph node (1) negative for carcinoma. - Immunohistochemistry for keratin is negative. B. Left axiliary lymph node biopsy (. Path Site : bruest, lowro outer quadrant 250.5 2/9/11. - One lymph node (1) negative for carcinoma. Immunohistochemistry for keratin is negative. C. Left axiliary lymph node biopsy l. - One lymph node (1) negative for carcinoma. Immunohistochemistry for keratin is negative. D. Left breast mastectomy: INVASIVE CARCINOMA, with lobular features, moderately differentiated Nottingham grade 2 (3 + 3 + 1= 7),. largest extent of tumor grossly measuring 2.0 cm (see note). IN SITU CARCINOMA, with lobular features, high nuclear grade, central comedo necrosis and calcifications is. present in 4 out of 12 slides (see note). Biopsy site is present. - Margins negative for in situ and invasive carcinoma. - No lymphovascular invasion is present. - Immunohistochemical results: Estrogen receptor: Positive. Progesterone receptor: Positive. HER-2: Positive (3+). E-Cadherin: Negative. Note: This is an unusual neoplasm with morphologic features of a lobular in situ and invasive carcinoma that is E-. cadherin negative, with high nuclear grade and necrosis, and positive HER-2. The biological behavior and clinical. course. of such neoplasms, which are sometimes referred to as Pleomorphic Lobular Carcinoma, may be similar to ductal. carcinomas. Surgical Pathology Tumor Summary. Specimen: Total breast. Procedure: Total mastectomy. Lymph node sampling: Sentinel lymph node. Specimen Integrity: Single intact specimen. Specimen Laterality: Left. Tumor Site: Lower outer quadrant. Tumor Size: Greatest dimension of largest focus of invasion over 0.1 cm: 2.0 cm. Tumor Focality: Single focus of invasive carcinoma. Skin: Invasive carcinoma does not invade into the dermis or epidermis without skin. Skeletal muscle: No skeletal muscle present. Lobular carcinoma in situ: Present. Histologic Type of Invasive Carcinoma: Invasive carcinoma with lobular features. Glandular (Acinar)/Tubular Differentiation: Score 3<10% of the tumor are forming glandular/tubular structures. Nuclear Pleomorphism: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in. In size and shape, occasionally with very large and bizarre forms. Mitotic count: Score 1. Overall grade: Grade 2: scores of 6 or 7. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1.2 cm from deep margin. Lymph-vascular invasion: Not identified. Lymph nodes: Number of sentinel lymph nodes examined: 3. SURGICAL PATHOL Report. Total number of lymph nodes examined (sentinel and nonsentinel): 3. Number of lymph nodes with isolated tumor cells (<0.2 mm and <200 cells): 0. Size of largest metastatic deposit (if present): 0. Extranodal extension: Not identified. Method of evaluation of sentinel lymph nodes: Immunohistochemistry (pending). Pathologic staging: pT1c: Tumor >10 mm but <20 mm in greatest dimension. pNO: (i+): Malignant cells in regional lymph nodes no greater than 0.2 cm and no more than 200 cells (detected by|H & E or IHC. including ITC). Distant Metastasis: Not applicable. Estrogen Receptor: Performed on this specimen. Results: Immunoreactive tumor cells present (>1%). Progesterone Receptor: Performed on this specimen. Results: Immunoreactive tumor cells present (>1%). HER2/neu: Performed on this specimen. Results: Positive (Score 3+). Microcalcifications: Present in situ carcinoma. NOTE: Some antibodies are amalyte specific reagents (ASRs) validated by ow labormary. These ASRs are clinically aseful indicators that do not require FDA approval. These clons are. ID5-ER PgR 636=PR,A485 HER2, H-II-EGFR All stains are used with formalin or molecular fixed, paruffin embeckded tissue. Detection is by Envision Method. The results are read by a. pathologist as positive or regutive. As the attending pathologist. I attest that I: (i) Examined the relevant preparation(s). for the specimen(s): and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: 1. Addendum Diagnosis. D. LEFT BREAST MASTECTOMY: The tumor cells are positive for HER2 gene amplification by CISH (performed at. Intraoperative Consultation. A. Left axilla 1. FS: No obvious malignancy; however, immunostains are pending. B. Left axilla 1. - FS: No obvious malignancy; however, immunostains are pending. C. Left axilla 1. FS: No obvious malignancy; however, immunostains are pending. Clinical History: Page 2 of. SURGICAL PATHOL Report. Patient with biopsy-proven infiltrating lobular carcinoma. Please evaluate margins and if sentinel nodes are H&E negative, do. immunohistochemistry. Operation Performed. Left total mastectomy with sentinel lymph node biopsy, possible axillary node dissection. Pre Operative Diagnosis: Infiltrating lobular carcinoma of left breast. Specimen(s) Rereived: A: Left axilla 1. FS. B: Left axilla 1. -FS. C: Left axilla 1. -FS. D: Left breast. Gross Description: A. Received fresh is a 1 x 1 x 0.2 cm adipose tissue fragment. The specimen is submitted in toto in one block for frozen. section. B. Received fresh is a 2 x 1 x 0.6 cm adipose tissue fragment. The specimen is submitted in toto in one block for frozen. section. C. Received fresh is a 0.5 x 0.4 x 0.1 cm adipose tissue fragment. The specimen is submitted in toto in one block for frozen. section. D. Received in formalin is an 871-gram, 20 x 16 x 6 cm mastectomy specimen. An ellipse of skin is identified it measures. 16 x 9 x 0.2 cm. The nipple and areola measure 1.8 cm and 4.5 cm, respectively. The specimen is orienteld with one. stitch superior and two stitches medial. The specimen is inked and cross sectioned in the frozen room. A 2 x 1.5 x. 1.2. cm, ill-defined lesion was identified in the left lower outer quadrant. This lesion is located 1.2 cm from the deep resection. margin (closest). A 0.2 x 0.1 cm tissue sample was taken by Dr. 0.3 x 0.3 cm tissue sample was taken for tissue. bank. A 0.5 x 0.4 x 0.1 cm tissue sample was taken by Dr. for research. An additional piece of adipose. tissue and skin accompanies the specimen; it measures 7.5 x 4 x 2.5 cm. The skin measures 7 x 2.5 x 0.1 cm. Cross. sections throughout the specimen show a multilobulated adipose tissue. No lesions are identified. The fat to stroma ratio. is 40:60. The specimen is submitted as follows: 1. Section of nipple and areola. 2. Lesion in relation to the deep margin (closest). 3-5. Remainder of lesion in toto. 6. Section of left upper inner quadrant. 7. Section of left lower inner quadrant. 8. Section of central compartment. 9. Section of left upper outer quadrant. 10. Section of left lower outer quadrant. 11&12. Sections of additional breast tissue segment.",BRCA,0,"The report states that there is no metastasis in the 3 sentinel lymph nodes examined, and there are no isolated tumor cells. This information aligns with rule 18, which states that a negative lymph node status (0/N) indicates no regional lymph node metastasis, where N is the total number of examined lymph nodes.",N0,43.0
674,TCGA-A8-A09I.AF12859A-D67A-488D-8BC2-ED28698F2ACA,1,"Diagnosis. 1. and 2. Poorly differentiated invasive ductal right breast carcinoma measuring up to 4.4 cm. with a minimum dorsal margin of 2.9 cm in the ablated breast tissue. Circumscribed ductal. carcinoma in situ (high-grade DCIS with comedo necrosis) in the tumor center, about 0.2 cm. in diameter. Lipomatous atrophy of the remaining breast tissue. Regular nipple. Regular skin. Sixteen right axillary lymph nodes free of metastases (0/16). Tumor classification: M-8500/3, G 3, pT2, pNO (0/16), pMX, stage II A.",BRCA,0,"The report states that 16 right axillary lymph nodes were free of metastases (0/16). This indicates that there is no regional lymph node metastasis, which corresponds to N0 stage.",N0,44.0
1120,TCGA-D8-A1JD.332880ED-FE4E-4EE4-9E96-0A61BFCCA27E,1,"Nos page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. xamination No.: Gender: F. Material: 1. Total organ resection - left breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast - outer upper quad. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+ ). Macroscopic description: Left breast sized 19 x 18 x 5 cm removed along with axillary tissues sized 11 x 4.5 x 1.5 cm and a 19. x 10 cm skin flap. Weight 620 g. Tumour sized 2.8 x 1.5 x 2.5 cm on the border of upper quadrants, 4.5 cm from the upper. boundary, 0.2 cm from the base and 1.0 cm from the skin. Another tumour sized 0.5 x 0.7 x 0.5 cm found 1.5 cm away from the first one (margins: lower. boundary - 10 cm; base - 0.1 cm; skin - 3.5 cm). Microscopic description: Both tumours showing similar pattern. Carcinoma ductale invasivum bifocal - NHG2 (2 + 3 +1/7 mitoses/10 HPF, visual area diameter 0.55. mm). Foci of carcinoma ductale in situ DCIS found within the tumour (solid and cribrate type with high. nuclear atypia and comedo necrosis, 5% of the tumour). Reactio lymphocytaria peritumoralis. Mamilla sine laesionibus. Glandular tissue showing mastopathia fibrosa et cystica. AXILLARY LYMPH NODES: Metastases carcinomatosae in lymphonodis No III/XIV. Infiltratio capsulae lymphonodis et telae perinodalis. page 2 / 2. Gender: F. Histopathological diagnosis: Carcinoma ductale invasivum bifocale mammae sinistrae. Invasive bifocal ductal carcinoma of the left breast. Metastases carcinomatosae in lymphonodis axillae No. III/XIV. Cancer metastases in axillary lymph nodes. No. III/XIV. (NHG2, pT2, pN1a).",BRCA,1,"The report mentions 'Metastases carcinomatosae in lymphonodis axillae No. III/XIV' which indicates metastasis in 1 to 3 axillary lymph nodes (N1 stage, rule Nos 2, 11, 19). The N stage is not affected by the size of the metastasis or the number of tumor cells in the lymph node (rule Nos 7, 13).",N1,45.0
874,TCGA-AR-A24O.887F0E3A-DC70-4CD4-AAAF-3C613195D895,2,"Final Diagnosis. Breast, left, modified radical mastectomy: Multifocal lobular carcinoma with focal ductal features, Nottingham grade I (of III). forming two separate masses, 5.3 x 2.7 x 1.4 cm and 1.2 x 1.0 x 1.0 cm in the inferior and medial breast respectively (AJCC. pT3). A biopsy cavity is identified adjacent to the tumor in the medial breast. Lymphovascular space invasion is not seen. The. remaining breast parenchyma shows adenosis and duct ectasia. The nipple shows no diagnostic abnormalities. Margins of. resection are negative for tumor (closest margin is anterior/inferior, free by at least 0.8 cm). Multiple (6 of 17) left axillary lymph. nodes are involved by metastatic lobular carcinoma (AJCC pN2). Focal extracapsular extension is also present. Her-2/NEU has been ordered on paraffin embedded tissue.",BRCA,2,"The report states that 'Multiple (6 of 17) left axillary lymph nodes are involved by metastatic lobular carcinoma (AJCC pN2)'. This indicates that the patient has metastasis in 4-9 axillary lymph nodes, which corresponds to N2 stage according to the rules.",N2,46.0
1329,TCGA-E9-A5UO.6C698240-6557-4F96-BF56-60792693920F,1,"Gross Description: There is a quadrant of the breast with tumor up to 3.5 x 3 cm in size. Lymph nodes. are soft hyperemic. Microscopic Description: Mucinous adenocarcinoma of the breast, G-2. Ten examined lymph nodes. demonstrated sinus histiocytosis. Diagnosis Details: Tumor Features: Indeterminate, Tumor Extent: T2 tumor size more than 2cm not. more than 5 cm, Venous Invasion: Absent, Margins: Absent, Treatment Effect: Comments: Formatted Path Reports: BREAST TISSUE CHECKLIST. Specimen type: Partial mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3 x 0 x 3.5 cm. Grossly evident lesion: Yes. Histologic type: Adenocarcinoma, mucinous type. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: Right.",BRCA,0,"The report states that 10 lymph nodes were examined and none of them were positive for metastasis (Axillary 0/10). This indicates that there is no regional lymph node metastasis, which corresponds to N0 stage.",N0,47.0
985,TCGA-BH-A0BR.6122CE59-23C0-4205-91B5-B71E39C6EAB8,0,"FINAL DIAGNOSIS: PART 1: LEFT AXILLA, SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR. PART 3: LEFT AXILLA, NON-SENTINEL LYMPH NODE, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR. PART 4: LEFI BREAST, SEGMENTAL MASTECTOMY WITH NEEDLE LOCALIZATION. A. INFILTRATING DUCTAL CARCINOMA. 1.1 CM, NOTTINGHAM SCORE 6/9 (TUBULES 3, NUCLEI 2, MITOSIS 1). B. DUCTAL CARCINOMA IN-SITU, CRIBRIFORM AND SOLID TYPES, WITH COMEDO NECROSIS REPRESENTING. 10% OF THE TUMOR VOLUME. C. FOCI OF DCIS IS SEEN AWAY FROM THE INVASIVE TUMOR. D. LYMPHOVASCULAR SPACE INVOLVEMENT IS NOT PROMINENT. E. INVASIVE TUMOR IS 0.4 CM FROM THE INFERIOR MARGIN. DUCTAL CARCINOMA IN-SITU, 0.2 CM FROM THE INFERIOR MARGIN. G. MARGINS FREE OF TUMOR. H. MICROCALCIFICATIONS ASSOCIATED WITH TUMOR AND BENIGN CHANGES. I. FIBROCYSTIC CHANGES. J. SKIN UNREMARKABLE. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Lower inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.1 cm. MULTICENTRICITY/MULTIFOCALIT OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. Comedo. Percent of tumor occupied by in situ component: 10 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 4 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 2 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.",BRCA,0,"The report states that 3 lymph nodes were examined and none of them had metastasis. This corresponds to N0 stage as per rule 18, 20, and 21.",N0,48.0
1370,TCGA-EW-A6S9.4FC32F17-7A4D-4FF6-A710-FFFBC610CB56,0,"F. x. x. Pathologic Interpretation: A. SENTINEL NODE #1. METASTATIC CARCINOMA to one lymph node (1/1). Largest tumoral deposit is 1mm. NOTE: Metastatic deposit is not identified in frozen section slide. B. SENTINEL NODE #2. Negative for carcinoma, one lymph node (0/1). C. SENTINEL NODE #3. Negative for carcinoma, one lymph node (0/1). D. RIGHT BREAST MASS: INVASIVE DUCTAL CARCINOMA, poorly differentiated, Nottingham grade 2 (3+2+2=7), 2.0 cm. Surgical resection margins are negative for invasive carcinoma; the closest one is the anterior at 6mm. DUCTAL CARCINOMA IN SITU, intermediate grade, solid and cribriform type with necrosis and retrolobular. involvement present in five out of 15 slides examined. Surgical resection margins are negative for in situ carcinoma; the closest one is the anterior at 10 mm. Lymphovascular invasion is identified. INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total Mastectomy, Including. Specimens. Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy With or Without Axillary. Contents) and. Mastectomy (Total, With or Without Axillary Contents; Modified Radical; Radical). Procedure. Excision without wire-guided localization. Lymph Node Sampling. Sentinel lymph node(s). Specimen Laterality. Right. Tumor Site: Invasive Carcinoma. Upper outer quadrant. Histologic Type of Invasive Carcinoma. Invasive ductal carcinoma (no special type or not otherwise specified). Tumor Size: Size of Largest Invasive Carcinoma. Greatest dimension of largest focus of invasion >1 mm: 20 mm. Additional dimensions: 15.0 x 10.0 mm. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation. Score 3: <10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism. Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and. shape. Mitotic Rate. Score 2 (4-7 mitoses per mm2). Overall Grade. Grade 2: scores of 7. Tumor Focality. Single focus of invasive carcinoma. Ductal Carcinoma In Situ (DCIS). DCIS is present. Size (Extent) of DCIS. Present in five out 15 slides examined. Architectural Patterns (select all that apply). Cribriform. Nuclear Grade (see Table 2). Grade Il (intermediate). Necrosis. Present, focal (small foci or single cell necrosis). Lobular Carcinoma In Situ (LCIS). Not identified. Margins. Invasive Carcinoma. Margins uninvolved by invasive carcinoma. Distance from closest margin: 6 mm. Specify margin: Anterior. DCIS. Margins uninvolved by DCIS. Distance from closest margin: 10 mm. + Specify margin: Anterior. Lymph Nodes. Number of sentinel fymph nodes examined: 3. Total number of lymph nodes examined (sentinel and nonsentinel): 3. Number of lymph nodes with macrometastases (>2 mm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 2 mm and/or >200 cells): 1. Number of lymph nodes without tumor cells identified: 2. Extranodal Extension. Not identified. Method of Evaluation of Sentinel Lymph Nodes. Hematoxylin and eosin (H&E), 1 level. Immunohistochemistry pending. Lymph-Vascular Invasion. Not identified. Pathologic Staging (based on information available to the pathologist) (pTNM). Primary Tumor (Invasive Carcinoma) (pT). pT1c: Tumor >10 mm but <20 mm in greatest dimension. Regional Lymph Nodes (pN). Modifier. (sn): Only sentinel node(s) evaluated. Category (pN). pN1mi: Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0. mm). Distant Metastasis (pM). Not applicable. Ancillary Studies. Performed on another specimen. Specify specimen (accession number): xx. Estrogen Receptor (ER). Results and interpretation: Positive Immunoreactive tumor cells present. Quantitation: 50%. Progesterone Receptor (PgR). Results and interpretation: Positive Immunoreactive tumor cells present. Quantitation: 50%. HER2 (results for invasive carcinoma performed on this specimen or a prior core needle biopsy or incisional biopsy). Immunoperoxidase Studies. Positive (Score 3+). Preliminary AJCC Classification (7th Edition): pT1c pN1mi pMn/a. (Final classification pending evaluation of keratin immunostain on sentinel nodes). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. Parts B-C: Immunohistochemistry for keratin is negative. Final AJCC Classification: pT1c pN1mi pMn/a. Intraoperative Consultation: A. SENTINEL NODE #1 ( ), FS: Negative lymph node. B. SENTINEL NODE #2 ( ), FS: Negative lymph node. C. SENTINEL NODE #3 ( ), FS: Negative lymph node. Reported to OR at. XX, MD. Clinical History: Not provided. Operation Performed: Right breast lumpectomy with sentinel node biopsy. Pre Operative Diagnosis: Right breast carcinoma. Specimen(s) Received/Processing Information: Fee Codes: A: A: SENTINEL NODE #1 (. ), FS Frozen section x 1, FS Perm x. 1. B: C: B: SENTINEL NODE #2 (. ), FS Frozen section x 1, FS Perm x 1, Cytokeratin Cocktail. (KER) x 1. D: C: SENTINEL NODE #3 (. 1, FS Frozen section x 1, FS Perm x 1, FSDeep 1 x 1,. Cytokeratin Cocktail (KER) x. 1. D: RIGHT BREAST MASS (1 STITCH SUPERIOR, 2 STITCHES LATERAL, 3 STITCHES. DEEP) H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1,. H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x. 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E. Gross Description: A. Specimen is received fresh and labeled ""Sentinel node #1 (. FS"". The specimen consists of one lymph. node measuring 1.6 x 0.9 x 0.4cm. Specimen is bisected and submitted in toto for frozen section. B. Specimen is received fresh and labeled ""Sentinel node #2 ( ), FS"". The specimen consists of one lymph. node measuring 1.3 x 0.9 x 0.3 cm. Specimen is bisected and submitted in toto for frozen section. C. Specimen is received fresh and labeled ""Sentinel node #3 ( ), FS"". The specimen consists of one lymph. node measuring 1.1 x 0.6 x 0.3 cm. Specimen is bisected and submitted in toto for frozen section. D. Specimen is received in formalin and labeled ""Right breast mass (1 stitch superior, 2 stitches lateral, 3. stitches deep"". The specimen consists of an 8.0 x 8.0 x 4.0 cm lumpectomy specimen, oriented with one. stitch at superior, two stitches as lateral and three stitches as deep. The specimen is inked for evaluation of margins: Posterior black. Anterior yellow. Superior blue. Inferior green. Lateral orange. Medial red. Serial sections are white-gray, ill-defined and firm. A mass is identified measuring 2.0 x 1.5 x 1.0 cm; the. mass is 1.0 cm from the superior margin, 2.0 cm from the inferior margin, 1.0 cm from the anterior margin,. 3.0 cm from the lateral margin, 1.5 cm from the medial margin and 1.0 cm from the deep margin. The. remainder of the specimen consists of yellow-white adipose tissue. No other lesions are identified. 90% of. the mass was submitted for microscopic examination. Representative sections are submitted as follows: Cassette #1. Superior margin perpendicular. Cassette #2. Inferior margin perpendicular. Cassette #3. Lateral margin perpendicular. Cassette #4. Medial margin perpendicular. Cassette #5. Anterior margin perpendicular. Cassette #6. Deep margin perpendicular. Cassettes #7-10. Mass and breast tissue adjacent. Cassettes #11-15. Other areas.",BRCA,1,"The pathology report indicates that there is metastatic carcinoma in one out of three examined sentinel lymph nodes (1/3). This corresponds to the N1 stage, as defined by rule 11, which states that N1 stage corresponds to metastasis in 1 to 3 axillary lymph nodes.",N1,49.0
834,TCGA-AQ-A7U7.2B30A85F-7A5F-46E4-BE22-28C902D5DFA3,1,"Diagnosis: A: Breast, left, total mastectomy. Tumor type: invasive lobular carcinoma. Nottingham combined histologic grade: 2. Tubule formation score: 3. Nuclear pleomorphism score: 2. Mitotic count score: 1. Focality of tumor: single focus. Tumor site: upper outer and lower outer quadrants. Tumor size (greatest dimension) : 4.1 cm (see comment). Lymphovascular invasion: none identified. Ductal carcinoma in situ (DCIS) : none identified. Lobular carcinoma in situ (LCIS) : present. Nipple involvement : not involved. Skin involvement : not involved. Skeletal muscle involvement: not applicable. Margin status: Invasive component : Margins free of carcinoma, closest is black. inked posterior margin at 2 mm. Size of largest metastasis : 4.1 cm. Extracapsular extension: absent. Axillary lymph nodes (from parts B-G) : Total number with metastasis : 2. Total number examined: 7. Size of largest metastatic focus: 0.7 cm. Extracapsular extension: absent. Microcalcifications: associated with benign breast changes. Other pathologic findings: Extensive stromal fibrosis with patchy amyloid deposition. - Fibrocystic changes. - Columnar cell change. - Epidermal inclusion cyst. - Previous biopsy site changes. AJCC PATHOLOGIC TNM STAGE: pT2 pN1a. BREAST STAGE GROUPING: IIB. Note: This pathologic stage assessment is based on information. available at the time of this report, and is subject to change. pending clinical review and additional information. Ancillary studies previously performed on core biopsy case and. reported as : Estrogen receptor: positive, 88%, 3+. Progesterone receptor: positive, 82%, 3+. HER2/neu: negative for overexpression, 0. B: Lymph node, left axillary sentinel lymph node #1, biopsy. - One lymph node positive for metastatic carcinoma (1/1) based. on H & E and cytokeratin stained slides. - Metastatic focus measures 0.5 cm. - No extracapsular extension is identified. - Amyloid present. C: Lymph node, left axillary sentinel lymph node #2, biopsy. - One lymph node negative for metastatic carcinoma (0/1) based. on H & E and cytokeratin stained slides. - Amyloid present. D: Lymph node, left axillary sentinel lymph node #3, biopsy. - One lymph node positive for metastatic carcinoma (1/1) based. on H & E and cytokeratin stained slides. - Metastatic focus measures 0.7 cm. - No extracapsular extension is identified. - Amyloid present. E: Lymph node, left axillary sentinel lymph node #4, biopsy. - Two lymph nodes negative for metastatic carcinoma (0/2) based. on H & E and cytokeratin stained slides. - Amyloid present. F: Lymph node, left axillary sentinel lymph node #5, biopsy. - One lymph node negative for metastatic carcinoma (0/1) based. on H & E and cytokeratin stained slides. - Amyloid present. G: Lymph node, left axillary sentinel lymph node #6, biopsy. - One lymph node negative for metastatic carcinoma (0/1) based. on H & E and cytokeratin stained slides. - Amyloid present. Clinical History: -year-old female with left breast invasive lobular carcinoma. Gross Description: Received are seven appropriately labeled containers. Container A: Specimen fixation: formalin. Time in fixative: 33 hours. Cold ischemic time: 71 mins. Type of mastectomy: left total mastectomy. Weight of specimen: 330 grams. Size of specimen: anterior to posterior, 2.5 cm; superior to. inferior, 19.0 cm; medial to lateral, 20.0 cm. Orientation of specimen: The specimen is oriented with a stitch. in the axillary tail. Inking: anterior=blue, posterior=black, axillary tail=dotted. yellow. Skin ellipse dimensions: 19.0 X 5.8 cm. Nipple/areola 1.4 cm/3.0 cm. Axillary tail: present, minimal tissue. Biopsy site: absent. Discrete Mass (es) : Area of fibrotic, homogeneously firm,. white/tar tissue. Number of discrete masses : one. Size of fibrotic tissue: 7.5 cm from medial to lateral, 6.7 cm. from superior to inferior, and 3.5 cm from anterior to posterior. Location of fibrotic tissue: upper inner quadrant, upper outer. quadrant, lower outer quadrant (includes the area deep to the. nipple/areola). Distance of mass/biopsy site from surgical margin: The fibrotic. tissue abuts the black inked deep margin extensively, it also. abuts the blue inked anterior margin in multiple slices. Gross involvement of skin or fascia/muscle by tumor: The tumor. extends very close to the skin, however, does not appear to. grossly involve the skin. Description of remaining breast : predominantly yellow lobular. adipose tissue. Other remarkable features : none. Tissue submitted for special investigations: Tumor and normal. submitted to Tissue Procurement foundation. Block Summary: A1 - nipple, perpendicular sections, in relation to the tumor. A2 - nipple, perpendicular sections, in relation to the tumor. A3, A4 - perpendicular sections of the areola, in relationship to. the deep tumor. A5, A6 - representative section of the tumor, in relation to the. blue inked inferior margin. A7, A8 - representative section of the tumor, in relation to the. black inked deep margin. A9,A10 - additional representative sections of the mass. A11 - representative section, upper outer quadrant. A12 - representative section, lower outer quadrant. A13 - representative section, upper inner quadrant. A14 - representative section, lower inner quadrant. Additional sections, upper outer quadrant surrounding metallic. clip, lateral to medial: A19 - one section bisected. A20 - one section bisected. A21-A22 - - one section bisected. A23-A24 - one section bisected. A25 - one section. A26 - one section. A27 - one section. A15-A18, A28-A67 additional sections from lateral towards. medial, respectively. Container B is additionally labeled ""lymph node, left axillary. sentinel lymph node #1. Received is a single, unoriented,. yellow lobular adipose tissue fragment, 3.7 X 3.0 X 1.0 cm. A. single lymph node candidate, 2.2 X 1.3 X 0.8 cm is identified. and is sequentially sectioned at 2 mm intervals. The entire. lymph node is submitted in blocks B1 and B2. Adipose tissue. remains in the container. Container C is additionally labeled ""lymph node, left axillary. sentinel lymph node #2. Received is a single, unoriented,. brown/tan fibroadipose tissue fragment, 3.4 X 2.3 X 1.3 cm. A. single, possibly two, lymph node candidates matted together are. identified, 2.3 X 2.3 X 0.8 cm. The lymph node candidate is. serially sectioned at approximately 2 mm intervals and is. entirely submitted in blocks C1-C3. Adipose tissue remains in. the container. Container D is additionally labeled ""lymph node, left axillary. sentinel lymph node #3. "" Received is a single, unoriented,. brown/tan fibroadipose tissue fragment, 1.8 X 1.8 X 1.5 cm. A. single lymph node candidate, 1.2 X 0.8 X 0.8 cm is identified,. is serially sectioned at approximately 2 mm intervals and. entirely submitted in blocks D1 and D2. Adipose tissue remains. in the container. Container E is additionally labeled ""lymph node, left axillary. sentinel lymph node #4. "" Received is a brown/tan, single,. unoriented fibroadipose tissue fragment, 1.5 X 1.0 X 0.9 cm. Two. lymph node candidates, 0.5 and 0.2 cm in diameter are. identified. The larger lymph node is bisected and submitted in. block E1. The smaller lymph node is submitted in block E2. without sectioning. Adipose tissue remains in the container. Container F is additionally labeled ""lymph node, left axillary. lymph node #5. "" Received is a single, unoriented, brown/tan. fibroadipose tissue fragment, 1.2 X 1.2 X 0.6 cm. A single lymph. node candidate, 1.1 X 0.8 X 0.6 cm is identified. The lymph node candidate is serially sectioned at approximately. 2 mm intervals and entirely submitted in block F1. Adipose. tissue remains in the container. Container G is additionally labeled ""lymph node, left axillary. sentinel lymph node #6. Received is a single, gray/tan,. unoriented, 1.0 X 0.9 x 0.6 cm lymph node candidate. The. specimen is serially sectioned, at approximately 2 mm. intervals, and entirely submitted in blocks G1 and G2,.",BRCA,2,"The report indicates that there are 2 positive lymph nodes out of a total of 7 examined lymph nodes. This corresponds to N1 stage as per AJCC rules 1, 2, 10, 11, 19, and 23.",N1,50.0
667,TCGA-A8-A099.34499A83-DFCE-4DB8-BAA0-A7590AF8BC07,3,"Diagnosis: 1. Ablated breast sample with a moderately differentiated invasive ductal carcinoma. (tumor diameter 105 cm) with focal ulceration of the skin and a satellite node. (diameter 0.9 cm) in the skin. Tumor-free dorsal resection margin. Together with the preliminary finding, this gives rise to the following tumor. classification: NOS, G II, pT4b pN3a(11/22)LOVORO. :34499A83-DFCE-4D88-BAA0-A7590AF8BC07.",BRCA,3,"The report mentions pN3a(11/22)LOVORO, which indicates metastasis in 11 out of 22 examined axillary lymph nodes. This corresponds to N3 stage according to the rules 2, 3, 4, 10, 12, and 22.",N3,51.0
966,TCGA-BH-A0B1.BAEB6705-FCDC-4B40-B1CB-D926B8287F92,1,"FINAL DIAGNOSIS: PART 1: RIGHT AXILLA, SENTINEL LYMPH NODE #1, EXCISION -. ONE LYMPH NODE, POSITIVE FOR METASTATIC DUCTAL CARCINOMA, 0.9 CM WITH FOCAL EXTRACAPSULAR. EXTENSION. PART 2: RIGHT BREAST, MODIFIED RADICAL MASTECTOMY -. A. MULTICENTRIC INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM SCORE 6/9 (TUBULES 3, NUCLEI 2,. MITOSES 3) CENTRALLY LOCATED AND INVOLVING ALL OF FOUR QUADRANTS. B. TUMOR NODULES RANGES FROM 0.2 TO 4.8 CM. C. TUMOR AGGREGATES UP TO 14.3 CM. D. DUCTAL CARCINOMA IN SITU, SOLID TYPE WITH COMEDO NECROSIS REPRESENTING LESS THAN 5% OF THE. TUMOR VOLUME. E. FOCAL LOBULAR CARCINOMA IN SITU. F. EXTENSIVE LYMPHOVASCULAR SPACE INVOLVEMENT SEEN. G. TUMOR IS 0.8 CM FROM LOWER INNER QUADRANT DEEP MARGIN. H. MARGINS FREE OF TUMOR. I. SKIN AND NIPPLE WITH DERMAL LYMPHOVASCULAR SPACE INVOLVEMENT. J. CHANGES CONSISTENT WITH BIOPSY SITE. K. MICROCALCIFICATIONS ASSOCIATED WITH BENIGN CHANGES AND TUMOR. L. FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA, COLUMNAR CELL CHANGES. M. FOURTEEN RIGHT AXILLARY LYMPH NODES, NEGATIVE FOR TUMOR. PART 3: LEFT BREAST, 344 GRAMS, BREAST REDUCTION -. A. FIBROCYSTIC CHANGES WITH MICROCALCIFICATIONS. B. SKIN NOT REMARKABLE. CASE arner WID. Site: breast, NOS C50-9 3/13/ for. SYNOPTIC -PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Central subareolar. SIZE OF TUMOR: Maximum dimension invasive component: 4.8 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 14.3 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. Comedo. DCIS admixed with invasive carcinoma. LCIS. Percent of tumor occupied by in situ component: 3 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 8 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: FAGE s VISCASE UF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 15. METHOD(S) OF LYMPH NODE EXAMINATION: SENTINEL NODE METASTASIS: H/E stain. ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH Diameter EXTRACAPSULAR of largest lymph EXTENSION: node metastasis: 9 mm. SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: M STAGE, PATHOLOGIC: pN1. ESTROGEN RECEPTORS: pMX. positive. PROGESTERONE RECEPTORS: HER2/NEU: positive. zero or 1+.",BRCA,1,"The report states that one out of fifteen examined lymph nodes is positive for metastasis (pN1). This is based on the AJCC staging system, which considers one to three positive axillary lymph nodes as N1 stage.",N1,51.0
952,TCGA-B6-A3ZX.B3CFFF02-89AA-43AE-B19B-BEE6817AA997,2,"AP Surgical Pathology: Additional info d. CLINICAL HISTORY: Rule out malignancy of left breast. Palpable left breast mass within large. axillary node. If invasive carcinoma, please obtain ER, PR, EGFR, HER2/Neu by. immunohistochemistry; for all 2+ IHC results please do FISH analysis. GROSS EXAMINATION: A. ""USNCB left breast, number of cores 4, 11:00 site 1"", received in formalin. is a 1 x 0.6 x 0.2 cm aggregate of yellow-tan fibrofatty tissue which is. submitted entirely in a mesh bag in block A1. B. ""USNCB left breast, number of cores 4, axilla site 2"", received in formalin. is a 0.9 x 0.6 x 0.2 cm aggregate of yellow-tan fibrofatty tissue which is. submitted entirely in a mesh bag in block B1. MICROSCOPIC EXAMINATION: Microscopic examination is performed. DIAGNOSIS: A. ""LEFT BREAST, 11:00, SITE ONE"" (ULTRASOUND GUIDED NEEDLE CORE BIOPSY). INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL, WITH LOBULAR FEATURES. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 2. IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: SOLID. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. ESTROGEN/PROGESTERONE RECEPTOR, HER2/NEU, AND EGFR ANALYSIS: PENDING. PARAFFIN BLOCK NUMBER: A1. RESULTS WILL BE ISSUED IN A SEPARATE REPORT FROM THE IMAGE CYTOMETRY. LAB. B. ""LEFT BREAST, AXILLA, SITE TWO"" (ULTRASOUND GUIDED NEEDLE CORE BIOPSY) : LYMPH NODE WITH METASTATIC DUCTAL ADENOCARCINOMA. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). - - ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es).",BRCA,1,"The report mentions 'LYMPH NODE WITH METASTATIC DUCTAL ADENOCARCINOMA' in the left breast axilla. This indicates that there is metastasis in at least one axillary lymph node, which corresponds to N1 stage according to the rules.",N1,52.0
512,TCGA-A2-A0SW.8401DFCF-8793-461A-B17E-E6584CE2423B,1,"Lab No.: F. Date Collected: Date Received: Doctor: M.R. No.: Room No: Hosp.No: CLINICAL HISTORY: PREOPERATIVE DIAGNOSIS: Right Breast Cancer. POSTOPERATIVE DIAGNOSIS: OPERATION: Lumpectomy Right Breast, Right Sentinel Lymph Node Biopsy. SPECIMEN: A) Right Breast Mass - 1 Short Anterior - 2 Short Superior - 1 Long. Medial, B) Sentinel Node #1 F.S., C) Sentinel Node #2 F.S., D) Axillary Contents E). Gross Margin Additional Inferior Margin Right Breast Mass suture New Inferior Margin. FROZEN SECTION DIAGNOSIS: A) GROSS MARGINS: VERY CLOSE (LESS THAN 1 MM), TO. INFERIOR MARGIN. B) SENT LYMPH NODE #1 - POSITIVE FOR METASTATIC. CARCINOMA. C) SENT LYMPH NODE #2 - POSITIVE FOR METASTATIC. CARCINOMA. Lab No.: F. Date Collected: Date Received: Doctor: M.R. No.: Room No: Hosp.No: FINAL DIAGNOSIS: A) RIGHT BREAST TISSUE - POORLY DIFFERENTIATED. INFILTRATING DUCTAL CARCINOMA. SCARFF-BLOOM-RICHARDSON GRADE III/III. THE TUMOR MEASURES 3.5 CM. IN MAXIMUM DIMENSION AND. FOCALLY CLOSE TO ANTERIOR AND POSTERIOR SURGICAL. MARGINS, (LESS THAN 1 MM.), SLIDES #5 AND #6. THE REMAINING SURGICAL MARGINS ARE FREE OF THE. LESION. LYMPHOVASCULAR INVASION IS IDENTIFIED. MICROCALCIFICATIONS ARE IDENTIFIED. B) SENTINEL LYMPH NODE - ONE (1) POSITIVE LYMPH NODE, (1/1). C) SENTINEL LYMPH NODE - ONE (1) POSITIVE LYMPH NODE, (1/1). D) AXILLARY CONTENTS - 2 OF 13 LYMPH NODES ARE POSITIVE FOR. MALIGNANCY, (2/13). E) ADDITIONAL RIGHT BREAST TISSUE - NEGATIVE FOR. MALIGNANCY. PTNM CLASSIFICATION: PIIIa, T2, N2, MX.",BRCA,2,"The report states that there are 2 out of 13 positive lymph nodes in the axillary contents (2/13). This corresponds to N2 stage, which is metastasis in 4-9 axillary lymph nodes.",N2,53.0
650,TCGA-A8-A08J.C1D59BA7-FC3E-46EA-B095-3B6DF42892B0,3,"Diagnosis: Ablated (right) breast sample with moderately differentiated invasive and focal ductal. 1. discrete intraductal components, angioinvasion resection ulceration of. the carcinoma skin. Tumor with size at least 7 cm. Paget's disease of the nipple. Dorsal. margin tumor-free. Tumor classification: NOS, G II, pT4bN1aL1 1VORO.",BRCA,3,"The report specifies a pT4bN1aL1 classification. The 'N1' in this classification indicates regional lymph node metastasis. The 'a' indicates micrometastasis, which is still considered positive lymph node metastasis according to rule 6. The exact number of positive lymph nodes is not specified, but the 'N1' stage categorically indicates 1 to 3 axillary lymph nodes with metastasis or in internal mammary nodes with clinically negative axillary nodes (rule 2, 19).",N1,54.0
634,TCGA-A8-A07U.1E7788D8-B5FC-473A-8A10-79910443799A,1,"Path site : Breast, 40Q C50.4 1/19/11 for. Diagnosis: 2. Right breast resection material with a 2.2 cm poorly differentiated invasive ductal breast. carcinoma with a minimum margin of almost 1 cm basally and at 6 o 'clock and surrounding. fibrolipomatous atrophic glandular tissue without any evidence of an intraductal tumor. component and tumor-free overlying skin, including the nipple. Tumor classification: M-8500/3, G3, pT2, pN2a, pMX, stage IIIA. R0.",BRCA,2,"The report indicates a pN2a stage, which corresponds to metastasis in 4-9 axillary lymph nodes. This matches rule 3 and 12.",N2,55.0
1133,TCGA-D8-A1JT.72AF26A2-FAD0-42FD-A63C-6E8E2597B84E,1,"page 1 / 2. copy No. 5. Examination: Histopathological examination. Cost of diagnostic procedure. Material: Multiple organ resection - left breast. Material received or. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by. Score = 2+, verification by the FISH method recommended. Macroscopic description: Left breast sized 26 x 20 x 5.5 cm removed along with axillary tissues sized 10 x 8 x 2.5 cm and a 25 x 14 cm skin. flap. Tumour sized 2.6 x 2 x 1.8 cm found in the outer lower quadrant, 5.3 cm from the lower boundary, 1.2 cm. from the base and 1.4 cm from the skin. Microscopic description: Carcinoma ductale partim papillare - NHG1 (2 + 2 +3/22 mitoses/ 10 HPF, visual area diameter: 0.55 m). Glandular tissue showing lesions of the type fibrosa et cystica, hyperplasia ductalis simplex. Invasive lesions reaching the base. Axillary lymph nodes: Lymphonodulitis chronica et lymphonodorum No XV. Examination: Histopathological examination 1. page 2 / 2. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by. HER2 DNA Probe Kit. HER-2 gene AMPLIFICATION NOT FOUND. Histopathological diagnosis: Mixed ductal and papillary invasive carcinoma of the left breast. Usual ductal hyperplasia (. 1. Fibrocystic. changes. Lymph nodes negative for cancer.",BRCA,0,"The report states 'Lymph nodes negative for cancer', which indicates no regional lymph node metastasis. This matches the definition for N0 stage.",N0,55.0
1508,TCGA-UL-AAZ6.1AD1E3C4-0D7C-447B-B330-0245F9159FCC,1,"SPECIMEN(S) RECEIVED. A: RIGHT TOTAL MASTECTOMY. B: SENTINEL LYMPH NODE #1 HOT. C: SENTINEL LYMPH NODE #2 HOT. D: SENTINEL LYMPH NODE #3 HOT. FINAL DIAGNOSIS. A. RIGHT TOTAL MASTECTOMY: SYNOPTIC REPORT. MICROSCOPIC: HISTOLOGIC TYPE: INVASIVE DUCTAL CARCINOMA. SIZE OF INVASIVE COMPONENT: 3.4 x 3.0 x 2.5 cm. TUMOR FOCALITY: SINGLE FOCUS OF INVASION. MACRO/MICRO EXTENT OF INVASIVE TUMOR. SKIN. TUMOR DOES NOT INVADE DERMIS/ EPIDERMIS. NIPPLE. DCIS DOES NOT INVOLVE THE NIPPLE EPIDERMIS. SKELETAL MUSCLE. SKELETAL MUSCLE IS PRESENT AND IS FREE OF CARCINOMA. DUCTAL CARCINOMA-IN-SITU (DCIS): DCIS IS PRESENT. EXTENSIVE INTRADUCTAL COMPONENT (EIC) NEGATIVE. LOBULAR CARCINOMA-IN-SITU (LCIS): NOT IDENTIFIED. HISTOLOGIC MODIFIED SCARFF-BLOOM-RICHARDSON GRADE: 2/3. MARGINS. MARGINS UNINVOLVED BY INVASIVE CARCINOMA. DISTANCE FROM CLOSEST MARGIN: 2.0cm (DEEP). MARGINS UNINVOLVED BY DCIS. DISTANCE FROM CLOSEST MARGIN: GREATER THAN 2.0cm (DEEP). MICROCALCIFICATIONS: PRESENT IN DCIS. TREATMENT EFFECT: RESPONSE TO NEOADJUVANT THERAPY. IN THE BREAST: NO KNOWN PRESURGICAL THERAPY. IN THE LYMPH NODES: NO KNOWN PRESURGICAL THERAPY. VENOUS / LYMPHATIC INVASION: NOT IDENTIFIED. SKIN / DERMAL LYMPHATIC INVASION: NOT IDENTIFIED. LYMPH NODES: NUMBER OF SENTINEL LYMPH NODES EXAMINED: 3. TOTAL NUMBER OF LYMPH NODES EXAMINED (SENTINEL AND NONSENTINEL): 4. NUMBER OF LYMPH NODES WITH MACROMETASTASES (>0.2 CM): 0. NUMBER OF LYMPH NODES WITH MICROMETASTASES (>0.2 MM TO 0.2 CM AND/OR >200 CELLS): o. NUMBER OF LYMPH NODES WITH ISOLATED TUMOR CELLS (0.2 MM AND 200 CELLS): 0. SIZE OF LARGEST METASTATIC DEPOSIT (IF PRESENT): o. EXTRANODAL EXTENSION: N/A. METHOD OF EVALUATION OF SENTINEL LYMPH NODES: H&E, MULTIPLE LEVELS. NOTE: ER/ PR/ HER-2/ MIB-1 RESULTS: SEE PRIOR REPORT. MACROSCOPIC. SPECIMEN TYPE: TOTAL BREAST. PROCEDURE: TOTAL MASTECTOMY. LYMPH NODE SAMPLING: SENTINEL LYMPH NODES WITH PARTIAL AXILLARY DISSECTION. SPECIMEN INTEGRITY: SINGLE INTACT SPECIMEN. SPECIMEN SIZE: 27 x 17 x 3.5 cm. LATERALITY: RIGHT. TUMOR SITE: 12 O'CLOCK POSITION. AJCC PATHOLOGIC STAGE (AJCC 7TH ED.): (pT2, pNO). B. SENTINEL LYMPH NODE #1 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. c. SENTINEL LYMPH NODE #2 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. D. SENTINEL LYMPH NODE #3 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. CLINICAL DIAGNOSIS AND HISTORY. Right breast cancer. See. right breast Ca. GROSS DESCRIPTION. The specimen is received fresh in four containers labeled with the patient's name, medical record number, and identified as A. ""Right Total Mastectomy"", B. ""Sentinel Lymph Node #1 Hot"", C. ""Sentinel Lymph Node #2 Hot"" and D. ""Sentinel Lymph Node #3. Hot"". Specimen A consists of a mastectomy (811.1 grams, 27 x 17 x 3.5 cm) with a 22 x 9.5 cm skin ellipse and a centrally located. unremarkable 1.2 cm nipple. The specimen has been oriented by the surgeon with a stitch indicating the tail of the specimen. The. deep margin is inked black. The specimen is serially sectioned to reveal an irregular firm tan colored mass with focal hemorrhage. and calcification (3.4 x 3 x 2.5 cm) in the 12:00 position, 2 cm to the deep margin, 1.2 cm to the anterior skin margin, and 2 cm to. the nipple. The remaining breast parenchyma appears grossly unremarkable. One 0.7 cm lymph node is identified in the tail of the. specimen. The specimen is submitted representatively as follows: A1 thru A3, tumor, A4-tumor and anterior skin, A5-anterior skin. margin, A6-posterior deep margin, 7-nipple, A8 and A9-lateral upper quadrant, A10 and A11-lateral lower quadrant, A13-medial. upper quadrant, A14 and A15-medial lower quadrant, 16-0.7 cm lymph nodes, bisected. Specimen B consists of a 2.2 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled B1 and B2. Specimen C consists of a 2.5 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled C1 and C2. Specimen D consists of a 1 cm sentinel lymph node with fibroadipose tissue. Lymph nodes are serially sectioned and submitted. entirety in two cassettes labeled D1 and D2. the diagnosis(es) related thereto.",BRCA,0,"The report states that out of the 4 lymph nodes examined (3 sentinel and 1 non-sentinel), none of them contained metastatic carcinoma. This indicates that there is no regional lymph node metastasis, which corresponds to N0 stage.",N0,55.0
998,TCGA-BH-A0DH.79B22278-2BA1-4904-BCA6-2B1368C77475,1,"To: P.9/33. OIAGNOSIS: f: AXILLARY CONTENTS. LEFT. RESECTION -. A. METASTATIC ADENOCARCINOMA (1H, 1Q-1R and 13-1T) INVOLVING THREE OF TWENTY-EIGHT LYMPH. NODES (3/28), UP TO 1.5 CM (1R). WITH EXTRACAPSULAR EXTENSION (0.2 CM). B. CHANGES CONSISTENT WITH PREVIOUS FINE NEEDLE ASPIRATION SITE, SEE PRIOR. PART 2: BREAST. LEFT. SEGMENTAL MASTECTOMY -. A. INFILTRATING OUCIAL CARCINOMA (ZA thru 21, 2M thru 20 and 2S), WITH ASSOCIATED. MICROCALCIFICATIONS. THE INVASIVE TUMOR INVOLVES THE POSTERIOR RESECTION MARGIN (2A),. THE INFERIOR RESECTION MARGIN (2F, 2N and 20), AND COMES TO WITHIN 0.2 CM FROM THE ANTERIOR. RESECTION MARGIN (2H). B. THE TUMOR SIZE IS 3.5 2.5 x 1.7 CM. C. NOTTINGHAM SCORE 6/9 (TUBULES 3. NUCLFI 2, MITOSIS 1). D. LYMPHOVASCULAR INVASION IS PRESENT. E. DUCTAL CARCINOMA IN SITU, SOUD AND CRIBRIFORM TYPES, NUCLEAR GRADE 2, WITH. COMEDONECROSIS, ASSUCIATED MICROCALCIFICATIONS AND RETROGRADE CANCERIZATION OF. LOBULES, REPRESENTING ABOUT 2% OF TUMOR VOLUME. F. DUCTAL CARCINOMA IN SITU IS PRESENT ADMIXED WITH INVASIVE TUMOR. G. ALL OTHER MARGINS OF RESECTION ARE FREE OF TUMOR. H. ATYPICAL DUCTAL HYPERPLASIA. I. DUCTAL PAPILLOMAS. J. RADIAL SCARS WITH DUCTAL EPITHELIAL HYPERPLASIA AND COLUMNAR CELL CHANGES,. K. PROLIFERATIVE FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA, COLUMNAR CELL. CHANGE8 AND MULTIFOCAL SCLEROSING ADENOSIS WITH ASSOCIATED MICROCALCIFICATIONS. L. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE, SEE PRIOR. M. IMMUNOHISTOCHEMICAL STAINING FOR ESTROGEN RECEPTOD D. ICRUME RECEPTOR AND HER. 2/NEU WERE PREVIOUSLY PERFORMED ON CORE BIOPSY. AND WERG REPORTED AS. FOLLOWS: ESTROGEN RECEPTOR - POSITIVE, PROGESTERONE RECEPTOR - POSITIVE AND HER-2/NEU. NEGATIVE (SCORE 0). PART 3: BREAST, LEFT, NEW POSTERIOR-LATERAL MARGINS, EXCISION -. A. MICROSCOPIC FOCUS OF INVASIVE DUCTAL CARCINOMA (3E), COMING TO WITHIN 0.3 CM FROM THE. NEW INKED RESECTION MARGIN (9ce comment). B. ATYPICAL DUCTAL MYPERPLASIA. c. DUCTAL PAPILLOMA. D. RADIAL SCARS WITH DUCTAL EPITHELIAL HYPERPLASIA AND ASSOCIATED MICROCALCIFICATIONS. E. PROLIFERATIVE FIBROCYSTIC CHANGES. CHANGES AND EXTENSIVE SCLEROSING ADENOSIS WITH ASSOCIATED MULTIFOCAL. MICROCALCIFICATIONS. F. MEDIAL CALCIFICATIONS OF BLOOD VESSEL. G. NEW RESECTION MARGINS ARE FREE OF TUMOR. CASE SYNOPSIS: SYNOPTIC PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmentel. SIZE OF TUMOR: Not specified. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasivo component: 3.5 cm. TUMOR TYPE (Invanive componant): Ductal adenocarcinoine. NOS. NOTTINGHAM SCORE: Nuclcar grade: 2. Tubule formation: 3. Mitotic activity scoie: 1. Total Nottingham score: A. ANGIOLYMPHATIC INVASION: Nollingham grede (1. 2, 3). 2. DERMAL LYMPHATIC INVASION: Not applicable. Yes, benign zones. TUMOR TYPE. IN SITU: Yes. malignent zones. Cribriform. Solld. DCIS admixod with invasivo cancinoma. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupied by In situ component: 2 %. Yes, diffuse. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPM NODES POSITIVE: 3. LYMPH NODES EXAMINED: 28. METHOD(S) OF LYMPM NODE EXAMINATION;. H/E stuin. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of targuet lymph node metastaus: 15 min. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: T STAGE, PATHOLOGIC: NON-NEOPLASTIC BREAST TISSUE: ADH, Redial scar, Papillonn, FCU. pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTOR9: positive. HER2/NEU: zoro or 1+.",BRCA,1,"The report states that there are 3 positive lymph nodes out of 28 examined (3/28). According to rule 11, metastasis in 1 to 3 axillary lymph nodes corresponds to N1 stage. Additionally, rule 15 states that the N stage is determined by the number of positive lymph nodes, regardless of the total number of examined lymph nodes.",N1,56.0
